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We are guilty of many errors and faults. 
But our worst crime is abandoning the children, 
neglecting the fountain of life. 
Many of the things we need can wait. 
The Child cannot. 
Right now is the time his bones are being formed, 
Right now his blood is being made, 
Right now his senses are being developed. 
To him we cannot answer “Tomorrow”. 
His name is “TODAY” 
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Abstract 
 
 
BACKGROUND 
Tackling severe acute malnutrition (SAM) is a global public health priority. This thesis explores 
two major influences on treatment outcomes:  
-Treatment efficacy  
-Patient-related risk factors 
  
OBJECTIVES 
1. To explore whether a pre/probiotic mixture (Synbiotic2000 Forte™) improves treatment 
outcomes (nutritional and clinical) in children affected by SAM. 
2. To describe long term outcomes from SAM and identify key mortality risk factors.  
 
METHODS 
All 1024 malnourished children admitted to a therapeutic feeding centre in Malawi from July 
2006 to March 2007 were eligible for:  
The PRONUT study (Pre and PRObiotics in the treatment of severe acute malNUTrition): 795 
were recruited into a randomised, double-blind, placebo-controlled trial. They received Ready-
to-Use Therapeutic Food either with or without Synbiotic2000 Forte™. Primary outcome was 
nutritional cure (weight-for-height >80% of NCHS median). 
The FUSAM study (Long term Follow-Up after Severe Acute Malnutrition): all children known 
to be still alive were followed up ≥1 year post discharge.  
 
RESULTS 
In PRONUT, nutritional cure was similar in both groups: 54%(215/399) for Synbiotic-enhanced 
RUTF and 51%(203/396) for controls (p=0.40). Main secondary outcomes were also similar 
(p>0.05).   
Overall mortality from SAM was 41%(427/1024).  Mortality was highest during initial inpatient 
treatment: 23%(238/1024).  In FUSAM, 8%(84/1024) more died within 90 days of admission and 
10%(105/1024) during long term follow-up. Cox regression identified HIV, low weight-for-
height, low mid-upper arm circumference and low weight-for-age as major risk factors for 
death (p<0.001). 
  
CONCLUSIONS 
In this high-mortality setting, Synbiotic2000 ForteTM, did not improve clinical or nutritional 
outcomes from SAM. A more promising strategy to improve outcomes might be to tackle the 
major risk factors for SAM mortality: HIV and severity of malnutrition disease. It is likely that 
earlier treatment would be beneficial. This is a focus of current strategies for both HIV and 
malnutrition. Rollout of such programmes should be supported and their impact on SAM 
evaluated.  
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Foreword 
 
Severe Acute Malnutrition (SAM) affects an estimated 19 million children worldwide(1). It is 
responsible for over 1 million deaths each year(2). The past decade has seen important advances 
in how SAM is treated(3). Yet in many settings, notably those where HIV is prevalent, mortality 
remains unacceptably high(4). The work presented in this thesis is a small contribution towards 
wider efforts to better understand and more effectively tackle SAM.  
 
 
Thesis outline 
In Chapter 1 I present the background to this thesis, outlining definitions of, treatment 
approaches to, and challenges around severe acute malnutrition. I highlight therapeutic food as 
a key intervention within the SAM treatment package and argue that a long term perspective is 
important to evaluating the true success and public health impact of treatment. 
In Chapter 2 I present the research hypotheses, aims and objectives 
In Chapter 3 I describe the core methodology, focusing on the study setting and population: all 
children admitted to MOYO nutritional rehabilitation unit, Queen Elizabeth Central Hospital, 
Blantyre, Malawi. 
In Chapter 4 I describe the PRONUT study (Pre and PRObiotics in the treatment of severe 
acute malNUTrition), a randomised, double-blind efficacy trial. 
In Chapter 5 I describe the FUSAM (Follow-up of Severe Acute Malnutrition) study, a 
longitudinal cohort study describing long term outcomes of all patients admitted to MOYO.  
In Chapter 6 I discuss key findings from the two studies and their implications for current and 
future nutrition treatment programmes 
In Chapter 7 I conclude with recommendations for policy and research 
The Appendices contain study forms, questionnaires, expanded results tables and other 
materials which are not included in the main body of the thesis for reasons of space and flow. 
Also listed are publications and presentations arising directly from and closely related to the 
research described.   
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Role of the investigator 
This thesis would not have been possible without the help and support of many individuals 
and organizations listed in the acknowledgements. My involvement in nutrition research began 
in September 2003 during a year working as a junior doctor in the Paediatric Department of the 
College of Medicine, Queen Elizabeth Central Hospital, Malawi. Following a Public Health for 
Developing Countries MSc at the London School of Hygiene & Tropical Medicine (2004-5), I 
returned to Malawi in January 2006. Again full time in-country and working as a clinician in the 
paediatric department, mainly on ‘MOYO’ nutrition ward, I was also principal investigator of 
PRONUT, the core study of my PhD. I was responsible for developing and implementing an 
earlier version of the PRONUT protocol. This involved managing a ward-based research team, 
developing detailed clinical protocols, data collection instruments and the study database. I also 
expanded the scope of the study beyond its originally perceived remit. When it became 
apparent that long term patient follow-up was important both to PRONUT and its several sub-
studies, I was co-applicant for a UNICEF grant funding the FUSAM study. I was responsible for 
the PRONUT / FUSAM database and led the major data analysis described in this thesis. For the 
published version of PRONUT I was lead author, writing the first version of the paper, co-
ordinating and editing inputs from co-authors and submitting the final version.   
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Chapter 1 
Severe Acute Malnutrition – 
Background 
 
1.1  Global epidemiology and impact of malnutrition 
Child malnutrition is a major international public health problem with consequences for both 
individuals and societies. Of 555 million children aged 0 to 5 years living in developing 
countries(1): 
 
177 million   (32.0%) are stunted (=chronic malnutrition) 
19 million (3.5%) are severely wasted (=severe acute malnutrition) 
112 million   (20.2%) are underweight (=mixed malnutrition) 
Box 1 Malnutrition burden of disease in developing countries.  
Source: Lancet Nutrition Series, 2008 
 
The importance of malnutrition highlighted by a role in 6 of 8 Millennium Development Goals 
(MDGs)(5),(6):  
• MDG 1 (Eradicate extreme poverty and halve hunger) and MDG 4 (Reduce child mortality)  
Malnutrition interacts with other major causes of mortality (figure 1) and underlies anywhere 
from  35%(1) to over 50% of all under-5 child deaths(7),(8). Severe acute malnutrition (SAM), 
though the least 
prevalent form of 
malnutrition is 
associated with 
the high mortality 
risk. SAM alone 
causes some 1-2 
million deaths per 
year.(9) 
 
 
 
 
 
Figure 1 Causes of death in under-5 children worldwide 
Modified from the Lancet 2005; 365: 1147–52 
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Malnutrition also has implications for: 
• MDG 2 - Universal primary education: malnutrition impairs school performance(10);   
• MDG 3 - Gender equality: malnourished girls are less likely to stay in school and receive 
the education so vital to their empowerment(11); 
• MDG 5 - Maternal Health: malnourished girls not reaching their full adult physical 
potential are at increased risk of maternity-related problems(12); 
• MDG 6 - Combat HIV/AIDS, malaria & other diseases: nutrition and infection interact: 
malnutrition can increase vulnerability to and severity of infection; infection can contribute 
to a worsening of malnutrition(13),(14)  
 
The effects of malnutrition are not just short term and confined to the affected individual but 
may have important long term and intergenerational consequences (figure 2). Effectively 
tackling malnutrition is therefore a global health priority with potential for far reaching impact. 
Figure 2 Life course and intergenerational effects of malnutrition  
(source: World Nutrition Situation, 4th Report) 
 
Whilst the various forms of malnutrition have different implications for different outcomes, 
they often overlap and can affect the same individual child. Specific micronutrient malnutrition 
may also be present.  This thesis focuses on SAM because: 
- it is associated with particularly high mortality risk 
- it is the current admission criterion for therapeutic feeding programmes (section 1.3) 
 Other forms are also however acknowledged as important and will be explored, 
particularly when describing long term outcomes following an episode of SAM.
 1.2 Case definitions of 
Severe acute malnutrition
oedematous malnutrition
SAM is treated, details of the case definition have
  
1.2.1 ‘Classical’ WHO 
In the seminal 1999 guideline
and other senior health workers”
Weight-for-height <
Box 2 World Health Organization (1999) definition of SAM
 
At the time, the median was based on 
references. Weight-for height <70%
SAM. This is similar but not identical to
population nutritional status
for possible entry to feeding and other treatment
 
1.2.2 ‘Modified’ definition 
In a 2003 letter to the Lancet, Collins & Yates
WHO definition. The aim was to differentiate between children who could be safely treated 
outpatients and those who needed 
considered alongside anthropometric
 
 
Severe Acute Malnutrition 
 (SAM) encompasses both wasting (loss of 
, commonly known as kwashiorkor. Reflecting 
 evolved over recent years:
definition 
, “Management of severe malnutrition: a manual for
(15), the World Health Organization define
-3 standard deviations (z-scores) from a reference median 
(WHZ<-3) 
or 
oedematous malnutrition 
 
National Centre for Health Statistics (NCHS) growth
 of the median (<70% WHM) was also recognised
 WHZ <-3. Whilst the former 
, WHM became the commonest criterion for assessing individual
 programmes(16).  
- complicated and uncomplicated SAM 
(17) proposed an important modification to
more intensive inpatient care. 
 status: 
In this new classification, children with 
moderate acute malnutrition (70% to <80% 
WHM or -3 to -2 WHZ) 
were also considered 
care.   
Figure 3 Complicated and uncomplicated 
malnutrition 
Source: Adapted from FANTA Technical note 
8. Community-based Therapeutic Care. 
Grobler-Tanner & Collins, 2004
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body mass) and 
changes in the way 
 
 physicians 
d SAM as: 
 
 as defining 
was ideal for reporting 
s 
 the 
as 
Clinical features were 
and complications 
eligible for inpatient 
(18)
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1.2.3 Mid-upper Arm circumference 
Mid-upper arm circumference (MUAC) reflects muscle and subcutaneous fat mass and is a 
useful marker of acute malnutrition. Evidence suggests strong associations between low MUAC 
and high mortality(19). Whilst not noted in the WHO 1999 guidelines, many countries and 
organizations currently use MUAC <110mm as an independent criterion defining SAM in 
children aged 6 to <60 months(16). A major advantage is simplicity and suitability for community 
health workers who are increasingly engaged in field-based case finding. With new WHO 
growth standards, the threshold has been changed from <110mm to <115mm(20) (see below). 
 
1.2.4  World Health Organization Child Growth Standards(21) 
In 2006, WHO released new growth curves aiming to set an international standard of how 
children “should grow when free of disease and when their care follows healthy practices such 
as breastfeeding and non-smoking”(22). A May 2009 joint statement from WHO and UNCIEF 
endorsed the new standards for identifying SAM(20). Whilst they are a considerable technical 
improvement on the old growth references(23), it is important to recognise key differences 
between NCHS and WHO-defined SAM, notably in terms of potential clinical caseload(16):  
Table 1 NCHS and WHO growth norms used to define SAM 
 NCHS WHO 
KEY CHARACTERISITICS 
 
  
Type of growth curve Reference Standard 
 
ACUTE MALNUTRITION CASE DEFINITIONS 
 
 
Oedematous malnutrition = 
SAM (irrespective of  
weight-for-height) 
Yes Yes 
   
SAM (% of median) <70% weight-for-height 
(WHM) 
not used 
   
SAM (z-score) <-3z weight-for-height 
(WHZ) 
<-3z weight-for-height 
(WHZ) 
   
MUAC-defined SAM 
( 6 to <60m children) 
 
<110mm <115mm 
IMPLICATIONS FOR CLINICAL CASELOAD 
relative numbers of 6 to <60 month children diagnosed with: 
SAM, as defined by: 
WHZ (NCHS) to WHZ (WHO) 
 
1 (reference) Increase in numbers 
diagnosed 
( 2 to 4x increase )(20) 
SAM defined by: 
WHM (NCHS) to WHZ (WHO) 
 
1 (reference) 
 
Large increase in numbers 
diagnosed 
( 8x increase in one study )(24) 
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1.2.5 Case definition of SAM used in this thesis 
The fieldwork described in this thesis was done in Malawi from January 2006 to September 
2008. At this time, Malawi national guidelines(25) defined SAM as: 
Weight-for-height <70% median (NCHS references)  
or 
kwashiorkor (oedematous malnutrition) 
or 
MUAC <11cm 
Box 3 Case definition of SAM used in this thesis (following Malawi National Guidelines) 
 
This definition is consistent with international best practice. Also consistent with international 
best practice, summary anthropometry in this thesis is expressed mainly as z-scores. As will be 
described in detail in chapter 3, National guidelines recognised complicated and uncomplicated 
SAM but the study setting at the time had no separate outpatient centres for direct treatment of 
uncomplicated disease. Children with uncomplicated SAM were thus admitted and treated 
together with children who had SAM plus complications. 
 
1.2.6 Why case definition matters 
The reason for reviewing case definitions is to emphasise that each will select a slightly different 
group of patients. Since nutritional status is a continuum, diagnosing a discrete category of 
SAM is inevitably challenging. Though anthropometry is key, it is not anthropometry that 
matters most. What matters is that it reflects other more important processes and risks, notably 
risk of death (see figure). Declining weight-for-height is related to(26) but not synonymous 
with(17) increasing risk of mortality. Implications of newer SAM definitions will be discussed in 
chapter 6. For now, it is important only to note that findings based on one group should only be 
generalised to another with caution.  
 
Figure 4 Conceptual illustration of continuous processes and discrete categories in 'malnutrition' 
Shaded arrow indicates the progressive nature of the risks. The boxes indicate that for practical programme use, categories 
necessary. 
severe acute 
malnutrition 
normally 
nourished 
mild / moderate  
acute malnutrition 
well Moderately impaired physiology 
 increased disease vulnerability 
( appetite OK ) 
Severe impaired physiology 
 high risk of illness 
( appetite decreased ) 
Clinical 
status 
Nutritional 
status 
DEATH Risk of 
death 
 1.3 Treatment programmes for 
Approaches to SAM have
PhD fieldwork. To contextualise 
to different types of treatment programme, 
 
1.3.1 Conceptual frameworks and r
Ideal strategies for tackling SAM involve a range of approaches, with resources allocated in 
proportion to cost-effectiveness and impact. 
problem can be tackled at three
• Primary prevention
• Secondary prevention
  
   
• Tertiary prevention
  
These can also be understood using
 
Figure 5 UNICEF conceptual framework for malnutrition
(Source: State of the World’s Children 1998)
 
childhood SAM 
 evolved considerably over recent years, even over 
the research results in this thesis and their potential application 
this section gives an overview o
oot causes 
A public health perspective recognises that 
 levels(27):  
 = reducing the development (incidence) of SAM
 = reducing prevalence of SAM by earlier detection of or better 
 treatment shortening the duration of an episode of 
 malnutrition 
 = reducing the negative impacts of established SAM
 the UNICEF conceptual framework below:
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time spanning this 
f common strategies. 
the 
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1.3.2 The Pathophysiology of SAM 
Understanding the pathophysiology of SAM is key to optimising its treatment. Whilst some 
details remain to be elucidated (e.g. why kwashiorkor is more common in some populations 
than others; what is its exact cause(28)),  many features are well understood and help shape and 
guide treatment strategies. The main features of SAM  are outlined in detail in J.C.Waterlow’s 
authoritative book “Protein-Energy Malnutrition”(29) and are summarized from that source 
below: 
• “A child with SAM is not just a scaled-down version of a normal child and must be 
treated accordingly. 
• When deprived of ‘normal’ nutrition over a period of time, the body often ‘adapts’, 
to the new state with changes in metabolism, structure and organ function. 
• There is preferential loss of muscle, fat and probably of skin (tissues which in 
resting state have relatively low metabolic activity) whilst essential organs like the 
brain are relatively well preserved. 
• Electrolyte and mineral balance is often disturbed. e.g. serum potassium levels are 
low; total body sodium is high but there is a paradoxical tendency to serum 
hyponatremia (a very poor prognostic sign); serum and urine phosphorous is low 
• Anaemia is common (though different studies suggest different underlying causes) 
• There are adverse effects on organ structure and function: 
o Cardiac impairment: with corresponding risk of cardiac failure 
o Liver impairment: notably if there are fatty infiltrations (fatty liver is often 
associated with kwashiorkor but is also found in marasmus) 
o Reduced pancreatic enzyme production 
o Impaired gut function: due to a multiplicity of causes ranging from a 
damaged epithelium to disturbed gut microflora and leading to several 
effects including reduced absorptive capacity and weakened immune 
barrier function 
o Impaired renal function: including a reduced ability to excrete acid and 
sodium and a reduced ability to concentrate urine 
o Skin changes: most notably the ‘flaky paint dermatosis’ of kwashiorkor 
o Impaired nervous system structure and function (though the brain is 
relatively protected from nutritional adversity, it is important to note that 
the protection is not absolute) 
• There are important metabolic changes, including impaired capacity for heat 
production, with corresponding higher risk of hypothermia 
• Endocrine changes include: 
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o Those that reflect or determine short term issues e.g. impaired insulin 
function and impaired ability to manage blood sugars leading to risk of 
hypoglycaemia; increased glucocorticoid production 
o Those that influence long term growth e.g. thyroid hormone and 
somatomedin 
• Trace elements are often depleted and can contribute to poor overall outcomes e.g. 
selenium, zinc and vanadium(30),(31) 
• The immune system is impaired and contributes to greater vulnerability to 
infection; greater potential severity of infection; altered manifestations of infection 
(e.g. children with severe SAM may not be able to mount a febrile response as 
would be normal).” 
 
Treatment strategies, notably those pioneered at the Tropical Metabolism Research Unit in 
Jamaica in the 1970’s to 1990’s recognised and took account of these pathophysiological 
features. Excellent outcomes were achieved by a multifaceted approach which directly 
addressed the core problems e.g.: 
• Specially formulated feeds which take into account common micronutrient and 
electrolyte deficiencies as well as energy and protein needs 
• A ‘phased’ approach to treatment whereby a physiologically vulnerable child is 
first ‘stabilized’ before moving onto a more nutrient-dense ‘recovery phase’ diet 
• Careful rehydration to avoid fluid overload and potential death from heart failure 
• Routine antibiotics in light of the high infection risk 
 
This structured, pathophysiologically-informed approach was eventually taken up by the 
World Health Organization and became the basis of the “10 steps” treatment guideline 
described in the next section (see in particular table 2). 
 
The same pathophysiological understanding still underpins all current treatments for SAM. 
Since appetite is affected by and thus becomes a clinically useful proxy of the severity of 
pathophysiological compromise, it is one of the key clinical features used to assess children at 
admission to treatment. A poor or absent appetite reflects a vulnerable and sick child with 
complicated SAM (see figure 3) in need of intensive inpatient treatment and close monitoring.  
In contrast, an active appetite reflects a child with uncomplicated SAM: he/she may have 
anthropometrically defined SAM but is clinically stable enough to be considered for home-
based treatment. 
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1.3.3 Therapeutic & Supplementary Feeding Programmes (TFP & SFP) 
Therapeutic Feeding Programmes (TFPs) are the mainstay of current SAM treatment. They 
focus on established SAM (tertiary prevention), though in-programme activities such as health 
education may have secondary and primary preventive effects on SAM recurrence in the same 
family or community. The aim of a TFP is to minimise mortality and morbidity by restoring 
normal nutritional status.  
An important part of the TFP treatment package is a diet of therapeutic food. This is 
defined by a micro and macronutrient content specially formulated for SAM(9). As indicated by 
the pathophysiology of SAM, other treatments such as antibiotics for infection are also essential 
and are provided as routine. 
  
 Supplementary Feeding Programmes (SFPs) are closely related to TFPs but focus on 
moderate acute malnutrition (MAM). Similar to TFPs, they aim to restore normal nutritional 
status through provision of supplementary foods such as corn-soy blend. Numbers of children 
affected by MAM are considerably greater than by SAM and SFPs are thus important in their 
own right. Individual mortality risk is however lower, so the general approach is outpatient 
based and less intensive. Relevant to this thesis, SFPs serve two key roles: 
• In an ideal setting, SFPs would prevent severe wasting because they would enrol and 
treat children before their malnutrition becomes severe. (Pre-empting kwashiorkor 
would be more difficult given no clearly defined prodromal phase to predict which 
children will develop disease)    
• Following successful therapeutic treatment of SAM, children are often referred to an 
SFP. In this role, SFPs monitor continued wellbeing and aim to prevent relapse. If such 
a SFP ‘safety net’ is not present, some TFPs keep children enrolled for longer or adjust 
their discharge criteria to a higher weight-for-height target.  
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1.3.4  Inpatient TFPs – Therapeutic Feeding Centres ( Nutritional Rehabilitation Units) 
Traditionally, children with SAM are treated in inpatient TFPs called therapeutic feeding 
centres (TFCs) or nutritional rehabilitation units (NRUs). Focus is on case management of the 
individual patient. WHO’s 1999 guideline, “Management of severe malnutrition: a manual for 
physicians and other senior health workers” is a key resource describing the main features of 
TFC care(32). It is based on the pathophysiological understandings described in section 1.3.2. 
Phased treatment is central 
to the strategy. This 
recognises that children 
with SAM are vulnerable 
and often have very 
compromised physiological 
systems which need to 
recover slowly.   
Picture 1 Inpatient TFC in 
Malawi (the setting of this 
PhD research) 
 
 
Nutritional treatment in the ‘stabilization phase’ (also known as ‘phase 1’) uses ‘F75’ 
milk. ‘Rehabilitation’ or ‘phase 2’ progresses to more nutrient dense ‘F100’ milk feeds. Some 
protocols suggest an intermediary ‘transition phase’. 
F75 and F100 milks can either 
be:  
-  locally made using 
commonly available 
ingredients fortified with a 
micronutrient mix 
 - imported as a dry powder 
‘formula’ milk which needs 
reconstitution in heated 
water. 
 
 
Picture 2 Distributing therapeutic milk 
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Medical treatments in WHO 1999 include routine antibiotics for infection. 
Also recognised is the importance of environment and psychosocial interventions towards 
improving outcomes from 
SAM. 
 
Nutritional, clinical and 
psychosocial treatments are 
all integrated in what is 
often known as the “10 steps 
approach” (table 2)  
 
 
Picture 3 Distributing medical 
treatments for SAM 
 
 
 
 
Table 2 WHO '10 Step' treatment of SAM  
(source - WHO 1999)
(15)
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1.3.5 Community Management of Acute Malnutrition (CMAM)  
CMAM (originally and still often known as CTC, Community-based Therapeutic Care(33)) is an 
integrated TFP strategy which combines with and complements WHO (1999) by focusing on 
population coverage(18),(34). It aims to maximise public health impact by treating large numbers 
of SAM-affected children. The modified SAM classification is used to distinguish between: 
• Sick children (‘complicated’ SAM) who need intensive inpatient care  
• Clinically stable, well children (‘uncomplicated’ SAM) who can safely be treated at 
home  
Though community-based approaches to SAM are not new(35), CTC was the first to formalize a 
detailed strategy and framework(36),(18) Key features of the treatment model are(34): 
• Access & high coverage - Large numbers of treatment centres ensure easy  
    access and consequent high programme coverage. 
• Timeliness   - Active case finding aims to recognise and treat 
children before they develop complicated SAM. Most 
can thus be admitted to the ‘Outpatient Treatment 
Programme’ (OTP). The few with complicated SAM go 
via inpatient ‘stabilization centres’ (SCs). Once 
clinically improved/stable, they are transferred to the 
OTP to complete their treatment  
• Sectoral integration  - CTC aims to integrate with other programmes (such 
as supplementary feeding programmes) and address 
wider factors underlying malnutrition. 
• Capacity building  - CTC aims to empower and encourage local 
 communities, and existing structures and networks. 
The basic principles of CTC/CMAM have since been incorporated into numerous national SAM 
guidelines and in 2007 were 
endorsed by major UN 
agencies(9).  The structure of 
and ‘flow’ through a typical 
programme is illustrated:(37) 
   
 
Figure 6 Structure of and patient 
'flow' within a CMAM TFP  
(source Valid CTC Manual, 
2006)
(37) 
Default 
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1.4 RUTF (Ready-to-Use Therapeutic Foods) 
Efficacious therapeutic food is central to a successful TFP. Ready-to-Use Therapeutic Food 
(RUTF) is the generic term for a nutrient-dense solid or semi-solid food paste suitable for 
children with SAM. It is the key technology making CMAM possible. 
 
1.4.1 History & Development of ‘Standard’, peanut-based RUTF 
Non-milk diets for malnutrition have a long history(38). In the 1970’s for example, Red Cross 
emergency teams used milk biscuits. The emphasis, as today, was on a commodity providing 
high nutrient quality yet easy to transport, store, and eat without complex or time-consuming 
preparation.   
The RUTF currently in use is based on the nutrient profile of F100 milk, the current ‘gold 
standard’ diet for SAM(15),(9). (see table below). The commonest recipe comprises a peanut butter 
base (25% weight), full fat milk powder (30% weight), sugar (28% weight), vegetable oil (15% 
weight) and multivitamin/mineral mix (1.6%, including iron)(39). One of the earliest trials 
comparing this RUTF to F100 was in 1999 in Chad. Higher energy intake was observed in the 
RUTF group(40). Another study influencing subsequent practice was published in 2003. In 
Senegal, an open label randomised trial tested the RUTF against F100 milk. Weight gain and 
duration of nutritional rehabilitation were both 
significantly better in the RUTF group(41).  
 
Picture 4 Eating RUTF 
 
 
Table 3 RUTF nutrient profile 
Source: UNICEF/WHO/WFP joint statement, 2007 
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1.4.2 The potential role of alternative recipe RUTF 
Peanut-based RUTF (also widely known under the largest manufacturer’s trade name, 
Plumpy’nut) remains dominant in CMAM programmes worldwide. This reflects the rapid and 
recent evolution of CMAM. Much of the background research was conducted using the best 
known, best validated,  formulation described in Chad(40) & Senegal(41). As programmes have 
scaled up, so has the manufacturing capacity and demand for this same peanut RUTF. So 
however have questions about alternative recipes.  
Three issues underlie discussions about alternative RUTF recipes: 
 
i) Cost minimization 
RUTF is the main cost component(42) of a CMAM feeding programme. Cheaper but equally 
effective recipes would improve cost-effectiveness.  
 
ii) Local ownership & local benefits 
Peanuts are not as common or acceptable in all parts of the world as in the African countries 
where the peanut RUTF recipe was first developed and tested.  Alternative recipes based on 
staples such as rice, chickpea or soya have the potential to better support local needs and local 
markets(43),(44). Using local ingredients to benefit local economies and make locally tailored 
RUTFs was one of the original principles underlying CMAM.  
 
iii) Enhanced efficacy 
Alternative recipes have the potential to improve on the efficacy of current ones. This is the 
rationale behind addition of a functional food to standard RUTF in this thesis. 
 
 
 
1.4.3 A note on RUTF (Ready-to-Use Therapeutic Food) & LNS (Lipid Nutrient Supplement) 
terminology 
Since this thesis was started, interest in “Ready to Use foods” has blossomed. With the growing 
evidence-base underlining RUTF for SAM, investigators and programme managers have been 
quick to try other plausible uses. These include for supplementary feeding, for HIV and for 
primary prevention of malnutrition. Lacking alternatives, the RUTF recipe originally described 
for SAM has been used for all these purposes. RUTF should however have a very precise use 
and meaning as a therapeutic food for SAM alone – this is how it is used in this thesis. 
Expanded uses do though need to be recognized. This is because functional additives, as 
explored in PRONUT may be relevant to conditions other than SAM. 
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“Ready-to-Use” food is a generic term, subsets of which include: 
• RUTF = ready-to-use THERAPEUTIC food – for SAM 
• RUSF = ready-to-use SUPPLEMENTARY food – for MAM 
• RUCF = ready-to-use COMPLEMENTARY food – for general use as a 
complementary food or for preventing malnutrition 
• RU_F-H = any of the above for HIV 
Ideally these would all be tailored to the particular needs of their patient group. Such work is 
ongoing.  
Lastly, lipid-nutrient supplement (LNS) nomenclature needs to be noted as its use is 
increasing. LNS are defined as multiple micronutrient supplements which have lipid as the 
primary source of energy(45). RUTF described in this thesis is therefore a type of LNS. 
 
 
 
1.5 Evidence gaps towards improved feeding programme impact 
 A 1996 review of SAM treatment outcomes reported case fatality rates averaging 20-
30% and sometimes as high as 50-60%(46). WHO 1999 guidelines were part of a successful 
international initiative addressing the problem(47),(48).  CMAM programmes have continued to 
build on this success and report data supporting both low mortality and high programme 
coverage(49). Given this existing evidence base for SAM treatment, some have argued that 
rollout of existing technologies and interventions should now be the international health 
priority(50, 51). In this thesis, I fully agree with that sentiment. I would add however that scaling-
up what is known is not incompatible with exploring what is not known. Knowledge gaps with 
potential to improve public health impact remain and are the motivation behind the work 
described.  
 
1.5.1 What is the true public health impact of a TFP? 
Most TFPs report outcomes when children are discharged from their care, typically after 2-3 
months treatment. Good outcomes at this stage are important but not necessarily sufficient. 
True public health impact depends on sustained, longer term benefit. Illustrating with an 
extreme hypothetical example: 
 - Programme A has a 5% short term, in-programme mortality. Yet if a further 50% of children 
die over the subsequent year, there is an obvious problem. This would not necessarily be 
identified through routine reporting. Many TFPs have neither the systems nor resources for 
long term follow-up. 
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- Programme B has a 30% in-programme mortality. Yet if only 5% of the survivors subsequently 
die, then the public health impact is actually greater than in A. 
To date, few studies have explored long term outcomes following an episode of SAM. The 
FUSAM sub-project addresses this issue. Consistency with and differences from this limited 
body of existing research will be discussed in chapter 6. 
 
1.5.2 Can poor outcomes in an HIV prevalent setting be improved? 
HIV is well recognised as having a major impact on both presentation and outcomes from 
SAM(52). A recent meta analysis shows mortality among HIV infected children with SAM to be 
consistently and significantly higher than in those without underlying HIV. (30.4 vs. 8.4%, RR = 
2.81, 95% CI 2.04—3.87)(53). Interventions with the potential to improve SAM outcomes in HIV 
prevalent settings are therefore important(4): PRONUT describes the potential of functional food 
to fulfil this role.  
Second, improving SAM outcomes in an HIV prevalent setting requires better 
understanding of factors, apart from the HIV itself, which are associated with good or adverse 
results. FUSAM addresses this question.  
 
1.5.3 Is there potential for RUTF enhanced by functional food to improve TFP outcomes? 
There is increasing international interest in the claim of ‘functional foods’ to confer “health 
benefits beyond the provision of essential nutrients.”(54),(55),(56),(57). The PRONUT sub-study 
explores the effect of: 
• Probiotics - “A preparation of, or a product containing, viable, defined 
microorganisms in sufficient numbers, which alter the microflora in a compartment 
of the host and by that exert beneficial health effects.”(58)   
and  
• Prebiotics - “a non-digestible food ingredient that beneficially affects the host by 
selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon.”(58).  
Recognising different but potentially synergistic effects, preparations of pre and probiotics 
together are termed “Synbiotics”(58).  
For some conditions like diarrhoea, evidence of functional food effect is strong and 
based on high quality evidence, notably meta-analysis of randomized controlled trials(59),(60). 
Most research however focuses on high income developed countries - where product sales are 
high, some $16 billion USD per year for probiotics alone(61). Few studies are set in low income 
developing nations - where it is SAM and preventable mortality that are high(62). This represents 
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an important research gap. There are several reasons, all underpinning the PRONUT study, 
why functional foods may have a role in the treatment of SAM:  
 
i) Likelihood of benefit via known mechanisms of action 
 In other patient groups, probiotics and prebiotics are known to have several effects, 
including: 
• Probiotics preventing diarrhoea (reducing incidence): in 2006 meta-analysis, diarrhoea 
of diverse causes was reduced by 34% (95% CI 8% to 53%) and antibiotic associated 
diarrhoea by 52% (95% CI 35% to 65%)(60).  
• Probiotics for treating diarrhoea (reducing adverse impact and prevalence): the authors 
of a 2004 Cochrane review concluded that “Probioics appear to be a useful adjunct to 
rehydration therapy in treating acute, infectious diarrhoea” (59). The evidence 
underpinning this statement was: reduced risk of diarrhoea at 3 days (relative risk 0.66, 
95% CI 0.55 to 0.77); reduced duration of diarrhoea by a mean of 30.5 hours (95% CI 
18.5 to 42.5 hours).  
• Prebiotics can promote a healthy gut flora: encouraging the growth of ‘good’ organisms 
and competitively excluding potentially pathogenic ones(63);  
• Probiotics can directly and indirectly modulate the immune system(64). They do this at 3 
levels: general (producing nutrients and anti-oxidants); humoral (stimulating IgA 
production; inhibiting IgE production; modulating cytokine responses); cellular 
(stimulating macrophage and natural killer cell function and promoting growth and 
regeneration)   
It is biologically plausible that these benefits shown in other patient populations would also 
apply to children with SAM. The actions are certainly relevant to SAM, in which the following 
are common problems: 
• impaired gut function, manifest as  diarrhoea and malabsorption(65),(66);  
• small bowel overgrowth(67);  
• increased intestinal permeability(68),  
• enteropathy(69);  
• gram negative (enteric) bacteraemia(70),(71);  
• suboptimal immune response(72),. 
 
ii) Potential for public health impact 
 Because CMAM programmes focus on high coverage(34) improved RUTF with even 
modest benefits to individual patients could translate to very substantial impacts at public 
health level. 
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iii) Concerns about probiotic use in immune compromised populations 
 Because of the small risk of probiotics causing invasive infection(73), caution is 
sometimes recommended in immune compromised patients(74). Better risk-benefit data is vital: 
the most vulnerable, most immune-suppressed children with SAM(75) and with HIV(76) are also 
those most needing therapeutic improvements.  
 iv)  Availability of a ‘delivery vehicle’ for functional additives: Ready-to-Use Therapeutic Foods (RUTF)  
 RUTF is a high energy, nutrient dense paste, formulated to WHO standards for the 
treatment of SAM(41). It is used in almost all CMAM programmes.  As the product is 
manufactured in food processing factories and packaged in hermetically sealed containers, 
inclusion of functional additives to the standard RUTF recipe can be readily achieved and has 
potential for large-scale rollout in feeding programmes. 
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Chapter 2 
Aims & Objectives 
 
 
2.1 Hypotheses 
In the two studies described in this thesis, two key factors influencing SAM mortality in a treatment 
programme are explored: 
 
i) Treatment efficacy 
Therapeutic food is a key intervention in a treatment programme for SAM. Improved 
therapeutic food therefore has the potential to improve outcomes.  
Hypothesis arising:  
i. In an HIV prevalent setting, addition of a pre/probiotic functional food (Synbiotic 2000 
Forte™) to a standard diet of Ready-to-Use Therapeutic Food (RUTF) will improve 
outcomes from an episode of SAM. 
 
ii) Patient characteristics 
If intervention efficacy is held constant or cannot be further enhanced, programme outcomes 
might still be improved by addressing patient-related risk factors. Understanding the impact of 
characteristics like nutritional status at admission, clinical status, family and socio-economic 
status will enable future programmes to better plan and respond to patient needs.  
Long term outcomes are of particular relevance since these best reflect the true public health 
impact of treatment. (i.e. minimizing long term mortality and morbidity are the most important 
programme goals but may not necessarily be reflected by short term, in-programme outcomes)    
Hypotheses arising:  
i. Short term and medium term outcomes, as routinely reported by therapeutic feeding 
programmes, adequately reflect long term outcomes following an episode of SAM  
ii. Post-SAM catch up growth is complete and comparable to family (sibling) controls 
iii. a.  Common risk factors underlie both short and longer term mortality  
b. Access to post-SAM treatment services (supplementary feeding for all children and 
TB / HIV services as clinically indicated) is associated with improved long term 
outcomes  
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2.2 Aims & Objectives 
 
2.2.1  Study 1 – PRONUT (Pre and PRObiotics in the treatment of severe acute malNUTrition) 
Aim 
To determine the efficacy of a probiotic/ prebiotic functional food (Synbiotic2000 ForteTM) for 
improving clinical and nutritional outcomes from SAM in a HIV prevalent setting 
 
Objectives:  
To determine whether addition of Synbiotic 2000 Forte™ to a standard Ready-to-Use Therapeutic 
Food (RUTF) diet will result in: 
i. A greater proportion of children achieving nutritional cure following SAM 
ii. Reduced mortality from SAM 
iii. Improvements to other programme-relevant clinical and nutritional  outcomes: 
a. less readmissions; less nutritional failures  
b. improved weight gain;  
c. shorter length of stay in-programme;  
d. less diarrhoea and other clinical problems  
 
 
2.2.2  Study 2 – FUSAM (Long term Follow-up after an episode of Severe Acute Malnutrition) 
Aim 
To describe long term (≥ 1 year post-discharge) mortality & morbidity following an episode of SAM 
Objectives:  
i. To describe the occurrence and timing of in-programme and post-treatment deaths 
following an episode of SAM   
ii. To describe the extent of catch-up growth in the year following an episode of SAM 
iii. To identify risk factors for mortality from SAM:  
a. Risk factors at original admission 
b. Risk factors related to post-SAM care 
c. To determine whether risk factors for short term mortality are similar to 
those for late deaths 
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Chapter 3 
Setting, participants & methods 
 
3.1 Setting 
3.1.1 Malawi, the warm (but malnourished) heart of Africa 
The research described in this thesis was set in MOYO (= ‘life’ or ‘health’ in the local language, 
Chichewa) therapeutic feeding ward, Queen Elizabeth Central Hospital, Blantyre city, Blantyre 
district, Malawi. Malawi is a densely populated, landlocked country whose 2008 GDP per capita of 
$800 (purchasing power parity basis) ranks it 220th of 229 countries(77).. Of 13.9 million people, 85% 
live in rural areas and work predominantly as smallholder farmers(78). Climate is sub-tropical with a 
rainy season lasting from approximately November to May each year. The staple crop, maize, is 
planted near the beginning of the rains and harvested around the time rains end.  
Often and aptly described as “The Warm Heart of Africa”, Malawi also has a less welcome 
reputation for high prevalence of malnutrition. The 2004 Demographic & Health survey reports: 
• 22% of under-5 children are underweight 
• 48% of under-5 children are stunted 
• 5.2% of under-5 children are wasted & 1.6% are severely wasted 
Consistent with this poor nutritional status, 
under-5 mortality is 133/1000 live births. 
The number of children affected by SAM 
regularly peaks during the rainy season 
(also the ‘hungry’ season) when:   
- many families have to ration what little 
food is still left over from last year’s harvest. 
- incidence and prevalence of water related 
diseases like malaria and diarrhoea peaks.  
Together, these result in adverse nutrition-
infection interactions(79) and exacerbate 
already prevalent background malnutrition. 
  
  Picture 5 Map of Malawi, showing Blantyre
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3.1.2 Therapeutic Feeding Programmes in Malawi 
For many years, Malawi had a network of about 92 NRU-style inpatient therapeutic feeding 
programmes. A poor harvest in 2001 was one of several factors resulting in a 2002 ‘famine’(80). This 
renewed focus on tackling SAM. 
In 2003, new national guidelines were developed, based on the WHO(1999) NRU model of 
care. Ministry of Health, UNICEF and international NGO Action Against Hunger were key players 
in a major national strategy of guideline dissemination, training and quality improvement.  
Around 2003, some of the earliest community-based approaches to SAM were also being 
developed in Malawi. A locally manufactured RUTF had been successfully produced and validated 
– two key projects actually based in MOYO(81),(82). Operational research in central region was 
pioneering the outpatient-based model of care central to CMAM(83). This growing evidence-base, 
backed by inspired national and international leadership, resulted in Malawi being one of the first 
countries to adopt a national CMAM strategy(25). 
The shift from NRU-style to CMAM-style TFPs led to many programmes having to adapt 
and evolve. MOYO was among those changing its approach to SAM. It illustrates a typical 
transition process:(84)   
• Up to 2003, care was fully inpatient based;  
• In mid 2003; outpatient-based rehabilitation began, but with children returning to 
MOYO rather than to a local OTP for review and RUTF collection;  
• Just prior to this PhD, RUTF replaced F100 milk in transition phase.  
• In mid 2008, (after PRONUT had finished but whilst long term FUSAM visits were 
still under way) a full CMAM programme began in Blantyre district, continuing the 
transition towards outpatient / public health focused treatment. 
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3.1.3 MOYO nutrition ward, Department of Paediatrics, Queen Elizabeth Central Hospital, 
College of Medicine, Blantyre. 
‘Moyo’ nutrition ward for children with SAM is one of several paediatric wards of Queen Elizabeth 
Central Hospital, Blantyre. Queen’s is the clinical base for the College of Medicine, Malawi’s only 
medical school. As a teaching hospital, Queen’s is also a tertiary referral centre. However, though 
the clinical and diagnostic expertise is greater than elsewhere in the country, there is not always 
significantly more that can be offered in terms of medical treatments. Certainly for SAM, the clinical 
caseload is thus more typical of a large district hospital than a tertiary referral centre†. According to 
the 2008 National Census, the district served comprises an:  
• Urban Blantyre population of 661,444  
• Rural Blantyre population of 338,047 
The network and distribution of health centres 
in Blantyre district is shown opposite. Two 
also have attached inpatient NRUs which 
share the SAM caseload with MOYO. 
Numbers admitted to these are small in 
comparison.  
Most malnourished children present either 
direct to Queen’s or arrive via local health 
centres after initial assessment by community-
based health workers. 
Queens and Moyo are part of the government 
health service and all services are provided 
free of charge. 
 
Figure 7 - Map of health centres and their 
catchment areas in Blantyre district 
(source: M.Kerac, from ArcView files obtained from the  Malawi National Spatial Data Centre, Lilongwe) 
The approximate area of urban Blantyre is outlined in grey. 
Approximate scale of this map at the widest points is 80km North-South and 40km East-West 
 
                                                 
†
 The only exception to this are very small numbers of post-surgical patients referred to MOYO for nutritional 
support.  
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3.2 Study participants: the MOYO case definition of SAM 
All patients admitted to MOYO nutrition ward were eligible for the PRONUT study and later for 
FUSAM. Following Malawi National Guidelines(25) and consistent with international guidelines(9), 
the MOYO  admission criterion and case definition of SAM was: 
• Weight-for-height <70% of median (NCHS reference)  
or 
• Mid-Upper Arm Circumference (MUAC) <11cm 
or  
• Kwashiorkor (oedematous malnutrition) 
 
CMAM was only started in Blantyre district in 2008, so the distinction into complicated or 
uncomplicated SAM was not applicable. All patients identified as having SAM were admitted for 
initial inpatient treatment (see discussion, chapter 6 for generalizability implications). Also 
sometimes admitted were a small number borderline SAM cases: mostly high risk children such as 
those rapidly dropping down growth chart centiles or HIV positive and sick. 
 
 
Picture 6 MOYO nutrition ward, Queen Elizabeth Central Hospital, Blantyre, Malawi
  Page  43 
ACCIDENT & EMERGENCY: 
Initial Assessment 
Not malnutrition 
 
Sent to other 
paediatric ward or 
home as appropriate 
Severe Acute 
Malnutrition 
 
Severe Acute 
Malnutrition 
but very sick, 
needing intensive 
nursing  
 initially admitted to 
‘Special Care’ ward 
then transferred to 
MOYO once stable 
 
 
MOYO 
nutrition ward 
 
(Severe Acute 
Malnutrition) 
but initially missed 
or develops during 
time spend on 
another ward 
 sent to MOYO for 
assessment and 
possible transfer 
 
3.3 Study participants: the MOYO patient care pathway 
 
3.3.1 Admission routes to MOYO 
All children presenting to Queen’s hospital were first seen in the Accident and Emergency (A&E) 
area. Here they were assessed, triaged and referred according to clinical indication: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 Admission routes to MOYO nutrition ward  
The thick line represents how most children are admitted to MOYO, dotted arrows represent occasional cases 
 
Initial assessment in A&E included routine weight and clinical assessment, looking specifically for 
oedema or visible wasting. Most SAM was thus identified and referred direct to MOYO. Borderline 
cases of possible SAM were frequently sent to MOYO for definitive assessment: weight-for-height, 
MUAC and oedema. Small numbers of patients arrived on MOYO via other paediatric wards. 
 
3.3.2 Initial assessment and treatment in MOYO (including anthropometry) 
This comprised: 
i) Anthropometry 
Measurement of weight, length and MUAC followed research standards(85).  (see 3.6.1 for details) 
ii) Clinical assessment 
Every patient was assessed by a MOYO clinician as soon as possible after admission. If admitted 
out-of hours, core details would be taken by the nurse in-charge or on-call doctor and full details 
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completed the next day. This allowed important urgent treatment to be started immediately (e.g. 
second or third line antibiotics) 
iii) Early feeds whilst awaiting assessment 
All children arriving on MOYO would be given an early feed of F75 milk. This was to minimise any 
risk of hypoglycaemia whilst awaiting assessment and admission to the main ward.  
 
3.3.3 Inpatient treatment 
This comprised two main treatments delivered in parallel according to clinical indication:  
a)  Nutritional treatments 
The quantity of therapeutic feeds, both milk and RUTF was adjusted according to the child’s weight 
using standard charts in the national guidelines. 
i) Stabilization phase (Phase 1) 
All children were initially fed F75 therapeutic milk given every 3 hours, including overnight. This 
“stabilization” phase lasted a minimum of 1 night.  
ii) Transition phase (Tr) 
Criteria for progression to transitional feeds were clinical improvement and return of active 
appetite, defined as easily finishing the prescribed volume of F75 milk (as reported by main carer).  
Consistent with new CMAM guidelines(37) but slightly different to WHO guidelines (which 
recommend F100 milk for transitional phase), Ready-to-Use Therapeutic Food (RUTF)(41) was 
introduced to the diet at this stage. A full RUTF prescription provided 200 kcal energy, per kg body 
weight, per day. For a 7 kg child (median NRU admission weight) this was approximately 300g 
RUTF/day. Recognising that not all children would be able or physiologically ready to eat the entire 
RUTF target amount at this stage, F75 was continued. Mothers were instructed to give initially 
small amounts of RUTF (e.g ½ teaspoonful every 3 hours, alongside the milk ration) and to 
gradually increase that amount as guided by the child’s appetite. As a guide to what the full target 
amount should ultimately be, they were each given a small ‘ticket’ with the number of RUTF pots 
per day pictured, plus the same amount expressed as teaspoons per 3 hours. Feeding instructions 
stressed that mothers should never to try to force the child to eat beyond what he/she demanded.  
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Similar to phase 1, Tr lasted for a minimum of 1 night. (see appendix D for MOYO guidelines 
on phase progression).  
iii) Rehabilitation phase (Phase 2) 
Active appetite reflects clinical improvement and again was the main criterion for moving forwards 
from transition phase. When easily eating at least ¾ of his/her RUTF target ration, a child had by 
definition moved him/herself onto phase 2 and hence this was a much more child / physiologically 
led process - in contrast to traditional phase transition, when the in-change clinician made the 
decision when the child was ready to move to phase 2. As long as clinically also well at this point, 
the child was ready for transfer to home-based rehabilitation at the next available opportunity 
(discharges from the ward were done twice a week).  
During phase 2, free fluids and other foods (e.g. likuni phala – a popular local brand of maize-based 
porridge fortified with micronutrients) were also allowed alongside the RUTF. F75 milk was 
stopped at this stage.  
b) Clinical treatments 
These were given according to clinical indication and again followed standard guidelines. At 
admission, all children had a PCV (packed cell volume, testing for anaemia) and thick film testing 
for malaria. Transfusions were rarely done: usually only in cases where anaemia was both very 
severe and clinically symptomatic. 
All children had empirical antibiotic treatment with co-trimoxazole. In cases of presumed 
sepsis, 2nd or3rd line antibiotics were also used. These are described in detail in chapter 4.2.4.  
 
3.3.4 OTP (Outpatient) treatment 
Once clinically well and on phase 2 feeds, children were transferred from ward-based care to 
outpatient care, to complete their nutritional rehabilitation at home. They took home sufficient 
RUTF rations and any other treatment needed (e.g. finishing a course of oral antibiotics) 
At fortnightly intervals, they attended outpatient clinics at MOYO for clinical review and to 
collect further rations of RUTF. During the study, transport money was reimbursed to minimise 
defaulting. 
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3.3.5 Discharge from MOYO TFP 
Clinical cure was defined as 2 consecutive visits above or at the target weight of 80% WHM. 
Minimum time spent in OTP to successful cure was thus 4 weeks (=2 fortnightly visits). On rare 
occasions when a patient had lost weight since last visit but was still >80% WHM, he/she would still 
be diagnosed cured but would be brought back for an extra OTP visit to ensure good subsequent 
progress. 
Maximum time on OTP was 10 weeks (=5 fortnightly visits). If still below target weight 
(two consecutive visits at >80% WHM) by this time, a child would be deemed a ‘nutritional failure’ 
and referred elsewhere for further treatment. The commonest reason for such onward referrals was 
HIV or disability. In most such cases nutritional failure was expected and the patient was referred 
well in advance of final OTP visit so that transfer to follow-on services should be quick and smooth. 
 
3.3.6 HIV & CD4 testing  
Prevalence of HIV on MOYO was over 40%, compared to a national NRU average of 24%(86).  
HIV counselling and testing was considered a key element of good patient care and was a 
routine part of ward protocols. An opt-out policy was operated whereby all patients and their 
carers were offered a test as soon as the child was stable enough to visit the upstairs office where 
testing was done. This service was provided by a dedicated team separate to MOYO clinical and 
study staff.  
Testing protocols involved two ELISA rapid tests (Determine® and Uni-GoldTM), with a 
third (Hema StripTM or SD-Bioline) for discordant results. With carer consent, results were stamped 
in patient notes and made available to the clinical team in order to guide treatment and facilitate 
further referrals as needed. PCR for definitive diagnosis in children <18 months of age was 
unavailable. In such cases, cotrimoxazole antibiotic prophylaxis was always started on a 
presumptive basis if a child was ELISA seropositive. Advice was given about the need for repeat 
testing at >18 months age to get a definitive diagnosis. More complex clinical decisions - such as 
whether to start antiretroviral medication - were made on a case-by-case basis. This happened if 
other problems such as TB had been excluded or treated yet a child continued to deteriorate. The 
timescale for such interventions was almost always after the patient had been discharged from 
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MOYO care. Hence it was not relevant to PRONUT results and only relevant to very small numbers 
of children in the FUSAM study. 
In around November 2006, CD4 testing became available via a separate project running in 
MOYO ward. Being part service provision, part operational research to help guide appropriate 
referrals to HIV-related treatments, only HIV positive patients were tested. Testing was done at the 
first outpatient visit so that results would be back for the second visit. Patients who died before first 
visit would thus have no CD4 result available. 
  
3.3.7 HIV treatment  
The key reason for opt-out testing of children and carers was to facilitate timely referral to HIV 
treatment services. HIV seropositive patients were treated according to national protocols. These 
included referral for antiretroviral (ARV) medication based on clinical staging criteria (notably 
persistent malnutrition despite treatment) and CD4 count if available. An ARV waiting list at the 
time of the PRONUT study meant that additional inputs rarely started during initial nutritional 
treatment.  
 All HIV positive patients were started on long term co-trimoxazole prophylaxis as soon as 
diagnosed.  
 
3.3.8 Other TFP-related services: SFP, TB, disability 
Keeping patients monitored and acting as a safety net to prevent nutritional relapse, all patients 
discharged from MOYO were referred to their nearest supplementary feeding centre for a further 4 
months supplementary feeds. These were located at health centres distributed throughout the 
district. SFP programmes used fortified corn-soy blend. 
  Other common referrals from MOYO were to TB and disability services. These gave specific 
support and treatment following relevant protocols. 
 
3.3.9 Patient flow summary & cohorts enrolled in PRONUT & FUSAM 
The flow chart on the next page summarises patient flow through the SAM treatment programme. 
Possible outcomes at each stage are shaded light blue. PRONUT focuses on medium term outcomes 
as reported by most field programmes. FUSAM describes long term outcomes from the whole 
cohort of patients originally admitted to the ward.  
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Figure 9 Flow chart overview of SAM treatment with short, mid and long term outcomes 
* Default is frequently cited by field programmes, but it is not definitive in the same way other outcomes. It is 
the outcome cited when no other can be determined. Common reasons for default include death or clinical 
improvement, so that the carer perceives no reason to return for further formal follow-up. 
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3.4 Methods: quality control systems 
Several aspects of study methodology are specific to either PRONUT or FUSAM and are described 
in their respective chapters. Common to both studies are quality control systems described here: 
 
3.4.1 Anthropometry 
High quality anthropometry is important for nutrition-focused research. For both PRONUT and 
FUSAM the following equipment was used and measures taken to optimise data quality: 
a) Weight measurement - scales 
Children were weighed naked (or with underclothes only for older children) on Tanita 1582 
digital scales accurate to 20 grams. These were portable enough for inpatient and OTP use in 
PRONUT and also for field-based measurement in FUSAM. Calibration was checked every day 
using 2.3kg and 5kg reference weights. 
b) MUAC measurement – insertion tape 
  MUAC was measured to the nearest 1 mm using insertion tapes procured by UNICEF. The 
same tapes were used for both PRONUT and FUSAM. 
c) Length/height measurement – length/height boards 
For PRONUT, this was measured to the nearest 1mm using specially adapted locally made 
length boards (see picture below – the tape measure has a clear window with red line marking 
exact length). For simplicity, only length was measured for all children. In the final study database 
children >2 years (whose reference tables are based on height), the length measurement taken on 
MOYO was converted to height by subtracting 0.5cm(15). 
 
 
 
 
 
 
 
 
 
 
 
Picture 7 MOYO length board 
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The MOYO height board was not portable and could not be used for FUSAM field visits. For these, 
a “Leicester Height Measure” (Harlow Healthcare) accurate to the nearest 1mm was used to 
measure standing height for children ≥2 years. Lengths of children <2 years old was measured 
using a Dunmow length mat (Harlow Healthcare). Data collection forms noted whether length or 
height was measured and where needed corrections could be made. 
d) Age assessment 
Age is a key independent variable, and is also critical to calculating anthropometry z-scores. To 
minimise errors, study questionnaires asked age and date of birth as separate questions. If answers 
were inconsistent, further details could be asked and true age determined with greater accuracy. 
e) Repeat measurements 
PRONUT followed research standard protocols whereby trained observers measured in pairs(85). If 
within set agreement limits, the mean of the two measurements was taken as correct. Otherwise, 
both observers would re-measure until their agreement was acceptable. Criteria for repeating were: 
• Their two MUAC measurements differ by >5mm 
• Their two length measurements differ by >7mm 
• The measured length decreased since last measurement 
• Length or MUAC increased by >20mm since last visit 
f) The MOYO chart 
To aid correct classification of weight-for-height/length into SAM or non-SAM, a low cost “MOYO” 
slide chart was developed(87). This replaced the traditional weight-for-height/length lookup table 
and is described in detail in 
appendix K (PhD Research 
articles). One feature of the 
MOYO chart was a focus on 
target weights for discharge 
rather than overly frequent 
weight-for-height/length 
recalculations. 
 
 
 
Picture 8 The MOYO chart 
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3.4.2 Patient records systems 
To enhance both study and routine data quality, several modifications were made to MOYO’s 
patient records systems. These included: 
• More detailed entries to admissions and outpatient registers; 
These provided information backup in case of lost files and also facilitated quick cross-checking 
as needed (e.g. to identify details of a previous admission). 
• Training and supporting MOYO staff on the importance of good data management;  
• Filing patient notes by sequential admission number rather than discharge date as had 
previously been done. This change alone was a key factor in low losses to follow-up for 
both PRONUT and FUSAM. Filed 
according to the new system, it 
was much easier to identify 
missing files; easier to refer to 
previous admission episodes; 
easy to find and organize old 
notes for FUSAM long term 
follow-up. 
Picture 9 (right) The purpose made filing 
system for MOYO patient records.  
Folders were colour coded: blue for PRONUT 
patients; yellow for those not enrolled in 
PRONUT; red for inpatient deaths; orange for outpatient deaths. For data protection, the cabinets were locked 
and kept on the ward. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pictures 10 (above) Old filing system – by discharge date 
Picture 11 (right) New filing system – by admission number
3.4.3 Patient held records
All children in Malawi were expected to have a health passport documenting health events such as 
immunizations, growth and clinical visits. 
routine MOYO care. A rubber stamp (see below) was designed to enable key information to be 
easily and quickly recorded: admission anthropometry; admission diagnosis; target weight; HIV 
  
 
3.4.4 Staff training and supervision
The budget for PRONUT included funding for extra
2 nurses; 1 homecraft worker (responsible for therapeutic food preparation)
(secondary school graduates responsible f
general ward tasks). Staff 
versions of the study forms. 
members of the MOYO team
and anthropometry measurement. During the study, they were directly supervised by MK, the 
 
 
Use was made of this ‘health passport’ to document 
status (coded as “EL
NR(non-reactive)) to protect privacy 
whilst simultaneously ensuring 
clinicians were aware and could thus 
offer appropriate treatments); details 
of other relevant conditions such as 
TB; details of progress at OTP review 
clinics; details o
Whilst designed to enhance routine 
clinical care, the MOYO stamp also 
benefitted 
‘backing up’ key information and 
enabling cross checks to be made 
when recording patient id number or 
anthropometry
paperwork
Picture 12 MOYO stamp in patient
health passport
 
 clinical staff. These
or detailed completion of study questionnaires as well as 
received training prior to study start and h
All were expected to contribute to routine ward 
. They alone however were responsible for study
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ISA” R(eactive) or 
f treatments given. 
quality of research data by 
 on separate study 
.  
-held 
 
 included: 1 clinical officer; 
; 3 patient attendants 
elped feed back on pilot 
duties alongside other 
-related paperwork 
study principal investigator. 
identified and discussed with the responsible st
FUSAM fieldwork was done by 3 senior nurses, supported by the study driver. This meant 
that appropriate clinical assessment, advice, and where necessary simple immediate treatment 
could be given. It was as important that these visits be of clin
benefit to the study. Again all 3 nurses had regular clinical duties and had a rota to take time off to 
do FUSAM visits. Returned forms were checked and quality controlled by a study co
fellow paediatrician, GC. 
 
 
3.5 Methods: the ‘verbal map’ and 
Home follow-up was important for both:
• PRONUT - being able to trace defaulters and find out whether they were alive or dead. 
• FUSAM - being able to determine long term outcomes.
It was made possible by using a ‘verbal map’ 
previous study(84). During their original admission, consenting patients provided detailed 
instructions how to reach their home location. An example of a typical (fictional) map is: 
“At Bangwe township, turn left just before the Kandodo supermarket minibus stop. Go 
straight along the dirt road until you get to the Pentecostal Church. Just opposite the 
entrance of the Church there is a group of charcoal sellers. Ask them for Mr Banda, 
he will show you the family home, which is just 5 minutes walk away”
 Taking an effective verbal map was helped by a physical map held on the ward. This 
showed Blantyre district villages, trading centres and schools, and enabled staff to record a help
description of local landmarks en route to the patients’ home.
 
Study forms were regularly checked. Problems or inconsistencies 
aff member. 
ical benefit to the patient as of research 
 
patient follow-up 
 
 
system which had been successfully used in a 
 Finally, some patients were given a 
lift home by the MOYO driver. 
This allowed GPS coordinates to 
be taken at the house, again 
making it possible to find the 
residence in the future.
 
 
Picture 
Blantyre district map
locate patients’ home locations
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were 
-author and 
 
 
and 
 
ful 
 
13 Close up detail of the 
 used to help 
 
Picture 14 Blantyre district map (full version)
The overlay grid helps locate 
10km x 10km. The smaller grid being held up is 1km x 1km (the thin lines are not visible on this picture, 
though row numbers and column letters can be seen)
 
 
 
 
3.6 Ethical Approval
The PRONUT study was first
(COMREC) in 2005. Initial plans had been to base the study
Malawi.  Updates to the protocol
2006.  
FUSAM was granted initial approval as an extension to the PRONUT study in mid 2007. 
Final approval was granted in 2008
(please see appendix C for letters from the Ethics committee)
 
 
the exact location of patients on the map. The large grid (visible blue lines)
. 
 
 approved by College of Medicine Research & Ethics Committee 
 in a CMAM programme in central 
, including the change of setting to MOYO 
 after UNICEF funding was confirmed
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 is 
were approved in late 
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Chapter 4 
‘PRONUT’ Study 
 
4.1 Aim 
To determine the efficacy of a probiotic/ prebiotic functional food (Synbiotic2000 ForteTM) for 
improving clinical and nutritional outcomes from SAM in a HIV prevalent setting 
 
4.1.1 Objectives:  
To determine whether addition of Synbiotic 2000 Forte™ to a standard Ready-to-Use Therapeutic 
Food (RUTF) diet will result in: 
i) A greater proportion of children achieving nutritional cure following SAM 
ii) Reduced mortality from SAM 
iii) Improvements to other programme-relevant clinical and nutritional  outcomes: 
a. less readmissions; less nutritional failures  
b. improved weight gain;  
c. shorter length of stay in-programme;  
d. less diarrhoea and other clinical problems  
(please see also chapter 2, for underlying rationale and hypothesis) 
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4.2 Methods 
4.2.1 Study design 
PRONUT was a double blind, randomized controlled efficacy trial. 
 
4.2.2 Setting & participants 
MOYO nutrition ward and its patient profile has been described in chapter 3 of this thesis. All 
children admitted to MOYO were eligible for recruitment following written informed consent 
To detect a possible subgroup effect, we made a-priori plans for a major secondary analysis. 
This subgroup excluded small numbers of children aged <6 or >60 months(88); those with very low 
weight (<4kg); cerebral palsy; an obvious dysmorphic syndrome; SAM secondary to major surgical 
problems; moderate acute malnutrition (MAM) with complications. Uniting this subgroup was a 
plausible biological reason why each ‘type’ of child may not respond so well to a feeding-centred 
intervention - e.g. children with disabilities often have growth curves different to those of their 
peers(89). The age range was chosen so as to be consistent with standard nutrition reporting and thus 
comparable with other studies. The 4kg cut off is often used as a proxy for age <6 months so again 
was excluded here for comparability with other studies(90). 
 Another secondary analysis explored a post-hoc hypothesis that Synbiotic benefits would 
be greatest in children during the outpatient phase of SAM treatment. This did not arise from 
multiple ‘data trawling’ post-hoc analyses, but follows logically from the original version of the 
PRONUT protocol. PRONUT was originally designed in 2004 and was initially set in Dowa district, 
Malawi which has an outpatient-based CMAM-style therapeutic feeding programme. In the 
original protocol, only outpatients were to be recruited. At the time, this equated to RUTF feeds 
(inpatient rehabilitation care used mainly F100 therapeutic milk). Due to logistical issues, the study 
was moved to its actual location of Moyo ward, Blantyre, in late 2005. By 2005, RUTF was 
increasingly used during final stages of inpatient care, as well as during outpatient care. This 
evolution of routine practice led to decision to randomize during latter stages of inpatient care 
rather than at entry to outpatient care. 
 
4.2.3 Interventions 
 As described in chapter 3, treatment on MOYO followed Malawi National Guidelines for 
the Management of Acute Malnutrition(25). All children were initially fed “F75” therapeutic milk. 
PRONUT began when a child progressed to “rehabilitation” phase feeds. Criteria for progression 
were clinical improvement and return of active appetite (easily finishing the prescribed volume of 
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F75 milk). Ready-to-Use Therapeutic Food (RUTF)(41) was introduced into the diet at this stage. 
RUTF prescriptions provided 200 kcal energy, per kg body weight, per day. For a 7 kg child 
(median NRU admission weight) this was approximately 300g RUTF/day. 
 Control children received standard RUTF. The intervention group received RUTF with 
added Synbiotic2000 Forte™ (Medipharm AB,Kågeröd, Sweden). This had been proven effective in 
other studies in other patient groups(91, 92) and as described in section 1.5.3 also therefore had 
potential for useful effects in SAM. Freeze-dried Synbiotic powder was factory-mixed into RUTF at 
a weight ratio of 1:50.  Batches of control RUTF were always made prior to batches of intervention 
RUTF to prevent cross-contamination. Synbiotic constituents were: 
i) Four different probiotic lactic acid bacteria (LAB): (1011 colony forming units, CFU of 
bacteria total) 
  ~ Pediococcus pentosaceus 16:1 LMG P-20608;  
  ~ Leuconostoc mesenteroides 23-77:1 LMG P-20607;  
  ~ Lactobacillus paracasei subsp paracasei F-19 LMG P-17806 
  ~ Lactobacillus plantarum 2362 LMG P-20606 
ii) Four prebiotic fermentable bioactive fibres: (2.5g of each per 1011 bacteria) 
  ~ Oat bran (rich in β-glucans); inulin; pectin; resistant starch 
For quality control, randomly selected samples of RUTF were regularly sent to Medipharm’s 
laboratories in Sweden within a week of manufacture and again after 2 months storage at local 
ambient temperature in Malawi. Medipharm’s microbiological culture results showed that 
intervention RUTF consistently contained >1x108 CFU of lactic acid bacteria per gram of RUTF. This 
equates to a prescribed average dose of >1x1010 CFU organisms per patient per day (please see 
appendix F.1 for details)  
 
Outpatient therapeutic feeding 
 Once clinically well and easily finishing at least ¾ of their daily RUTF ration, children were 
transferred from inpatient care to outpatient treatment, to complete their nutritional rehabilitation 
at home. They continued original group allocations of either control or Synbiotic-enhanced RUTF. 
RUTF prescriptions remained at 200 kcal energy, per kg body weight, per day. At fortnightly 
intervals, children attended outpatient clinics for clinical review and to collect further rations of 
RUTF.  
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4.2.4 Trial Safety & Sepsis monitoring 
RUTF safety and quality control 
 The Valid Nutrition RUTF factory in Lilongwe, Malawi (which supplied this study and 
mixed the Synbiotic into intervention RUTF) was licensed for the manufacture of food products.  
RUTF samples were regularly monitored by the Malawi Bureau of Standards for: 
- Conformity to product specifications (macronutrient profile within range; water content 
sufficiently low – please see table 3, RUTF nutrient profile ) 
- Microbiological safety  
- Aflatoxin (levels within safe limits) 
 
Data Safety & Monitoring Board (DSMB) 
 To monitor trial safety, an interim analysis reviewed the main outcomes, % cure and % 
deaths. Early Stopping criteria were group differences exceeding the Peto-Haybittle rule (p<0.001), 
or serious adverse events(93). Neither occurred. 
 
Probiotic related sepsis & antibiotic regimes 
 On admission, all children routinely started a 7 day course of co-trimoxazole antibiotics. 
Dose was 120mg twice a day (bd) for children weighing <10kg; 240mg bd for children 10-25kg and 
480mg bd for those >25kg. HIV seropositive children were continued on long term daily 
prophylaxis (dose 120mg co-trimoxazole once a day (od) for children <10kg; 240mg bd for children 
10-25kg; 480mg bd for those >25kg). According to clinical need, some also received parenteral 2nd or 
3rd line antibiotics. Standard 2nd line regime was chloramphenicol and gentamicin. 3rd line was 
ceftriaxone or ciprofloxacin plus gentamicin.  
 In cases of presumed sepsis in a sick child, a blood culture was taken. To identify possible 
probiotic sepsis we developed additional microbiology protocols involving culture on MRS agar 
(Oxoid Ltd,  Cambridge, UK) and subsequent bacterial subspecies identification (figure 10 and 
appendix F.2). These were never needed as no suspicious organisms grew at the initial culture 
stage.  
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Figure 10 Identification of possible probiotic associated sepsis 
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4.2.5 Outcome variables 
PRIMARY OUTCOME was % of children achieving nutritional cure. This was defined as two 
consecutive outpatient visits, a fortnight apart, with weight-for-height ≥ 80% of median (NCHS 
reference) 
 
SECONDARY OUTCOMES were: 
i) Routine nutrition programme performance indicators: (88),(37) 
• Death rate (%)  
• Default rate (%) ~ defined as missing two consecutive outpatient visits (approximately 4 
weeks without contact). Defaulters were followed up by a mobile team. Deaths at home 
were classed as outpatient deaths. 
• Nutritional failure rate (%) ~ defined as not achieving cure despite 5 visits (approximately 
10 weeks) of follow-up. Failures (most commonly due to underlying HIV) were referred for 
further care, including to anti-retroviral (ARV) services. 
• Readmissions to hospital (%) 
• Maximum weight gain (g/kg/day) ~ calculated using minimum observed inpatient weight 
as the baseline weight (this is the closest approximation to ‘dry weight’. It is important to 
note however that some children died or absconded whilst still oedematous. Rarely, some 
children were discharged to outpatient care despite still having some oedema: this is 
consistent with CMAM programmes which safely treat oedematous children at home) 
•  Length of stay in programme (days)  
ii) Carer reported clinical & progress outcomes 
 Trained study staff used pre-piloted, standardized questionnaires (please see appendix D 
for details of these forms). Symptoms were reported and signs recorded daily whilst the child was 
an inpatient. At baseline, and at each fortnightly outpatient clinic, carers were asked about 
symptoms in the preceding 2 weeks. 
 
 
4.2.6 Sample size 
 Data from 2003-4 was used to estimate baseline/control group outcomes(84)  A 10% increase 
in cure was chosen as clinically relevant. Using α=0.05 and power of 80%, 348 patients per group 
were needed to detect an improvement from 65% control group cure in to 75% Synbiotic cure 
(StatCalc, EpiInfo v.3.3.2TM, CDC, Atlanta, USA). To account for follow-up losses and ensure 
adequate numbers for subgroup analyses, the aim was to recruit 800 patients.   
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4.2.7 Randomization 
Sequence generation 
A random sequence representing the two study groups was computer generated independently of 
the field team. Permuted blocks of 50 (25 group ‘1’, 25 group ‘2’ per block) ensured balanced groups 
for interim DSMB safety analysis.  
Allocation concealment 
Referring to the above ‘master list’, an independent volunteer inserted one of two sticky labels 
(printed “Group 1” and “Group 2”) into sealed, opaque, sequentially numbered envelopes.   
Implementation 
When consenting and eligible patients (those starting transitional phase feeds) went to receive 
RUTF for the first time, study staff would open the next numbered envelope to reveal the label 
concealed inside. This assigned the patient to one of the two RUTF groups. To ensure the correct 
group was maintained for all subsequent RUTF distribution rounds, the label was stuck in the back 
page of the child’s health passport, which the carer held at all times. 
 
 
4.2.8 Blinding 
The study was double but not triple blind: 
Patients 
 Taste, colour and texture of standard (control) and intervention (Synbiotic) RUTF were 
indistinguishable so patients were blind to their group allocation. A small printed label on the 
RUTF bottle lid was the only way to identify the correct group. At the beginning of the study, the 
RUTF factory manager decided independently and at random whether group “1” or “2” should 
contain Synbiotic. 
Field Staff 
 Project field staff were unaware of whether group “1” or “2” contained the Synbiotic. They 
were also blind as to whether a patient was even group “1” or “2” when assessing or managing a 
particular patient. Group “1” or “2” allocation was recorded hidden inside the child health passport 
for the purpose of correct food distribution but nowhere else on patient or study files. Strict 
instructions were given that this should only be referred to by staff distributing RUTF at the end of 
the clinic or end of ward round 
Investigators  
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 All investigators except MK were unaware of study codes. MK was inadvertently 
unblinded part way into the study whilst coordinating RUTF quality control testing. I believe the 
study design was robust enough to prevent this causing any biases: main outcomes were hard and 
objective (e.g. weight, death); other staff remained fully blinded; group randomization, 
concealment and allocation were all independent of MK; randomization data was entered and 
stored independently from other databases and merged only prior to final data analysis. 
 
 
4.2.9 Statistical methods & data handling 
 Data were entered in EpiData 3.1 (EpiData Association, Odense, Denmark, 2003-4). Simple 
macros (‘Check’ files) helped ensure high quality data entry, e.g. variables plausible, in-range and 
consistent with other related variables. Key data (anthropometry, dates, final outcomes, HIV status) 
were double entered. WHO Anthro 2005 v1 (World Health Organization, Geneva) was used to 
calculate anthropometric Z-scores using the NCHS reference, still current in Malawi.  
 Main analyses were performed using SPSSv15 (© SPSS Inc., USA). StatCalc (CDC, Atlanta, 
USA, 1993) and Stata Intercooled 10.0TM(StataCorp LP, USA) were used for additional analyses. 
 Chi-square tables and approximate confidence limits for relative risk were used to examine 
categorical data. Normality of continuous variables was explored visually (histogram, Q-Q plots) 
and numerically (Kolomogorov-Smirnov and Shapiro-Wilk tests). Either independent t-tests or 
Mann-Whitney U tests were performed accordingly.  
 To assess the role of HIV as a possible confounder or effect modifier, all major analyses 
included HIV serostatus (positive or negative) as a stratification level. 
 Analysis was on an intention-to-treat basis. 
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4.3 RESULTS 
4.3.1 Study flow chart  
From 12th July 2006 to 7th March 2007, 1024 children were admitted to the ward. Their progress is  
summarized in the study flowchart below: 
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A total of 399 were randomised to Synbiotic RUTF and 396 to control. The commonest reason for 
non-enrolment was early death whilst still on stabilization phase (n=124). 67 patients declined to 
participate and received non-study RUTF. 
 
4.3.2 Patient characteristics at baseline 
 Table 4 (supplementary tables in annexes F3 and F4) show that main patient characteristics 
were similar in both groups at baseline. SAM subtypes (kwashiorkor and wasting) were balanced 
between groups and did not affect any subsequent results. HIV serology was known for 95% of 
children. Sero-positivity was non-significantly lower in the Synbiotic group: 170/399(42.6%) vs. 
192/396(48.5%), p=0.09. HIV status was included as a stratification level in all major subsequent 
analyses. 
Table 4 Main baseline patient characteristics 
  
Synbiotic                 
(n=399) 
Control                    
(n=396)     
1) Age & Sex profile     
  Age in months median ± IQR 22 ± 17 21 ± 16 
  Boys (%) 214/399  (53.6%) 216/393  (55.0%) 
2) Nutritional Diagnosis       
  
Wasting (<70% weight-for-height (NCHS) 
and/or MUAC <11cm, no oedema) 
142/399  (35.6%) 146/396  (36.9%) 
  Kwashiorkor (oedematous malnutrition) 238/399  (59.6%) 217/396  (54.8%) 
3) Anthropometry (mean Z score ± sd)*     
  Height-for-Age (HAZ)  - 3.19  ± 1.5  - 3.12 ± 1.4 
  Weight-for-Height (WHZ) - 2.19 ± 1.2 -2.33 ± 1.3 
  Weight-for-Age (WAZ) -3.50 ± 1.3 -3.58 ± 1.3 
 MUAC (mean cm) 11.78 ± 2.0  11.55 ± 2.0 
4) Child HIV Status (%)       
  HIV seropositive 170/399 (42.6%) 192/396  (48.5%) 
  HIV seronegative 203/399 (51.0%) 190/396  (48.0%) 
  Not tested or unknown 26/399  (6.5%) 14/396  (3.5%) 
5) Family & Socioeconomic 
Status 
      
  Main carer is mother 329/387  (85.0%) 321/384  (83.6%) 
  Mother literate 246/378  (65.1%) 243/366  (66.4%) 
  Household water source  - piped 208/386  (53.9%) 217/382  (56.8%) 
                           - borehole / protected well 132/386  (34.2%) 117/382  (30.6%) 
  
Household toilet               
                         - traditional pit latrine 
373/386  (96.6%) 367/382  (96.1%) 
* Z-scores are based on admission weight rather than minimum weight unless otherwise stated. 
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4.3.3 Main outcomes – programme cure and mortality 
Table 5 shows main study outcomes. Primary outcome, nutritional cure was 53.9% (215/399) in 
Synbiotic patients and 51.3% (203/396) in controls (p=0.40). Total deaths during the study period 
were also similar between groups: 27.1% (108/399) Synbiotic deaths vs 30.0% (119/396) control 
deaths (p=0.31).  Other secondary outcomes were also similar. Less than 10% of patients defaulted. 
When followed-up in the community after 1st default episode, 19/32 (59.4%) Synbiotic defaulters 
and 23/36 (63.9%) controls were seen or reported to be alive and well (p=0.70). Information was 
unavailable for only 6/32 (18.8%) Synbiotic defaulters and 4/36 (11.1%) controls (p=0.37) who could 
not be located. 
Table 5 Main PRONUT study outcomes 
  
Synbiotic              
(n=399) 
Control                    
(n=396)     
relative risk  
or                                                                 
mean difference                    
(95% confidence 
interval) 
p
PRIMARY OUTCOME:          
1) NUTRITIONAL CURE (total) 215/399 (53.9%) 203/396 (51.3%) 1.06 (0.93 to 1.21) 0.40 
HIV seropositive cures 66/170 (38.8%) 71/192 (37.0%) 1.05 (0.81 to 1.37) 0.71 
HIV seronegative cures 145/203 (71.4%) 131/190 (68.9%) 1.04 (0.91 to 1.18) 0.59 
SECONDARY OUTCOMES:      
   2) DEATHS (TOTAL)† 108/399 (27.1%) 119/396 (30.0%) 0.90 (0.72 to 1.12) 0.31 
   3) OUTPATIENT DEFAULTERS or WARD 
ABSCONDERS 
27/399 (6.8%) 36/396 (9.0%) 0.74 (0.46 to 1.20) 0.23 
   4) FAILURES OF NUTRITIONAL 
TREATMENT 
14/399 (3.5%) 14/396 (3.5%) 0.99 (0.48 to 2.05) 0.98 
   5) READMISSIONS 27/399 (6.8%) 16/396 (4.0%) 1.67 (0.92 to 3.06) 0.08 
   6) Other: (transfers out; final outcome 
unknown) 
8/399 (2.0%) 8/396 (2.0%) 1.12 (0.44 to 2.86) 0.81 
        7) Rate of weight gain (mean 
g/kg/day ± SD) 
4.18 ± 4.0 4.14 ± 4.1 
0.04 (-0.53 to 
0.61) 
0.65 
        8) Length of stay in programme 
(median days to cure ± IQR) 
37 ± 14 38 ± 13   0.42 
Outcomes stratified by treatment phase 
  
~   Deaths (inpatient, during 1st 
admission) 
61/399 (15.3%) 52/396 (13.1%) 1.16 (0.83 to 1.64) 0.38 
  
~   Deaths (any time during remainder 
of study) 
47/338 (13.9%) 67/344 (19.4%) 0.71 (0.51 to 1.00) 0.05 
  
total deaths during all inpatient 
treatment episodes (incl. 
readmissions) 
78/486 (16.1%) 74/467 (15.9%) 1.01 (0.76 to 1.36) 0.93 
  
total deaths during all 
outpatient treatment episodes 
(incl. readmissions) 
30/394 (7.6%) 45/387 (11.6%) 0.65 (0.42 to 1.02) 0.06 
† Please see table 6 for detailed breakdown of deaths according to phase of treatment. 
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 Also in table 5 are main outcomes stratified by treatment phase. There were no group 
differences in initial inpatient deaths (p=0.38). Deaths at any time during the remainder of the study 
period showed a possible trend in favour of the Synbiotic group: 47/338 (13.9%) vs. 67/344 (19.4%), 
p=0.05. Details of deaths during each subsequent readmission episode are shown in table 6. In all, 
there were 486 patient admission episodes in the Synbiotic group and 467 in controls. Total deaths 
during inpatient care did not differ between groups (p=0.93), but total deaths during outpatient 
care showed a possible trend towards being lower in the Synbiotic group (p=0.06). The observed 
group differences were greatest: 
- during the outpatient phase of the 1st admission episode: 18/324 Synbiotic deaths vs. 39/338 control 
deaths, p=0.006. 
- among HIV seronegative outpatients (all admission episodes): 3/202 Synbiotic deaths vs. 11/194 
deaths, p=0.02.  
One related result not shown in table is that weight gain (g/kg/day) during outpatient treatment 
was no different in the Synbiotic group compared to controls (p=0.48). 
Table 7 explores whether these apparent outpatient difference might be explained by group 
imbalances at the point of discharge from 1st admission episode to outpatient care. HIV prevalence 
was marginally lower in the Synbiotic outpatient group than in controls: 135/331 (40.8%) 
seropositive Synbiotic outpatients compared to 157/341(46.0%) seropositive controls (p=0.17). 
Weight-for-height Z-score (WHZ) was also different at OTP baseline, with Synbiotic mean WHZ of 
-2.24±1.1 against control mean WHZ of -2.44±1.1 (p=0.02).  
Two points are important to note when interpreting this table: 
- Nutritional diagnosis refers to that at admission and does not imply that patients were still 
oedematous at discharge from the ward. The great majority of children had lost all visible 
oedema before discharge. Only a very small number were discharged home with residual 
pitting (consistent with CMAM programmes which have good experience of safe 
outpatient treatment of clinically stable children with good appetites but minimal oedema) 
Since this table excludes those patients who died during initial inpatient care, z-scores cannot be 
directly compared with those of all patients at admission to the ward (table 4) and inferences 
cannot be made regarding weight changes during the initial treatment. Many patients lost some 
weight since their admission – mostly due to loss of oedema. By discharge, most had started to gain 
weight.
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Table 6 Details of timing of death: stratified by admission episode; inpatient or outpatient care; HIV status 
  Synbiotic Control 
risk ratio  
(95% confidence interval) 
p-value 
All admissions TOTAL PATIENT ADMISSION EPISODES 486 467   
 TOTAL DEATHS 108/486 (22.2%) 119/467 (25.5%) 0.87 (0.69 to 1.09) 0.24 
 
total deaths during inpatient treatment 
episodes 
78/486 (16.1%) 74/467 (15.9%) 1.01 (0.76 to 1.36) 0.93 
 HIV +ve inpatient deaths 47/234 (20.1%) 55/246 (22.4%) 0.90 (0.64 to 1.27) 0.54 
 HIV -ve inpatient deaths 18/227 (7.9%) 13/207 (6.3%) 1.26 (0.63 to 2.51) 0.51 
 
total deaths during outpatient treatment 
episodes 
30/394 (7.6%) 45/387 (11.6%) 0.65 (0.42 to 1.02) 0.06 
 HIV +ve inpatient deaths 26/186 (14.0%) 31/189 (16.4%) 0.85 (0.53 to 1.38) 0.51 
 HIV -ve outpatient deaths 3/202 (1.5%) 11/194 (5.7%) 0.26 (0.07 to 0.92) 0.02 
Admission 1 Total 1st admissions 399 396   
          Inpatient deaths total 61/399 (15.3%) 52/396 (13.1%) 1.16 (0.83 to 1.64) 0.38 
 HIV +ve inpatient deaths 34/170 (20.0%) 35/192 (18.2%) 1.10 (0.72 to 1.68) 0.67 
 HIV -ve inpatient deaths 14/203 (6.9%) 11/190 (5.8%) 1.19 (0.55 to 2.56) 0.65 
          Outpatient deaths total 18/324 (5.6%) 39/338 (11.5%) 0.48 (0.28 to 0.82) 0.006 
 HIV +ve outpatient deaths 15/134 (11.1%) 25/155 (16.1%) 0.69 (0.38 to 1.26) 0.23 
 HIV -ve outpatient deaths 2/182 (0.5%) 11/179 (6.1%) 0.18 (0.04 to 0.80) 0.010 
Admission 2 Total 2nd admissions 68 61   
          Inpatient deaths total 12/68 (17.6%) 19/61 (31.1%) 0.57 (0.30 to 1.07) 0.07 
 HIV +ve inpatient deaths 9/49 (18.4%) 17/46 (37.0%) 0.50 (0.25 to 1.00) 0.04 
 HIV -ve inpatient deaths 3/19 (15.8%) 2/15 (13.3%) 1.18 (0.23 to 6.20) 1.0* 
          Outpatient deaths total 11/56 (19.6%) 3/42 (7.1%) 2.75 (0.82 to 9.24) 0.08 
 HIV +ve outpatient deaths 10/40 (20.0%) 3/29 (10.3%) 2.42 (0.73 to 8.01) 0.12 
 HIV -ve outpatient deaths 1/16 (6.3%) 0/13 (0.0%) - 1.0* 
Admission 3 Total 3rd admissions 16 10   
          Inpatient deaths total 5/16 (31.3%) 3/10 (30.0%) 1.04 (0.32 to 3.44) 1.0* 
 HIV +ve inpatient deaths  4/13 (30.8%) 3/8 (37.5%) 0.82 (0.24 to 2.75) 1.0* 
 HIV -ve inpatient deaths 1/3 (33.3%) 0/2 (0.0%) - 1.0* 
          Outpatient deaths total 1/11 (0%) 3/7 (42.9%) 0.21 (0.03 to 1.66) 0.24* 
 HIV +ve outpatient deaths 1/10 (10.0%) 3/5 (60.0%)  0.17 (0.02 to 1.22) 0.08* 
 HIV -ve outpatient deaths 0/2 (0.0%) 0/2 (0.0%)  -  - 
Admission 4 Total 4th admissions 3 0   - 
          Deaths 0 n/a -  - 
(NB) Note that HIV positive and negatives do not always add up to total because of a small number of unknowns. *Fisher exact 
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Table 7 Patient characteristics at point of entry to outpatient care (=point of discharge from inpatient care) 
 
 
  Synbiotic                 
(n=331) 
Control                    
(n=341)     
relative risk (discrete variables)                                  
or                                                  
mean difference  
(continuous variables)                      
  (95% confidence interval) 
p-value
1) Demographic profile     
 Age in months (mean ± sd) 30.8 ±25.3 28.4 ± 23.2 2.35 (-1.32 to 6.02) 0.21 
 Boys (%) 181/331 (54.7%) 186/341 (54.5%) 0.99 (0.86 to 1.13) 0.86 
2) Nutritional Diagnosis (at admission to ward)     
 Wasting (<70% weight-for-height (NCHS) 
and/or MUAC <11cm, no oedema) 
76/331 (23.0%) 84/341 (24.6%) 0.93 (0.71 to 1.22) 0.61 
 Kwashiorkor (oedematous malnutrition) 215/331 (65.0%) 201/341 (58.9%) 1.10 (0.98 to 1.24) 0.11 
3) Anthropometry (mean Z score ± sd)     
 Height-for-Age (HAZ) -3.13 ± 1.5 -3.09 ± 1.3 -0.44 (-0.26 to 0.17) 0.69 
 Weight-for-Height (WFZ) -2.24 ±  1.1 -2.44 ± 1.1 0.20 (0.03 to 0.37) 0.02 
 Weight-for-Age (WFZ) -3.49 ± 1.2 -3.64 ± 1.1 0.15 (-0.02 to 0.32) 0.08 
4) Child HIV Status (%)     
 HIV seropositive 135/331 (40.8%) 157/341 (46.0%) 0.89 (0.74 to 1.05) 0.17 
 HIV seronegative 186/331  (56.2%) 179/341 (52.5%) 1.07 (0.93 to 1.23) 0.34 
 Not tested or unknown 10/331 (3.0%) 5/341 (1.5%) 2.06 (0.71 to 5.96) 0.17 
NB. This table includes patients successfully discharged from inpatient care (n=324 Synbiotic group, n=338 control)  
plus absconders from inpatient care (n=7 Synbiotic group, n=3 control). Absconders are included since they were also followed up in the community to discover final 
outcome (e.g. whether alive and well when seen at community 'default' visit; whether dead at default visit) 
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4.3.4 Secondary outcomes – carer reported clinical symptoms   
Table 8 shows carer-reported post randomization clinical symptoms. Total days of outpatient 
observation were less in the Synbiotic group. This was partly because mean time to death was 
shorter in Synbiotic outpatients who died than in control outpatients who died. Sixteen synbiotic 
group outpatient deaths contributed a total 617 days of outpatient observation (mean 38.6 days 
observation per death) whilst 39 control outpatient deaths contributed 1726 days (mean 44.3 days). 
 Inpatients consuming Synbiotic had more days cough (p=0.05) and vomiting (p=0.05). They 
also had more days (p=0.01) of severe diarrhoea (≥6 abnormally loose or watery stools). Preceding 
this increase in severe diarrhoea, non-significant baseline imbalances should be noted (annex F3): 73 
days/1000 severe inpatient diarrhoea in the Synbiotic group) vs. 65 days/1000 in controls.  
 Outpatient symptoms were similar between groups. Overall outpatient diarrhoea did not 
differ, but there was a trend to less severe diarrhoea in the Synbiotic group (p=0.07). Consistent 
with symptom reports, unscheduled outpatient visits and use of non-routine outpatient medication 
were similar. 
Table 8 Clinical outcomes (carer reported symptoms) 
  Synbiotic Control p 
1) CLINICAL SYMPTOMS ~ total patient days with symptom / 1000 days patient observation   
 TOTAL DAYS PATIENT OBSERVATION (median ±IQR) 12909 (32 ± 25) 14124 (33 ± 25) 0.04 
 TOTAL DAYS INPATIENT OBSERVATION median ±IQR  2517 (5 ± 4) 2525 (6 ± 4) 0.35 
 TOTAL DAYS OUTPATIENT OBSERVATION, median ± IQR 10408 (32.0 ± 25) 11562 (33 ± 25) 0.03 
  DIARRHOEA                         ~ as inpatient  250 202 0.31 
                                  ~ severe diarrhoea as inpatient 80 51 0.01 
                                                  ~ as outpatient 41 41 0.95 
                    ~ severe diarrhoea as outpatient 11 16 0.07 
  VOMITING                            ~ as inpatient 273 215 0.05 
                                                                 ~ as outpatient 12 12 0.64 
  ABDOMINAL PAIN              ~ as inpatient 160 166 0.57 
                                                                 ~ as outpatient 19 15 0.43 
  FEVER                                    ~ as inpatient 310 265 0.21 
                                                                 ~ as outpatient 42 47 0.26 
  COUGH                                 ~ as inpatient 476 421 0.05 
                                                                 ~ as outpatient 124 106 0.69 
  FAST / DIFFICULT BREATHING         ~ as outpatient 5 7 0.15 
2) OUTPATIENT VISITS median ± IQR (total visits) 2 ± 2 (667) 2 ± 2 (702) 0.34 
3) USE OF NON-ROUTINE DRUGS ~ prescribed elsewhere since last review or prescribed at OTP clinic review  
 Total visits at which any drugs used / total OTP visits (%) 246/667 (36.9%) 258/702 (36.8%) 0.96 
 Total visits at which antibiotics used / total OTP visits (%) 151/667 (22.6%) 169/702 (24.1%) 0.53 
4) UNSCHEDULED OUTPATIENT CONSULTATIONS  (visits/1000 
patient days) 
9 8 0.93 
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 Table 9 shows indicators of Synbiotic safety: RUTF was tolerated equally well in both 
groups during inpatient care (p=0.77). During outpatient care, less problems eating RUTF were 
reported by Synbiotic patients. RUTF (p=0.02). This did not affect the total amount consumed: if 
RUTF was left unfinished, the amount was small (just over 1 pot unfinished = approx 1 day’s 
ration/14 days) and similar in both groups (p=0.35).  
 There were no group differences in incidence of sepsis episodes. Similar numbers of 
patients needed blood cultures (p=0.89) and similar numbers of blood cultures were positive 
(p=0.28). No cases of probiotic-associated sepsis were detected.  
 Addressing safety concerns about probiotic use in HIV, table 9 also shows deaths stratified 
by HIV serostatus. There was no excess mortality among HIV seropositive Synbiotic patients 
(p=0.80).  
Table 9 Indicators of Synbiotic safety 
  Synbiotic Control 
relative risk                                  
or                                                                 
mean difference                    
(95% confidence 
interval) 
p 
1) PROBLEMS WITH RUTF          
  
AS INPATIENT (patient not 
tolerating RUTF or clinically 
worsening ->needing F100 milk 
instead) 
6/396 (1.5%) 5/393 (1.3%) 1.19  (0.37 to 3.87) 0.77 
  
AS OUTPATIENT number of visits 
with problem/total outpatient 
visits (%) 
26/667 (3.9%) 48/702 (6.8%) 0.57 (0.36 to 0.91) 0.02 
  
Bottles of RUTF remaining (if ration 
unfinished), mean, ± SD 
1.17 ± 2.4 1.35 ± 2.3 -0.18 (-0.57 to 0.20) 0.35 
2) BLOOD CULTURES & SEPSIS         
  Blood culture taken 68/399 (17.0%) 69/396 (17.4%) 0.98 (0.72 to 1.33) 0.89 
  
Positive blood culture (of those 
taken) 
17/68 (25.0%) 23/69 (33.3%) 0.75 (0.44 to 1.27) 0.28 
  
Probiotic associated blood culture 
(of those taken) 
0 (0%) 0 (0%) - - 
3) DEATHS ~ by HIV status         
  Total HIV seropositive deaths 73/170 (42.9%) 85/192 (44.3%) 0.97 (0.77 to 1.23) 0.80 
  Total HIV seronegative deaths 21/203 (10.3%) 25/190 (13.1%) 0.79 (0.46 to 1.36) 0.39 
4) TOTAL READMISSION EPISODES* 87/399 (21.8%) 71/396 (17.9%) 1.22 (0.92 to 1.61) 0.17 
  Readmissions who eventually died 29/87 (33.3%) 28/71 (39.4%) 0.85 (0.56 to 1.28) 0.43 
* Same patient can have more than one readmission episode. Maximum admission episodes was 4.  
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4.3.5 Kaplan-Meier time-to-death analysis 
Figure 11 is a Kaplan-Meier time-to-death graph, split by HIV status, showing all deaths during the 
course of the study. The adverse effects of HIV manifest quickly in both Synbiotic and control 
patients. In both HIV positive and negative children there were initially more Synbiotic than control 
deaths, though as detailed in tables 5 and 6, these early inpatient deaths were statistically not 
different between groups. Median time to death was 8(± IQR 8) days in Synbiotic patients who 
died, and 11(± IQR 22) days in controls (p=0.004). A log-rank test for overall time-to-death curves 
was non-significant (p=0.36). Overall Synbiotic/control differences are non-significant in both HIV 
classes. 
.  
 
Figure 11 Kaplan-Meier time-to-death graph, by HIV status.  
(All deaths in the study are shown)  
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4.3.6 Subgroup Analyses 
 Analyses were repeated for the pre-specified subgroup of children who we thought might 
benefit most from Synbiotic actions: those aged 6 to 60months and without disability or other direct 
surgical or other cause of SAM.   Overall trends and patterns of difference were similar to the whole 
group. Only main subgroup outcomes are shown in the table below: 
 
Table 10 Main PRONUT study outcomes – main subgroup analysis 
  
Synbiotic                 
(n=333) 
Control                    
(n=318)     
relative risk  
or                                                                 
mean difference                    
(95% confidence 
interval) 
p
PRIMARY OUTCOME:          
1) NUTRITIONAL CURE (total) 189/333 (56.8%) 172/318 (54.1%) 1.05 (0.91 to 1.23) 0.49 
HIV seropositive cures 58/141 (41.1%) 58/153 (37.9%) 1.07 (0.84 to 1.36) 0.57 
HIV seronegative cures 127/173 (73.4%) 113/154 (73.4%) 1.00 (0.79 to 1.26) 0.99 
SECONDARY OUTCOMES:      
   2) DEATHS (TOTAL) 85/333 (25.5%) 90/318 (28.3%) 0.93 (0.78 to 1.11) 0.42 
   3) OUTPATIENT DEFAULTERS or WARD 
ABSCONDERS 
23/333 (6.9%) 30/318 (9.4%) 0.84 (0.61 to 1.15) 0.24 
   4) FAILURES OF NUTRITIONAL 
TREATMENT 
11/333 (3.3%) 12/318 (3.8%) 0.93 (0.60 to 1.44) 0.75 
   5) READMISSIONS 20/333 (6.0%) 11/318 (3.5%) 1.28 (0.97 to 1.68) 0.13 
   6) Other: (transfers out; final outcome 
unknown) 
5/333 (1.5%) 3/318 (0.9%) 1.23 (0.71 to 2.11) 0.52 
        7) Rate of weight gain (mean 
g/kg/day ± SD) 
4.39 (4.0) 4.14 (4.1) 
0.24 (-0.39 to 
0.86) 
0.45 
        8) Length of stay in programme 
(median days to cure ± IQR) 
37 (34 to 48) 38 (34 to 47)  0.66 
Outcomes stratified by treatment phase 
  
~   Deaths (inpatient, during 1st 
admission) 
47/333 (14.1%) 38/318 (11.9%) 1.09 (0.89 to 1.35) 0.41 
  
~   Deaths (any time during remainder 
of study) 
38/286 (13.3%) 52/280 (18.6%) 0.81 (0.63 to 1.05) 0.09 
  
total deaths during all inpatient 
treatment episodes (incl. 
readmissions) 
59/397 (14.9%) 56/366 (15.3%) 0.98 (0.81 to 1.19) 0.87 
  
total deaths during all 
outpatient treatment episodes 
(incl. readmissions) 
26/338 (7.7%) 34/310 (11.0%) 0.82 (0.61 to 1.10) 0.15 
 
total outpatients deaths 
following 1
st
 admission only 
13/238 (5.5%) 30/280 (10.7%) 0.65 (0.40 to 1.01) 0.03 
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Chapter 5 
‘FUSAM’ study 
(Follow-Up of long term outcomes from  
Severe Acute Malnutrition) 
 
 
5.1 Aims 
To describe long term (≥ 1 year post-discharge) mortality and morbidity following an episode of 
SAM 
 
5.1.1 Objectives:  
i. To describe the occurrence and timing of in-programme and post-treatment deaths 
following an episode of SAM   
ii. To describe the extent of catch-up growth in the year following an episode of SAM 
iii. To identify risk factors for mortality from SAM:  
a. Risk factors at original admission 
b. Risk factors related to post-SAM care 
c. To determine whether risk factors for short term mortality are similar 
to those for late deaths 
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5.2 Methods 
5.2.1 Study design 
FUSAM was a longitudinal cohort study. 
 
5.2.2 Setting & participants 
FUSAM participants were all children cared for on ‘MOYO‘ nutrition ward, Queen Elizabeth 
Hospital, Blantyre Malawi. All admissions during the period of the PRONUT study from 12th 
July 2006 to 14th March 2007 were eligible. This spans both the dry (July to December) and rainy, 
‘hungry’ season (December to March). MOYO is profiled in detail in chapter 3. 
Those successfully cured in MOYO’s OTP programme were asked to return for ward-
based review on the 1 year anniversary of their cure date. Non-cures and those failing to return 
for assessment were followed-up at the home address they had given at original admission. 
 Where possible and appropriate, information was also collected on siblings of the ex-
MOYO patient and the parents or carer of the ex-MOYO patient. 
 
5.2.3 Outcome variables 
FUSAM focused on the following: 
PRIMARY OUTCOMES 
• Mortality 
Total mortality consisted of: 
o Short term deaths, whilst still an inpatient on MOYO 
o Medium term deaths, within the 1st 90 days of admission but after the inpatient 
treatment phase  
o Long term deaths, defined as death >90 days following programme admission.  
Short plus medium term deaths approximate ‘in-programme’ deaths and are considered 
together in FUSAM analyses whilst long term deaths approximate post-treatment deaths. In 
reality the division is less distinct since for example: readmissions can be under MOYO care for 
longer periods; some children may proceed quickly through the treatment programme and be 
discharged from care, yet still die within 90 days of original admission; some carers abscond not 
having completed full treatment. The 90 day cut-off was chosen to be consistent with upper 
limits of time a patient would normally spend in a therapeutic feeding programme: 10 weeks as 
an outpatient before being defined as ‘nutritional failure’ plus a preceding 3 weeks of inpatient 
care. 
• Long term survival 
Defined as seen alive by the FUSAM study team (or reliably reported to be alive) at ≥1year after 
the original admission date to MOYO.  
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SECONDARY OUTCOMES 
• Anthropometric status at 1 year (catch-up growth):  
To calculate weight-for-height, height-for-age and weight-for-age z-scores, we measured the 
weight, height, MUAC and exact age of: 
o The ex-MOYO child. 
Longitudinal data were thus available at: day of admission to MOYO; day of minimum 
weight on ward (this was the closest approximation to ‘dry’/non-oedamtous weight, 
though it is important to note that some patients died whilst still oedematous); day of 
discharge from ward to OTP; each OTP clinic visit (weight and MUAC only); day of 
OTP exit; day of 1 year follow-up. 
o Siblings - defined as children born to the same mother and living in the same family 
 
The following outcomes variables also served as potential explanatory variables in a 
mathematical model exploring which factors predicted long term survival and mortality:  
• .  Clinical progress in the year since MOYO admission 
o Recurrence of acute malnutrition 
o Other (non-SAM) health problems resulting in inpatient admission or 
outpatient visit 
o Clinical symptoms in the previous 2 weeks 
These morbidity questions mirrored what was asked about the 2 weeks prior to 
original admission to MOYO and at each 2 week interval between OTP visits. In the 
case of deaths, it also served as a verbal autopsy report. 
• Access to and use of  TFP-related services 
o For how long, if at all, the child received supplementary feeds following MOYO 
discharge? 
o Use of TB and HIV-related services, if clinically indicated. 
• Health education activities and basic nutrition-related knowledge 
o Did the carer attend any health education sessions whilst on MOYO? 
o Did any differences result from the health education sessions? 
o Did the carer know about basics of nutrition, specifically about Malawi’s ‘six 
food groups’ (vegetables, fruits, staples, fats, animal foods, legumes & nuts) 
and about ideal duration of breastfeeding? 
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5.2.4 Data sources and measurement 
 
Baseline variables 
The following groups of independent variables, all potentially affecting FUSAM outcomes, 
were obtained at original admission to MOYO. Measurement details are described in chapter 3 
• Age and anthropometry 
• HIV status (including CD4 count, at 1st OTP visit, for HIV seropositive children) 
• Clinical status in the 2 weeks prior to ward admission 
• Signs and symptoms used for clinical staging of HIV disease (according to 2006 WHO 
case definitions)(94) 
• Past medical history 
• Family and socioeconomic status 
 
Sources of baseline variables 
Baseline variables were the same as those collected and entered in the PRONUT study 
database. Whilst a small number of patients declined to be randomized in PRONUT, routine 
clinical data were available on all patients. Additional data, taken on separate PRONUT forms, 
were obtained, with permission, from most carers. A key question enabling long term follow-up 
was the ‘verbal map’ described in chapter 3.5. This was critical to both low loss to follow-up in 
PRONUT, but also laid the ground for the later FUSAM study. All data collection forms, both 
routine ward forms and PRONUT/FUSAM-specific data collection forms are shown in Annexes 
D and E.  
 
FUSAM data 
FUSAM data collection forms are shown in Annex G. A dedicated FUSAM study team 
of 3 senior nurses participated in piloting of these forms and were trained to use the final 
versions.   
 FUSAM reviews were done either at MOYO if a carer returned for a 1 year visit, or at a 
patient’s home if an address was available to trace the patient. Target time for long term follow-
up was at least 1 year after original discharge from MOYO treatment. 
 Some minor differences from PRONUT data collection were: 
• Measurement of anthropometry.  
In PRONUT, two observers had measured in pairs and were able to repeat any measurements 
likely to be incorrect: identified by incompatible measurements or implausibly fast growth. In 
FUSAM field visits logistical constraints (a small field team) meant that the study nurse 
measured alone, with the trained study driver helping steady and reassure the child. When 
  Page  77
measuring siblings, there were no previous measurements to compare against. In such field 
conditions there was greater potential for error and extreme z-scores were therefore considered 
more likely to represent measurement errors than a child who is truly very small or very large. 
Following standard criteria(95), individuals with extreme z-scores were thus excluded from 
anthropometry-related analysis: 
- weight-for-height z-scores, WHZ (NCHS) <-4 or > +6 or 
- weight-for-age z-score, WAZ (NCHS) <-6 or >+6 or 
- height-for-age z-score HAZ (NCHS) <-6 or >+6 
Z-scores were calculated from weight, height/length, age and sex variables using ENA for 
SMART software, version October 2007(96).  
• Dates 
In PRONUT, accurate event dates were mostly available since they were observed on the ward. 
In FUSAM, especially when asking neighbours about date of death, there was on rare occasions 
some uncertainty. Where the month but not exact date was known, the 15th of the month was 
taken as the best estimate. If a sibling’s age but not year or month of birth was known, then the 
date was estimated as 1st July of the year which would give the stated age.  
 
 
 
5.2.5 Bias 
Several factors might have biased results: 
• Missing data due to  logistics constraints 
Completing or fully completing the FUSAM questionnaire was not always possible due to 
logistical reasons: 
- If a home address was not available no visit could be attempted and no information was 
available on long term outcomes.  
- Due to only one field team, one project vehicle and limited project funding, FUSAM visits 
were only made to children known not to have died before the study started in summer 2007. 
Some children were known to have died before this time, full FUSAM details were not always 
known since the full questionnaire had not yet been developed (e.g. asking about compliance 
with supplementary feeding and HIV treatment services). 
- Repeat visits to the same address were rarely made for collecting secondary outcomes alone. 
(e.g. sibling anthropometry).  
• Missing data due to patient confidentiality constraints 
In the community setting, it was not always appropriate to ask all the questions covered by the 
FUSAM questionnaire. e.g. relatives of neighbours sometimes reported that a family had moved 
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away. In such cases, it was often appropriate to ask whether the ex-MOYO child was alive or 
dead, but mostly inappropriate to ask further clinical questions.  
• Hawthorne effect 
FUSAM children, whether or not also enrolled in PRONUT, were treated in MOYO during the 
period of a research study. Though it was primarily a service ward rather than a specialised 
research unit, the extra staff, inputs and attention to carefully following protocols may have 
affected treatment impact. This possible effect of this cannot be quantified or adjusted for in 
analyses and may or may not have implications for generalizability which will be discussed 
later.   
• Recall bias 
This might have occurred if carers of children who died systematically recalled details of care 
and clinical progress differently to those who were still alive at FUSAM visit. For example, 
carers of children still alive might selectively remember better aspects of their original treatment 
and forget the worse aspects. The opposite might be true for carers of children who died as they 
seek to understand and explain the death. 
• Selection bias due to MOYO admissions system 
MOYO admissions are not representative of all SAM in the community and could even under-
represent cases of SAM presenting to the paediatric A&E at Queen Elizabeth Hospital: 
- Very sick patients might die in the admissions area or on the special care ward before 
transfer to MOYO 
- Borderline cases might be missed and wrongly sent to the normal paediatric wards 
instead of to MOYO. 
Whilst possible, the potential for these selection biases to influence the overall direction or 
interpretation of study results is minimal. Firstly, the two biases would likely cancel each other 
out: the first would cause underestimation of true SAM mortality; the second would 
underestimate SAM survival since it is the mild, low risk cases who are most likely to be 
missed.  
Furthermore, over the period of this study efforts were made to sensitise all staff in A&E and on 
the general wards to correctly identify and transfer children with SAM to MOYO. Nursing 
capacity on MOYO was also good. Patients who in previous years might have been admitted to 
other wards to receive oxygen or blood or similar were increasingly being looked after on 
MOYO itself. 
Minimising biases 
Exploring whether biases might have affected our overall conclusions, I examined 
baseline characteristics (thus not susceptible to recall bias) of all children. Comparing the profile 
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of unknowns against those known alive and those known dead gave some indication of what 
the unknown outcome is more likely to have been. 
5.2.6 Study Size 
Since baseline data for FUSAM relied on admission information collected by PRONUT, study 
size was determined by the numbers of children admitted to MOYO during the period of 
PRONUT enrolment (see chapter 4.2.6). FUSAM was a follow-on project rather than a 
completely separate study. Separate a-priori calculations were not therefore done prior to 
FUSAM.  
The strength of any positive findings can be easily seen by confidence intervals. 
Possible false negative findings can be harder to identify. An advantage of PRONUT in this 
respect is that it ranks among the larger SAM-related studies. The original sample size of 400 
per group was large enough, at 95% significance, 80% power, and accommodating 100 total 
losses to follow-up, to detect an inter-group difference of 65% vs. 75% cure. To show inter 
group mortality difference of 25% vs. 15%, 270 patients would be needed per group. Given that 
1024 patients were analysed in FUSAM (compared to 796 in PRONUT) it is clear that the effect 
of most clinically important exposures, even if unevenly distributed, would likely be observed. 
 
 
5.2.7 Quantitative variables 
Time to event in Kaplan-Meier analysis and Cox regression 
 Beginning time 0 was date of admission to MOYO ward. Small numbers of patients 
died within hours of admission to the ward. So that they would still be counted in the model, all 
those who died on day 0 were recoded as 0.5days of FUSAM follow-up. Time to FUSAM 
follow-up for other patients was calculated in days by subtracting date of admission from date 
of final known outcome (alive, dead or unknown/other).   
Time to follow-up was not constant for all patients, and could be longer for some 
patients than others because FUSAM visits were organized in batches, according to their home 
location. Repeat visits were also sometimes necessary to chase missing information, when for 
example a family was away from home when first visited. With only one follow-up team, it was 
logistically impossible to visit each patient at a fixed time post admission.  
 
5.2.8 Statistical methods 
Data entry and cleaning 
Similar to PRONUT, FUSAM data were entered in EpiData 3.1 (EpiData Association, Odense, 
Denmark, 2003-4). A dedicated data entry file was written with simple macros (‘Check’ files) 
that helped ensure high quality data entry, e.g. variables plausible, in-range and consistent with 
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other related variables. Key data (anthropometry, dates, final outcomes, HIV status) were 
double entered. This FUSAM database was then merged with the PRONUT database, 
describing complete patient care from original admission to final outcome.  
During data cleaning, inconsistent or unexpected results like long times to final 
outcome were cross checked against original patient files to ensure no data transcription or 
entry errors.  
Data analysis 
 Main analyses were performed using Stata Intercooled 10.0TM(StataCorp LP, USA).  
Chi-square tables and approximate confidence limits for relative risk were used to 
examine categorical data using StatCalc (CDC, Atlanta, USA, 1993). Where cell numbers are 
small, Fisher exact results are noted. 
 To assess the role of HIV as a possible confounder or effect modifier, major analyses 
included HIV serostatus (positive or negative) as a stratification level. 
Wealth index 
The PRONUT questionnaire recorded wealth-marking asset ownership (e.g. radio 
ownership, land ownership, access to electricity, type of water source). These were based on 
validated questions from the Malawi 2004 Demographic and Health Survey(97). Principal 
component analysis(98) was used to convert the multiple wealth items into a single index divided 
into wealth quintiles. 
 Kaplan-Meier analysis 
Time-to-death ‘step-up’ curves rather than ‘step-down’ survival curves are presented, 
in accordance with suggested best practice(99). This emphasises mortality as the primary study 
outcome, and also better demonstrates inter-group differences.  
Cox regression 
As evident from the initial curves, the effect of HIV appeared to change over time and 
thus violated the proportional hazards assumption. This was confirmed by a formal test using 
Schoenfeld residuals. Subsequent analyses are therefore presented stratified by HIV. Other 
major adjustor variables (admission oedema, admission age, admission MUAC, admission 
WAZ) did not violate the assumption. 
As will be discussed, there is no reason to believe that censored children due to 
unknown final outcomes had an atypical risk of death compared to non censored children.  
Due to tied times to failure especially early on in treatment, the ‘exactp’ option within 
Stata’s ‘stcox’ command was specified in all reported regression models. This was 
computationally more complex and hence slower but was the appropriate option in this study 
given the early tied failures. Using the default option gave minor differences in the detail of the 
results but no overall important differences which would have led to different conclusions.  
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5.2.9 Ethics 
Following completion of PRONUT, specific permission to follow up children long term was 
obtained from the COMREC (College of Medicine Research and Ethics Committee). Funding for 
the study was only obtained in mid 2007, so though the idea had been considered for some 
time, it was not previously known whether the study would be possible.  
Home follow-up is routine in nutrition programmes, follows a previous study based at 
MOYO(84) and has the particular advantage of being of direct benefit to the patient: being able to 
identify any problems, advise on, and where necessary refer for further care. 
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5.3 Results - Study flow chart and summary outcomes 
From 12th July 2006 to 14th March 2007, 1024 children were admitted to MOYO. Long term 
outcome information was found on 899/1024(88%). Short, medium and long term outcomes are 
summarized in the study flow chart: 
 
Figure 12 FUSAM study flow chart - all admissions to MOYO 
Key long term outcomes are defined as: 
• Late death  = death ≥90 days after original admission to the ward 
• Alive   = known alive at ≥ 1year after original admission to the ward. 
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5.3.1 FUSAM summary - total survivors 
A total of 462/1024(45%) children were known to be still alive at a year or more after discharge 
from treatment. Of these 432/462 (94%) were seen in person by the study team and 30/462 (6%) 
were reported by family or neighbours to be alive. 
Long term survival was greatest amongst children who had been successfully cured 
following initial treatment. Of 471 discharged from the OTP as nutritionally cured, 365/471 
(77%) were still alive at a year or more after their first admission. 
 
5.3.2 FUSAM summary - total mortality 
A total of 427/1024 (42%) children were known to have died. As will be explored in subsequent 
analyses, most deaths were early in the programme:  
• 238/427 (56%)  children died during initial inpatient treatment 
• 84/427 (20%) died in the medium term, within 90 days of programme admission 
• 105/427 (25%) died over the longer term follow-up period   
Most deaths were in children with underlying HIV: 
• 274/427 (64%) of all deaths were known seropositive. Differently expressed, 
274/445(62%) of known seropositive children died. 
• 77/427  (18%)  of all deaths were known seronegative. Differently expressed, 77/459 
(17%) of known seronegative children died.  
• 76/427  (18%) of all deaths were of unknown status. These were almost all very early 
ward deaths who died before a test could be done. 
 
5.3.3 FUSAM summary - Total unknown final outcome  
Final 1 year status was unknown for 135/1024 (13%) of children originally admitted: 
• 45/135  (33%)  could not be traced at the address given 
• 42/135  (31%)  did not give an address in the first place 
• 31/135  (23%)  had missing notes 
• 7/135   (5%)  lived too far away for the follow-up team to visit 
• 10/135  (7%) were reported alive but at <1year following the original admission. This 
happened where a family had moved from their original address and relatives or 
neighbours reported that the child was alive when last seen. In such cases, the date of 
final outcome was the date of that last reliable sighting. No assumptions were made 
about current status of the child at the 1 year visit. 
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5.4 Results – Baseline patient profile at admission to MOYO  
In this section I present patient characteristics at admission to the MOYO nutrition ward. The 
results columns highlight key issues which will be explored in subsequent analyses: 
• Which admission characteristics are associated with death and which with being still 
alive ≥1 year later 
• Are there any differences between those children who die early (inpatient or OTP 
deaths) and those who die late (>90 days after admission) 
• Do admission characteristics of children whose 1 year outcome is unknown suggest that 
they are more likely to be dead or alive (i.e. is there a likely systematic bias that would 
affect the validity of comparing known deaths vs. known live children) 
 
For simplicity, statistical comparisons between the groups are not presented here. 
Multivariable analyses will be presented later: these are important and necessary to account for 
issues like weight-based z-score indices in oedematous patients. Because of its known adverse 
effect on outcomes, relevant results are however stratified by HIV status. 
 
5.4.1 Age & sex profile 
Table 11 shows that children who died were younger than those still alive at 1 year. The 
youngest group were late deaths. The age of those whose final outcome was unknown was 
more similar to survivors than deaths. 
Sex ratio on admission was balanced close to 50% for all outcome groups except late deaths, 
who have a preponderance of boys.  
  
Table 11 Age and sex of MOYO patients, by final outcome 
 All patients 
 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at ≥1 
year post 
admission 
(n=462) 
Unknown 1 
year 
outcome 
 
(n=135) 
Age in months 
(median, IQR) 
21.5 (15 to 32) 19.4 (13 to 30) 18.8 (12 to 29) 23.3 (17 to 34) 23.8 (16 to 36) 
Boys 543/1024(53%) 156/322 (48%) 66/105 (63%) 251/462 (54%) 70/135 (52%) 
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5.4.2 Nutritional profile 
Table 12 shows that oedematous SAM was the dominant form of malnutrition, accounting for 
almost 70% of admissions. It was most prevalent among HIV negative patients, 85% of whom 
had oedematous SAM.  Children whose HIV status was unknown had a prevalence of 
kwashiorkor somewhere between those who were known seropositive and seronegative.  
 Risk of death was lower in oedematous than in non-oedematous SAM. Whilst severe 
wasting accounted for 27% of all admissions, it accounted for almost half of all deaths. Most 
wasted patients had both low weight-for-height and low MUAC. Twelve percent had a low 
MUAC <11cm alone; one percent had a normal MUAC but low weight-for-height. (annex H.1) 
 The admission profile of the unknown final outcome group was again more similar to 
those known alive than those known to have died 1 year. 
 
Table 12 Nutritional diagnosis of MOYO patients at admission, according to final outcome 
 All patients 
 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at ≥1 
year post 
admission 
(n=462) 
Unknown 1 
year 
outcome 
(n=135) 
Kwashiorkor (all) 697/1024 (68%) 175/322 (54%) 45/105 (43%) 383/462 (83%) 94/135 (70%) 
In  HIV ○-  391/459 (85%) 37/57 (65%) 13/20 (65%) 278/315 (88%) 63/67 (94%) 
In HIV ○+  237/445 (53%) 89/191 (47%) 31/83 (37%) 98/139 (71%) 19/32 (59%) 
In HIV unknown 69/120 (58%) 49/74 (66%) 1/2 (50.0%) 7/8 (88%) 12/36 (33%) 
Severe wasting (all) 275/1024 (27%) 135/322 (42%) 55/105 (52%) 69/462 (15%) 16/135 (12%) 
In  HIV ○-  61/459 (13%) 19/57(33%) 7/20 (35%) 33/315 (10%) 2/67 (3%) 
In HIV ○+  184/445 (41%) 92/191 (48%) 48/83 (58%) 32/139 (23%) 9/32 (28%) 
In HIV unknown 30/120 (25%) 24/74 (32%) 0/2 (0%) 1/8 (13%) 5/36 (14%) 
Not SAM or 
unknown 
52/1024 (5%) 12/322 (4%) 5/105 (5%) 10/462 (2%) 25/135 (19%) 
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5.4.3 Malnutrition severity (weight-for-height, weight-for-age and height-for-age z-scores) 
Admission anthropometry is shown in Table 13. An expanded version of this table is show in 
annex H.1.2, where each index is stratified by oedematous and non-oedematous malnutrition, 
and by HIV status.  
The message from this simple version of the results is clear: children who are more 
malnourished at baseline – whether defined by WHZ, WAZ or HAZ – are more likely to die 
than those with better z-scores.  
Yet again, those with unknown final outcomes have a z-score profile more similar to 
known survivors than to known deaths. 
 
Table 13 Weight-for-height, weight-for-age and height-for-age mean z-scores at admission, according to 
final outcome (SD) 
 All 
admissions 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 
year post 
admission 
(n=462) 
Unknown 1 
year 
outcome 
 
 (n=135) 
Weight-for-height -2.25 (1.3) -2.77 (1.2) -2.65 (1.2) -1.92 (1.2) -1.86 (1.3) 
Weight-for-age -3.59 (1.3) -4.13 (1.1) -4.30 (1.1) -3.18 (1.2) -3.14 (1.4) 
Height-for-age -3.23 (1.4) -3.43 (1.4) -3.88 (1.3) -3.03 (1.4) -2.94 (1.5) 
MUAC 11.6 (2.0) 10.6 (1.7) 10.6 (1.8) 12.3 (1.9) 12.2 (2.0) 
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5.4.4 HIV related profile 
Table 14 shows that HIV was prevalent in the MOYO population. For ease of interpretation, 
only death and survivor columns are shown: the full version of the table with additional 
columns for all patients and those with unknown final outcome is in annex H.1.3  
HIV status was known for almost 90% of all children. Large numbers of seronegative 
children also had symptoms and signs which would traditionally be considered as HIV staging 
criteria. Common reasons for them to have a stage 3 or 4 diagnosis include previous admissions 
to SFP, TFP and oral candida. 
 Clinical staging in both HIV seropositive and seronegative patients was more advanced 
among patients who died than in those alive at 1 year. CD4 was also lower among deaths, 
whether expressed as mean of all values or as % of children below the age-adjusted ‘severely 
low’ threshold.  
 
Table 14 Baseline HIV profile, according to final outcome 
 Inpatient or OTP 
death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 year post 
admission 
(n=462) 
Child HIV status    
HIV ○-  57 (18%) 20 (19%) 315 (68%) 
HIV ○+  191 (59%) 83 (70%) 139 (30%) 
HIV unknown 74 (23%) 2 (2%) 8 (2%) 
HIV staging: 
HIV ○-  only n=52 n=20 n=307 
Stage 0 7 (14%) 3 (15%) 86 (28%) 
Stage 1 or 2 6 (12%) 5 (25%) 51 (17%) 
Stage 3 35 (67%) 8 (40%) 129 (42%) 
Stage 4 4 (8%) 4 (20%) 41 (13%) 
HIV staging: 
HIV ○+  only n=185 n=83 n=134 
Stage 0 14 (8%) 9 (11%) 19 (14%) 
Stage 1 or 2 21 (11%) 6 (7%) 26 (19%) 
Stage 3 101 (55%) 53 (64%) 65 (49%) 
Stage 4 49 (27%) 15 (18%) 25 (18%) 
CD4* n=31 n=63 n=93 
CD4 severely low  
(age adjusted %)† 
27 (87%) 40 (63%) 45 (48%) 
CD4%, mean (SD) 12.9 (8.4) 17.1 (8.2) 20.5 (10.6) 
* Taken for HIV positive patients only, mostly taken at 1
st
 outpatient visit, 2 weeks after 
discharge from ward. Small numbers also available for ward patients. 
†Age adjusted thresholds for low CD4 were: CD4 <25% for infants aged <12 months; <20% for 
those aged 12 to 35 months; <15% for those aged 36 to 59months; <15% for those aged 60 
months or older (Source: ARV therapy of HIV infection in infants and children in resource-
limited settings, towards universal access: Recommendations for a public health approach 
(2006 revision) World Health Organization) 
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5.4.5 Clinical profile 
Table 15 shows the clinical profile of children at admission. For simplicity, only death and alive 
at 1 year columns are presented, with the full version of the table in Annex H.1.4.  
Several issues are important to note: 
- Almost all children present with symptoms of illness other than malnutrition. These were 
severe enough to have justified, for most children, visits to OTP clinics or taking of medication 
in the two weeks prior to MOYO admission. 
- Symptom prevalence was highest in children who died as inpatients or during OTP. For some 
but not all symptoms it was lowest in the 1 year survivors. 
- Common use of traditional charms (commonly necklaces, bracelets and string waist bands) 
may indicate prevalent beliefs in and use of traditional medicines prior to seeking MOYO care. 
- Prevalence of breastfeeding until 2 years was low, and lowest among those who died. 
- Clinically obvious disability was not uncommon and mostly comprised neurodisability such 
as cerebral palsy. Disability was commonest amongst those children who died.    
Table 15 Baseline clinical profile, according to final outcome 
 Inpatient or OTP 
death 
(n=322) 
Late death  
 
(n=105) 
Alive at >1 year post 
admission 
(n=462) 
Symptoms in previous 2 weeks 
Any 309/311 (99%) 102/105 (97%) 447/460 (97%) 
Fever 205/311 (66%) 73/104 (70%) 293/458 (64%) 
Diarrhoea 231/310 (75%) 72/105 (69%) 280/456 (61%) 
Vomiting 163/313 (52%) 42/105 (40%) 203/458 (44%) 
Abdominal pain 123/269 (46%) 37/104 (36%) 188/452 (42%) 
Fast or difficult 
breathing 
45/303 (15%) 20/104 (19%) 62/457 (14%) 
Cough 193/308 (63%) 76/105 (72%) 254/459 (55%) 
Anorexia 169/294 (57%) 51/104 (49%) 230/454 (51%) 
Flaky paint dermatosis 49/306 (16%) 14/104 (13%) 89/452 (20%) 
Other 84/314 (27%) 34/104 (33%) 101/454 (22%) 
Outpatient consultations in 2 weeks prior to admission (any) 
Any 204/271 (75%) 68/102 (67%) 318/456 (70%) 
Medication use in last 2 weeks prior to admission 
Any  264/296 (89%) 95/103 (92%) 394/450 (88%) 
Anaemia    
Any (PCV<30) 103/294 (35%) 39/96 (41%) 141/424 (33%) 
Severe (PCV <15) 11/294 (4%) 1/96 (1%) 5/424 (1%) 
Malaria  
(+ve thick blood film) 
9/292 (3%) 3/94 (3%) 21/415 (5%) 
Has traditional medicine 
amulet or charm 
87/266 (32%) 25/100 (25%) 108/444 (24%) 
Breastfed  
(<2 year olds only) 
102/192 (53%) 47/69 (68%) 79/243 (33%) 
Disability 
(any) 
24/282 (9%) 9/102 (9%) 22/453 (5%) 
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5.4.6 Past medical history 
Table 16 shows past medical history. Again only three columns are shown for simplicity, the 
full table is in Annex H.1.5.  
High morbidity is experienced by all children. Many have had recent inpatient 
admissions or admissions for previous SAM. Almost all had outpatient episodes in the last 6 
months. Almost one quarter of those with outpatient visits reported signs of symptoms 
consistent with SAM – yet were not then referred for inpatient treatment which at the time was 
standard treatment (CTC was not then available in Blantyre district). 
  
Table 16 Past medical history 
 Inpatient or OTP 
death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 year 
post admission 
 
(n=462) 
Past inpatient and outpatient episodes  (any) 
Inpatient admissions   
(non-SAM,  
in past year) 
88/283 (31%) 22/102 (22%) 69/444 (16%) 
Inpatient admissions 
 (for SAM, ever) 
47/282 (17%) 15/102 (15%) 57/452 (13%) 
Outpatient episodes  
(last 6 months) 
233/253 (92%) 90/98 (92%) 396/440 (90%) 
Outpatient episodes 
(last 6 months, with 
symptoms suggestive of 
malnutrition) 
60/254 (24%) 26/97 (27%) 84/437 (19%) 
Outpatient episodes 
(for SFP, ever) 
62/267 (23%) 29/102 (28%) 93/445 (21%) 
Ex Low Birth weight 
(reported by carer) 
29/257 (11%) 13/98 (13%) 39/449 (9%) 
Ever  had TB 15/273 (5%) 4/103 (4%) 10/450 (2%) 
Ever had measles vaccine 232/290 (80%) 81/98 (82%) 401/448 (90%) 
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5.4.7 Family and socioeconomic status 
 
Table 17 shows the family profile (full table in annex H.1.6). Key results include: 
- There is a high prevalence of orphaning: 
- Almost a quarter of families have lost a previous child 
- There was no obvious pattern in birth order of the MOYO child 
- Most mothers reported having had at least primary school education, yet almost a third also 
described themselves as illiterate. 
- Fathers were overall better educated than mothers, with fewer reports of illiteracy. 
Table 17 Family profile 
 Inpatient or OTP 
death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 year 
post admission 
 
(n=462) 
Orphan    
Mother died 18/264 (7%) 10/102 (10%) 36/457 (8%) 
Father died 22/261 (8%) 9/102 (9%) 28/452 (6%) 
Both dead 9/240 (4%) 4/91 (4%) 10/410 (2%) 
Previous child death in family 76/306 (25%) 24/103 (23%) 110/457 (24%) 
Birth order of MOYO child    
First 76/272 (28%) 26/103 (25%) 126/453 (28%) 
Second 70/272 (26%) 26/103 (25%) 115/453 (25%) 
Third 60/272 (22%) 20/103 (19%) 87/453 (19%) 
Fourth or later 66/272 (24%) 31/103 (30%) 125/453 (28%) 
Maternal education    
None 30/254 (12%) 13/98 (13%) 51/433 (12%) 
Primary school 164/254 (65%) 70/98 (71%) 303/433 (70%) 
Secondary school 60/254 (24%) 15/98 (15%) 79/433 (18%) 
Paternal education    
None 10/176 (6%) 1/68 (1%) 14/337 (4%) 
Primary school 77/176 (44%) 31/68 (46%) 156/337 (46%) 
Secondary school 89/176 (51%) 36/68 (53%) 167/337 (50%) 
Mother  illiterate 88/256 (34%) 35/100 (35%) 160/437 (37%) 
Father illiterate 25/233 (11%) 5/93 (5%) 36/423 (9%) 
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Table 18 shows socioeconomic status (and annex H.1.7 the full version of this table).  
Three results are noteworthy: 
- Over half of all children arrive to MOYO having been referred from their local health centre. 
(NB This should not count as visit to outpatient clinic in the last two weeks, though I cannot 
exclude the possibility that some patients misinterpreted the question) 
- Children from richer families appear to be at greater risk of death than those from poorer 
families.  
- Most families have access to piped or borehole water which is generally good drinking 
quality.  
Table 18 Socioeconomic status & residence 
 Inpatient or OTP 
death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 year 
post admission 
 
(n=462) 
Mother’s occupation    
Housewife 135/322 (42%) 55/105 (52%) 242/462 (52%) 
Ganyu* 44/322 (14%) 16/105 (15%) 81/462 (18%) 
Employee/ self employed 63/322 (20%) 25/105 (24%) 95/462 (21%) 
Other or unknown 80/322 (25%) 9/105 (9%) 44/462 (10%) 
Father’s occupation    
Unemployed 76/322 (24%) 17/105 (16%) 66/462 (14%) 
Ganyu* 38/322 (12%) 17/105 (16%) 86/462 (19%) 
Employee/self 
employed/other 
or unknown 
208/322 (65%) 71/105 (68%) 310/462 (67%) 
Rural residence 82/256 (32%) 34/99 (34%) 191/451 (42%) 
Admitted to MOYO:    
Direct to MOYO or 
readmission 
90/244 (37%) 35/98 (36%) 124/427 (29%) 
Via other QECH  paediatric 
ward 
22/244 (9%) 10/98 (10%) 21/427 (5%) 
Referred from other clinic 132/244 (54%) 53/98 (54%) 282/427 (66%) 
Wealth quintile    
Poorest 43/240 (18%) 17/95(18%) 97/426 (23%) 
2
nd
 poorest 49/240 (20%) 14/95 (15%) 92/426 (22%) 
Middle 44/240 (18%) 23/95 (24%) 82/426 (19%) 
2
nd
 richest 50/240 (21%) 15/95 (16%) 83/426 (19%) 
Richest 54/240 (23%) 26/95 (27%) 72/426 (17%) 
Main household water source    
Piped 156/264 (59%) 59/101 (58%) 227/455 (50%) 
Borehole 74/264 (28%) 29/101 (29%) 177/455 (39%) 
Well or spring 34/264 (13%) 13/101 (13%) 51/455 (11%) 
Main household toilet    
Flush toilet 5/264 (2%) 4/101 (4%) 12/455 (3%) 
Traditional pit (own) 110/264 (42%) 30/101 (30%) 179/455 (39%) 
Traditional pit (shared) 148/264 (56%) 67/101 (66%) 259/455 (57%) 
Bush toilet or other 1/264 (0.4%) 0/101 (0%) 5/455 (1%) 
*Ganyu is short term seasonal labour such as clearing overgrown roadside grass after the rainy 
season, in return for cash or in-kind payment. 
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5.5 What explains mortality or survival? Kaplan-Meier failure curves and Cox regression 
 
5.5.1 Kaplan-Meier failure curve – all patients 
A total of 1003 children were included in this analysis. Of the 21/1024(2.1%) of original 
admissions not included, date of final outcome was unknown for 1 child who died and for 20 
whose long term outcome was unknown.  
Mean follow-up time was 278 days (SD 249), range 0.5 days to 809 days. Median time to 
final long-term outcome was 287 days, IQR 11 to 529. 
The unadjusted curve in figure 13 confirms a key message already noted in the study 
flow chart: most mortality occurs soon after admission to programme. Median time to death 
was 10 days, IQR 3 days to 69 days. This compares to median time in programme (defined as 
from admission to final programme outcome e.g. time-to-cure; time to failure of nutritional 
therapy) of 33 days, IQR 9 to 43 days. 
278/427 (65%) of deaths occurred within 30 days of admission. The 1 year Kaplan-Meier 
mortality rate was 42% (95%CI 39% to 45%) and the 2 year mortality rate was 48% (95% CI 44% 
to 52%). 
 
 
 
 
 
 
 
 
Figure 13 Kaplan 
Meier failure curve, all 
patients in the study. 
 
 
The table below the graph shows: 
- numbers of children ‘at risk’ at the beginning of a particular time period (e.g. 1003 children are 
in the study at time=0; 525 remain under follow-up at 6 months.) 
- (in parentheses), deaths in a given time period (e.g. 368 children died between 0 and 6 months; 
31 died between 6 and 12 months) 
The number at risk in a particular time period is not simply the number previously at-risk 
minus the number died. Other outcomes are also possible (e.g. default; moved away). These 
children also drop out of the analysis (are ‘censored’): hence the denominator changes and the 
y-axis is mortality probability rather than percentage. 
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5.5.2 Kaplan-Meier failure curves – by HIV 
Failure curves by HIV serostatus illustrate the marked adverse impact of HIV on mortality.  
 
Figure 14 Kaplan Meier failure curves, by HIV serostatus 
 
 
For both HIV negative and positive patients, most deaths occur soon after admission. For HIV 
negative patients, ongoing mortality after the first 90 days does occur but is limited. This 
contrasts with HIV positive patients who experience high rates of ongoing mortality, even later 
than 1 year post-admission (table 19). HIV related risks are not thus constant over the whole 
time period, which is why most of the reported Cox regression tables are presented stratified by 
HIV. The Log-rank test for difference between HIV negative and positive mortality was 
p<0.0001. 
 
Table 19 Kaplan-Meier failure function showing early mortality probability at 30 and 90 days, and late 
mortality probability at 1 and 2 years after admission to programme 
 Time after admission to programme 
 30 days 90 days 1 year 2 years 
HIV negative 
(n=459) 
12% (9 to 15) 13% (11 to 17) 16% (13 to 20) 19% (15 to 23) 
HIV positive 
(n=445) 
35% (30 to 39) 46% (42 to 51) 60% (55 to 65) 69% (63 to 74) 
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5.5.3 What explains adverse SAM outcomes – malnutrition severity? 
Severity of malnutrition at admission to a therapeutic feeding programme is known to strongly 
predict short term mortality. Table 20 shows that it also predicts total (short, mid and long term 
combined) mortality in the FUSAM study. Adjusting for age, oedema and HIV, low baseline 
MUAC <11cm, WHZ <-3 and WAZ <3 are all strongly associated with death, whereas low HAZ 
is not. The effect of age is inconsistent, with under 12month olds alone having significantly 
elevated hazards for mortality. There is no clear age-related hazard gradient. 
 
Table 20 Cox regression exploring baseline anthropometry as a predictor of death at 2 years 
Risk factor  Number 
of deaths 
% dead by 2 
year 
Hazard ratio 
(95% CI) 
Adjusted hazard 
ratio* (95% CI) 
P  
(adj.) 
Sex Girls 202/469 
(43%) 
48 (43 to 54) Ref. Ref.  
 Boys 221/530 
(42%) 
48 (43 to 53) 0.92 (0.76 to 1.12) 1.00 (0.81 to 1.24) 0.97 
Age group 
(in months) 
>= 60m 30/88 
(34%) 
37 (28 to 49) 1.11 (0.58 to 2.12) 1.14 (0.55 to 2.37) 0.72 
 48 to 
<60m 
13/42 
(31%) 
33 (21 to 51) Ref. Ref.  
 36 to 
<48m 
25/68 
(37%) 
40 (29 to 54)† 1.27 (0.65 to 2.49) 1.69 (0.80 to 3.55) 0.17 
 24 to 
<36m 
85/230 
(37%) 
37 (31 to 44)† 1.26 (0.70 to 2.25) 1.19 (0.61 to 2.32) 0.61 
 12 to 
<24m 
176/430 
(41%) 
47 ( 41 to 53) 1.42 (0.81 to 2.49) 1.45 (0.76 to 2.78) 0.26 
 0 to 
<12m 
97/145 
(67%) 
67 (59 to 75) 2.89 (1.62 to 5.17) 2.30 (1.17 to 4.51) 0.02 
Oedema No 205/305 
(67%) 
74 (68 to 80) Ref. Ref.  
 Yes 220/694 
(32%) 
35 (31 to 40) 0.37 (0.30 to 0.44) 0.56 (0.44 to 0.71) <0.001 
MUAC ≥ 11cm 152/563 
(27%) 
30 (26 to 34) Ref. Ref.  
 < 11cm 266/428 
(62%) 
69 (64 to 75) 2.94 (2.40 to 3.60) 1.71 (1.29 to 2.28) <0.001 
WHZ ≥ -3 217/674 
(32%) 
38 (33 to 43) Ref. Ref.  
 < -3 189/295 
(64%) 
69 (63 to 75) 2.62 (2.15 to 3.20) 1.81 (1.42 to 2.31) <0.001 
WAZ ≥ -3 57/314 
(18%) 
22 (17 to 29) Ref. Ref.  
 < -3 365/681 
(54%) 
59 (55 to 64) 3.71 (2.80 to 4.91) 2.23 (1.58 to 3.13) <0.001 
HAZ ≥ -3 132/415 
(32%) 
35 (30 to 41) Ref. Ref.  
 < -3 282/570 
(49%) 
56 (51 to 61) 1.71 (1.39 to 2.11) 1.21 (0.95 to 1.55) 0.13 
HIV Negative 77/459 
(17%) 
19 (15 to 23) Ref. Ref.  
 Positive 273/443 
(62%) 
69 (63 to 74) 4.93 (3.82 to 6.36) 4.06 (3.10 to 5.30) <0.001 
* Adjusted for age, oedema, and HIV 
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Table 21 shows the same risk factors expressed as continuous rather than categorical variables. Due to the non-proportionality of risks, HIV negative and positive 
children are shown separately. Adjusted for admission oedema and age, higher admission WHZ, WAZ and MUAC and oedema are all associated with decreased 
risk of death. The hazard ratios represent the reduction in risk for each unit increase in z-score or cm of MUAC. As with the previous analysis, low HAZ is not 
associated with increased mortality.  For HIV negative children, the magnitude of risk reduction per unit improved WHZ, WAZ and MUAC is similar for both short 
and long term mortality. For HIV positive patients, adjusted WHZ and MUAC are not associated with short term mortality risk but are highly associated with long 
term risk.  WAZ is related to both, but more strongly to long term outcomes than short term outcomes, as evidenced by the lower hazard ratio of 0.76 vs 0.85.  
Table 21 Cox regression exploring baseline anthropometry as a risk factor for death in 1
st
 90 days vs. all deaths, by HIV serostatus (adjusted hazard ratios) 
Risk factor  Hazard ratio for death in 1
st
 90 days*  Hazard ratio for all deaths (short, mid and long term)* 
  HIV negative p HIV positive p  HIV negative p HIV positive p 
Sex Boys 0.93 (0.54 to 1.60) 0.80 0.95 (0.71 to 1.28) 0.75  1.12 (0.71 to 1.76) 0.63 0.95 (0.74 to 1.21) 0.69 
Age >= 60m 0.60 (0.06 to 6.10) 0.67 0.51 (0.18 to 1.46) 0.21  0.80 (0.20 to 3.32) 0.75 1.31 (0.56 to 3.10) 0.54 
 48 to <60m Ref. - Ref. -  Ref. - Ref. - 
 36 to <48m 0.82 (0.09 to 7.78) 0.87 0.49 (0.17 to 1.44) 0.20  0.79 (0.18 to 3.56) 0.76 2.17 (0.91 to 5.17) 0.82 
 24 to <36m 0.86 (0.11 to 7.04) 0.89 0.51 (0.19 to 1.36) 0.18  0.60 (0.16 to 2.18) 0.44 1.45 (0.66 to 3.21) 0.35 
 12 to <24m 1.81 (0.24 to 13.68) 0.57 0.48 (0.18 to 1.26) 0.14  0.92 (0.28 to 3.00) 0.88 1.77 (0.82 to 3.84) 0.15 
 0 to <12m 1.78 (0.22 to 14.30) 0.59 0.53 (0.19 to 1.44) 0.21  1.68 (0.48 to 5.86) 0.41 2.57 (1.15 to 5.75) 0.02 
Oedema present  0.33 (0.17 to 0.63) 0.001 0.89 (0.65 to 1.22) 0.49  0.35 (0.21 to 0.58) <0.001 0.63 (0.48 to 0.81) <0.001 
Admission WHZ 0.72 (0.56 to 0.93) 0.01 0.89 (0.76 to 1.03) 0.13  0.72 (0.57 to 0.90) 0.004 0.77 (0.68 to 0.88) <0.001 
Admission WAZ 0.66 (0.51 to 0.86) 0.002 0.85 (0.73 to 1.00) 0.05  0.66 (0.53 to 0.82) <0.001 0.76 (0.66 to 0.87) <0.001 
Admission HAZ 0.85 (0.71 to 1.02) 0.10 0.93 (0.83 to 1.05) 0.25  0.85 (0.72 to 1.00) 0.06 0.95 (0.86 to 1.05) 0.33 
Admission MUAC 0.77 (0.65 to 0.93) 0.005 0.92 (0.83 to 1.03) 0.15  0.77 (0.65 to 0.90) 0.001 0.83 (0.76 to 0.91) <0.001 
 Hazard ratios represent hazard of death for each unit increase. e.g. for 1 z-score increase in admission WHZ, the hazard ratio for death in 1st 90 days for HIV negative 
patients is 0.72 (0.56 to 0.93), (=”the risk of death significantly decrease as WHZ improves”). 
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Table 22 explores how discharge anthropometry, adjusted for admission status affects mortality risk. Only those children whose initial OTP outcome was cure are 
analysed in this table. This is to avoid autocorrelation: were deaths included, that would be misleading, since anthropometry at death for those who die soon after 
admission is very close to anthropometry at admission and anthropometry at admission has  already been shown to predict death. So the purpose of this table is to 
add some temporal ‘gap’ and discriminate between those who have a better and worse discharge anthropometry whilst controlling for how they were at admission. 
 The table shows that a better weight gain (in g/kg/day) is associated with significantly less deaths, but in HIV positive patients only. It also shows that 
higher discharge MUAC is associated with significantly less death, but in HIV negative patients only. For every 1cm better MUAC at discharge (adjusted for 
admission MUAC, oedema, sex, age and admission WAZ), the hazards of death is reduced by 0.41 (95% CI 0.19 to 0.91). Though not significant, there is also a trend 
towards the same finding in HIV positive children (p=0.13).  
 
Table 22 Cox regression exploring discharge anthropometry as a risk factor for death, by HIV serostatus 
Risk factor  Hazard ratio for all deaths (short, mid and long term)* 
  HIV negative p HIV positive p 
Discharge WHZ  0.83 (0.36 to 1.91) 0.67 0.74 (0.41 to 1.32) 0.30 
WHZ change (z-scores)  0.56 (0.25 to 1.28) 0.17 0.65 (0.40 to 1.07) 0.09 
Weight gain (g/kg/day)  1.01 (0.81 to 1.27) 0.92 0.87 (0.77 to 0.99) 0.03 
Discharge WAZ  0.63 (0.20 to 2.00) 0.44 0.68 (0.35 to 1.32) 0.26 
WAZ change (z-scores)  0.63 (0.20 to 2.00) 0.44 0.68 (0.35 to 1.32) 0.26 
Discharge MUAC (cm)  0.41 (0.19 to 0.91) 0.03 0.73 (0.49 to 1.09) 0.13 
MUAC change (cm)  0.59 (0.26 to 1.32) 0.20 0.73 (0.48 to 1.10) 0.13 
* Adjusted for admission oedema, age, and sex, WAZ and MUAC 
  Page  97
5.5.4 What explains adverse SAM outcomes – HIV status? 
Hazard ratios in table 23 and subsequent tables are adjusted for sex and age as well as admission oedema and WAZ. This is because they may plausibly 
affect clinical, family and socioeconomic variables. For example, carers may selectively prioritize older children or male children when seeking medical care. Hence 
even though not associated with mortality on univariate analyses, age and sex are kept in the model. Only MUAC rather than MUAC and WHZ is included because 
both are markers of wasting and hence highly correlated with each other. WAZ meanwhile represents another facet of nutritional status and is included. HAZ is not 
included since on univariable analysis (table 20) it is not shown to predict mortality. 
The strong adverse impact of HIV seropositivity has already been noted in Kaplan-Meier failure curves in section 5.5.2. Table 23 addresses the hypothesis 
that more advanced disease, assessed by WHO clinical staging criteria for HIV severity, is associated with worse outcomes. As noted in section 5.4.4, both HIV 
positive and HIV negative malnourished children have signs and symptoms consistent with WHO criteria that are usually applied only to HIV positive children. 
Both are therefore presented.  
Table 23 shows that severity of illness at admission, expressed by WHO clinical stage, is not related to ether short or long term mortality risk. Severely low 
CD4 does however predict mortality. The hazard ratio is highest for short term mortality though wide confidence intervals mean it is not statistically significant. 
Severely low CD4 (which, is in effect, terminal AIDS) is a highly significant predictor of long term mortality, though the hazard ratio is just 1.89 (1.18 to 3.03).   
Table 23 Cox regression exploring signs and symptoms of HIV disease a risk factor for death in 1
st
 90 days vs. all deaths, by HIV serostatus 
Risk factor  Hazard ratio for death in 1
st
 90 days*  Hazard ratio for all deaths (short, mid and long term)* 
  HIV negative p HIV positive p  HIV negative p HIV positive p 
HIV stage 0  Ref. - Ref. -  Ref. - Ref. - 
Stage 1 or 2  0.60 (0.16 to 2.30) 0.46 1.11 (0.55 to 2.24) 0.77  1.80 (0.76 to 4.28) 0.19 0.81 (0.46 to 1.43) 0.46 
Stage 3  1.47 (0.60 to 3.64) 0.40 0.88 (0.50 to 1.57) 0.67  1.88 (0.92 to 3.83) 0.08 1.14 (0.72 to 1.79) 0.58 
Stage 4  0.63 (0.16 to 2.45) 0.51 0.86 (0.46 to 1.63) 0.65  1.22 (0.45 to 3.30) 0.69 1.28 (0.76 to 2.14) 0.35 
Severe low CD4 
(age-adjusted) 
 n/a - 3.24 (0.92 to 11.4) 0.07  n/a - 1.89 (1.18 to 3.03) 0.008 
* Adjusted for admission oedema, age, sex, WAZ and MUAC. NB. Stage 0 represents no signs and symptoms of HIV. Stage 4 represents advanced disease. 
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5.5.5 What explains adverse SAM outcomes – baseline clinical severity of illness? 
Table 24 explores clinical factors predicting short and long term mortality. Of symptoms in the previous 2 weeks, diarrhoea in HIV negative patients is associated 
with increased hazards of short term mortality. Fast or difficult breathing is associated with short term death in HIV negative patients and long term deaths in HIV 
positive patients. In both cases however, the hazards are reduced rather than increased, as might be clinically more plausible. This highlights the risk of multiple 
analyses: chance alone may yield statistically significant findings which are not necessarily indicative of real processes or risks. 
 Other statistically significant findings which are more plausibly real are  
- Increased mortality hazards for severe anaemia in HIV negative patients in the short term and for HIV positive patients in the long term. 
- Increased mortality hazards for not breastfeeding in HIV negative children for short term mortality alone 
- Increased mortality hazards associated with disability. The hazard is elevated for all groups, though wide confidence intervals mean it is only significant for short 
term HIV positive deaths and long term HIV negative deaths. 
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     Table 24  Cox regression exploring clinical status at admission as a risk factor for death in 1st 90 days vs all deaths, by HIV serostatus 
Risk factor  Hazard ratio for death in 1
st
 90 days*  Hazard ratio for all deaths (short, mid and long term)* 
  HIV negative p HIV positive p  HIV negative p HIV positive p 
Symptoms in previous 2 weeks         
Fever  0.66 (0.35 to 1.25) 0.20 0.97 (0.70 to 1.34) 0.84  0.96 (0.58 to 1.58) 0.87 0.85 (0.65 to 1.12) 0.25 
Diarrhoea  2.04 (1.05 to 3.97) 0.04 0.81 (0.57 to 1.14) 0.23  1.59 (0.95 to 2.68) 0.08 1.15 (0.88 to 1.51) 0.31 
Vomiting  1.71 (0.91 to 3.22) 0.10 1.20 (0.88 to 1.62) 0.25  0.84 (0.52 to 1.37) 0.49 1.23 (0.96 to 1.58) 0.10 
Abdominal 
pain 
 1.38 (0.72 to 2.63) 0.33 1.28 (0.92 to 1.78) 0.14  1.41 (0.86 to 2.30) 0.17 0.99 (0.76 to 1.28)  0.92 
Fast or 
difficult 
breathing 
 0.32 (0.14 to 0.77) 0.01 0.82 (0.54 to 1.25) 0.36  1.12 (0.59 to 2.12) 0.72 0.71 (0.51 to 0.99) 0.04 
Cough  0.93 (0.49 to 1.76) 0.83 1.03 (0.75 to 1.42) 0.19  1.06 (0.65 to 1.74) 0.80 1.03 (0.79 to 1.36) 0.80 
Anorexia  1.15 (0.58 to 2.28) 0.68 1.21 (0.87 to 1.66) 0.26  0.75 (0.46 to 1.22) 0.25 1.17 (0.91 to 1.51) 0.22 
Flaky paint 
dematosis 
 1.00 (0.52 to 1.94) 0.99 0.99 (0.60 to 1.67) 0.99  1.66 (0.93 to 2.96) 0.09 1.14 (0.75 to 1.72) 0.54 
Other  0.95 (0.49 to 1.83) 0.87 0.91 (0.65 to 1.26) 0.57  1.10 (0.65 to 1.87) 0.72 1.04 (0.80 to 1.35) 0.78 
Outpatient visits (any) 1.65 (0.76 to 3.58) 0.21 1.14 (0.79 to 1.63) 0.49  1.29 (0.75 to 2.20) 0.36 1.03 (0.77 to 1.38) 0.83 
Any drugs  1.08 (0.42 to 2.77) 0.88 1.19 (0.68 to 2.11) 0.54  0.80 (0.42 to 1.52) 0.49 1.11 (0.67 to 1.83) 0.69 
Anaemia           
Any (PCV<30)  0.90 (0.47 to 1.74) 0.76 0.92 (0.66 to 1.28) 0.61  1.08 (0.65 to 1.80) 0.76 1.05 (0.80 to 1.36) 0.73 
Severe (PCV <10) 11.95 (1.66 to 86.19) 0.01 1.38 (0.59 to 3.23) 0.45  2.19 (0.66 to 7.23) 0.20 2.62 (1.18 to 5.84) 0.02 
Malaria  0.28 (0.04 to 2.18) 0.22 0.93 (0.36 to 2.38) 0.88  0.26 (0.04 to 1.88) 0.18 0.94 to 0.46 to 1.95) 0.88 
Has traditional medicine 
amulet or charm 
1.25 (0.67 to 2.32) 0.48 0.98 (0.67 to 1.42) 0.90  1.40 (0.81 to 2.40) 0.23 1.00 (0.73 to 1.35) 0.99 
Not breastfed (<2 year olds 
only) 
3.06 (1.34 to 6.95) 0.01 1.36 (0.80 to 1.35) 0.13  0.67 (0.36 to 1.26) 0.21 0.98 (0.70 to 1.38) 0.92 
Disability (any) 1.97 (0.82 to 4.69) 0.13 2.37 (1.11 to 5.07) 0.03  2.77 (1.43 to 5.34) 0.002 1.76 (0.94 to 3.28) 0.08 
* Adjusted for oedema, age, sex , admission WAZ and admission MUAC 
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5.5.6 What explains adverse SAM outcomes – risk factors in past medical history? 
Table 25 explores features of a child’s past medical history as a risk factor for death. Differences by HIV serostatus are evidenced by differing hazard ratios, though 
few are statistically significant. Ever having had TB is the only factor which significantly increases the hazards of mortality: then only in HIV positive patients and 
only for short term deaths alone. The magnitude of this effect is not great: 2.20 (1.18 to 4.10) increased hazards. 
   
Table 25 Cox regression exploring past medical history as a risk factor for death in 1
st
 90 days vs all deaths, by HIV serostatus 
Risk factor  Hazard ratio for death in 1
st
 90 days*  Hazard ratio for all deaths (short, mid and long term)* 
  HIV negative p HIV positive p  HIV negative p HIV positive p 
Past inpatient and outpatient episodes  (any)         
Inpatient admissions   
(non-SAM, in past year) 
0.78 (0.34 to 1.77) 0.54 1.46 (1.03 to 2.05) 0.03  1.03 (0.55 to 1.91) 0.94 1.31 (0.99 to 1.75) 0.06 
Inpatient admissions 
 (for SAM, ever) 
0.65 (0.14 to 3.08) 0.58 0.84 (0.59 to 1.28) 0.42  0.49 (0.18 to 1.35) 0.17 1.22 (0.86 to 1.75) 0.27 
Outpatient episodes  
(last 6 months) 
1.60 (0.49 to 5.21) 0.44 1.10 (0.58 to 2.09) 0.76  0.69 (0.34 to 1.40) 0.30 0.69 (0.40 to 1.21) 0.20 
Outpatient episodes 
(last 6 months, with 
symptoms suggestive of 
malnutrition) 
1.89 (0.82 to 4.34) 0.14 0.75 (0.52 to 1.09) 0.13  1.33 (0.74 to 2.41) 0.34 1.00 (0.74 to 1.36) 1.00 
Outpatient episodes 
(for SFP, ever) 
1.30 (0.62 to 2.72) 0.49 0.72 (0.49 to 1.06) 0.10  0.72 (0.40 to 1.32) 0.29 0.92 (0.69 to 1.23) 0.58 
Ex Low Birth weight 
(reported by carer) 
1.99 (0.79 to 4.98) 0.15 1.17 (0.70 to 1.96) 0.55  1.39 (0.69 to 2.81) 0.36 0.74 (0.49 to 1.12) 0.16 
Ever  had TB  4.85 (0.50 to 47.11) 0.17 2.20 (1.18 to 4.10) 0.01  2.81 (0.35 to 22.7) 0.33 1.27 (0.77 to 2.09) 0.35 
Ever had measles vaccine 1.59 (070 to 3.63) 0.27 0.70 (0.40 to 1.20) 0.19  1.60 (0.71 to 3.58) 0.26 0.96 (0.61 to 1.50) 0.85 
* Adjusted for oedema, age, sex, admission WAZ and admission MUAC  
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5.5.7 What explains adverse SAM outcomes – family and socioeconomic risk factors? 
Table 26 shows that adjusted for age, sex and admission oedema, WAZ and MUAC, and most types of orphaning have no significant effect on mortality. There is a 
possible trend to effect in HIV negative double orphans (p=0.07). Parental education or literacy likewise have no clear effect on mortality. Birth order is statistically 
relevant, but only for short term mortality: hazards are increased for third-born HIV positive children and for fourth-born (or later) HIV negative children (though 
the wide confidence intervals likely reflect small numbers). Hazards are lowest for children who were second-born. 
Table 27 explores socioeconomic risk factors for mortality. Parental occupation does not appear to have a role, and neither does rural residence, water source, or 
socioeconomic quintile. There is no clear socioeconomic risk gradient: essential background for interpreting the sole elevated hazard of short term death in 2nd 
richest HIV positive patients. 
Admission route to MOYO also does not appear to affect mortality risk. There is a non-significant trend towards increased hazards of short term death for those 
admitted first to another of the Queen’s hospital paediatric wards and only then to MOYO. This is plausible given that most such admissions were very sick children 
admitted to the “Special Care ward” on account of better overnight nursing numbers in the high dependency unit.   
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Table 26 Cox regression exploring family risk factors for death in 1
st
 90 days vs all deaths, by HIV serostatus 
Risk factor  Hazard ratio for death in 1
st
 90 days*  Hazard ratio for all deaths (short, mid and long term)* 
  HIV negative p HIV positive p  HIV negative p HIV positive p 
Orphan         
Mother died 1.48 (0.32 to 6.82) 0.62 1.24 (0.66 to 2.33) 0.50  0.97 (0.35 to 2.70) 0.95 0.72 (0.45 to 1.15) 0.17 
Father died  1.88 (0.52 to 6.87) 0.34 1.10 (0.62 to 1.93) 0.75  1.33 (0.52 to 3.42) 0.56 1.35 (0.84 to 2.16) 0.21 
Both dead  2.18 (0.43 to 10.94) 0.35 1.27 (0.46 to 3.48) 0.65  2.78 (0.92 to 8.34) 0.07 1.07 (0.47 to 2.45) 0.17 
Previous child death in 
family 
0.59 (0.24 to 1.48) 0.27 1.04 (0.73 to 1.47) 0.84  0.54 (0.26 to 1.14) 0.11 0.89 (0.67 to 1.18) 0.42 
Birth order of MOYO child          
First  1.43 (0.63 to 3.24) 0.39 1.88 (1.22 to 2.91) 0.005  1.05 (0.55 to 2.02) 0.88 0.95 (0.66 to 1.36) 0.77 
Second  Ref - Ref.   Ref.  Ref.  
Third  1.11 (0.38 to 3.26) 0.85 1.57 (1.01 to 2.42) 0.04  0.78 (0.35 to 1.74) 0.55 1.03 (0.72 to 1.47) 0.87 
Fourth or 
later 
 8.16 (3.06 to 21.71) <0.001 1.66 (1.06 to 2.61) 0.03  0.97 (0.48 to 1.93) 0.92 0.83 (0.58 to 1.18) 0.29 
Maternal education          
None  Ref.  Ref.   Ref.  Ref.  
Primary school 1.05 (0.41 to 2.63) 0.93 0.74 (0.42 to 1.30) 0.29  1.06 (0.53 to 2.13) 0.87 0.78 (0.51 to 1.20) 0.27 
Secondary school 0.47 (0.13 to 1.76) 0.26 0.84 (0.46 to 1.53) 0.57  0.57 (0.21 to 1.54) 0.27 0.97 (0.60 to 1.57) 0.91 
Paternal education          
None Ref.  Ref.   Ref.  Ref.  
Primary school 1.53 (0.17 to 13.47) 0.70 1.26 (0.51 to 3.12) 0.61  2.84 (0.38 to 21.26) 0.31 0.89 (0.39 to 2.04) 0.79 
Secondary school 0.76 (0.08 to 6.93) 0.81 1.28 (0.53 to 3.08) 0.58  2.31 (0.30 to 17.53) 0.42 0.80 (0.35 to 1.84) 0.60 
Mother  illiterate 1.24 (0.66 to 2.34) 0.51 1.01 (0.70 to 1.48) 0.94  1.16 (0.71 to 1.91) 0.54 0.97 (0.73 to 1.30) 0.85 
Father illiterate 1.12 (0.39 to 3.24) 0.21 1.11 (0.61 to 2.05) 0.73  1.05 (0.44 to 2.48) 0.91 0.85 (0.50 to 1.45) 0.56 
* Adjusted for oedema, age, sex and admission WAZ and admission MUAC 
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Table 27 Cox regression exploring socioeconomic risk factors for death in 1
st
 90 days vs all deaths, by HIV serostatus 
Risk factor  Hazard ratio for death in 1
st
 90 days*  Hazard ratio for all deaths (short, mid and long term)* 
  HIV negative p HIV positive p  HIV negative p HIV positive p 
Mother’s occupation         
Housewife Ref.  Ref.   Ref.  Ref.  
Ganyu  1.37 (0.62 to 3.01) 0.43 1.27 (0.79 to 2.05) 0.33  1.13 (0.62 to 2.05) 0.70 1.03 (0.70 to 1.52) 0.88 
Employee/ self employed 1.08 (0.48 to 2.45) 0.86 1.07 (0.73 to 1.57) 0.72  1.45 (0.78 to 2.72) 0.24 0.95 (0.70 to 1.29) 0.74 
Other or unknown 1.22 (0.56 to 2.68) 0.61 1.38 (0.91 to 2.11) 0.13  2.51 (1.27 to 4.95) 0.008 1.08 (0.76 to 1.54) 0.65 
Father’s occupation          
Unemployed Ref.  Ref.   Ref.  Ref.  
Ganyu  1.09 (0.40 to 2.96) 0.86 0.77 (0.43 to 1.36) 0.37  0.75 (0.35 to 1.62) 0.47 0.81 (0.51 to 1.30) 0.39 
Employee/self 
employed/other 
or unknown 
1.08 (0.50 to 2.33) 0.84 0.85 (0.57 to 1.27) 0.44  0.83 (0.44 to 1.58) 0.58 1.00 (0.72 to 1.38) 0.98 
Rural residence  0.97 (0.49 to 1.94) 0.94 0.80 (0.56 to 1.15) 0.22  0.67 (0.39 to 1.13) 0.13 0.82 (0.62 to 1.10) 0.62 
Admitted to MOYO:          
Direct to MOYO or 
readmission 
Ref.  Ref.   Ref.  Ref.  
Via other QECH  paediatric 
ward 
2.77 (0.90 to 8.54) 0.08 1.74 (0.95 to 3.21) 0.07  1.56 (0.60 to 4.07) 0.37 0.90 (0.56 to 1.43) 0.65 
Referred from other clinic 0.89 (0.39 to 2.00) 0.77 1.00 (0.69 to 1.46) 0.99  0.68 (0.39 to 1.18) 0.18 0.86 (0.65 to 1.14) 0.29 
Wealth quintile          
Poorest Ref.  Ref.   Ref.  Ref.  
2
nd
 poorest 1.32 (0.42 to 4.20) 0.64 1.17 (0.63 to 2.14) 0.62  1.35 (0.63 to 2.89) 0.43 0.67 (0.41 to 1.09) 0.10 
Middle 0.72 (0.24 to 2.18) 0.56 1.15 (0.67 to 1.98) 0.61  1.11 (0.50 to 2.44) 0.80 0.95 (0.61 to 1.47) 0.82 
2
nd
 richest 1.16 (0.37 to 3.61) 0.80 2.08 (1.19 to 3.65) 0.01  1.49 (0.69 to 3.26) 0.31 0.93 (0.59 to 1.45) 0.75 
Richest 0.72 (0.17 to 3.11) 0.66 1.16 (0.70 to 1.94) 0.56  0.95 (0.38 to 2.42) 0.92 0.91 (0.60 to 1.38) 0.66 
Main household water source         
Piped Ref.  Ref.   Ref.  Ref.  
Borehole 1.08 (0.54 to 2.16) 0.83 0.85 (0.59 to 1.24) 0.40  0.72 (0.42 to 1.23) 0.23 0.90 (0.67 to 1.21) 0.50 
Well or spring 1.08 (0.46 to 2.55)  0.86 0.92 (0.54 to 1.59) 0.77  1.09 (0.51 to 2.32) 0.83 0.90 (0.60 to 1.37) 0.63 
* Adjusted for oedema, age, sex, admission WAZ and admission MUAC 
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5.6 Results - Profile of children found at long term FUSAM follow-up 
This section profiles the children found by the FUSAM follow-up team. A total of 667/1024 
(65%) original admissions were eligible for a visit. The other 357/1024 (35%) were already 
known to have died: 322/1024 (31%) as inpatients or during the first 90 days of outpatient 
treatment; a further 35 (3%) after 90 days of original admission, most often following a 
readmission episode). 
Of the 667 eligible for FUSAM follow-up (figure 15): 436/667 (65%) were seen in person 
by the FUSAM study team; 107/667 (16%) were reported on by relatives or neighbours; 44/667 
(7%) could not be found at the address given; 42/667 (6%) did not give an address in the first 
place; 31/667 (5%) had missing notes so could not be traced; 7/667 (1%) lived too far away to 
make a visit possible. 
  
Figure 15 Outcome of FUSAM visit (n=667 patients eligible for visit) 
 
 
Children found at FUSAM visit to be late deaths were compared against those found to 
be still alive. Characteristics of HIV positives children and HIV negative children were also 
compared. So that the latter comparison was not confounded by higher HIV-related mortality, 
HIV positive children still alive were compared with HIV negative children still alive.  
It is important to note minor differences in the denominators in the tables: this reflects 
missing information where for example a close relative who was not the primary carer (e.g. 
father or grandmother) was answering but did not know details about a treatment, or where it 
was inappropriate to ask a neighbour about HIV related issues. 
 
 
65%
16%
7%
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Seen in person by FUSAM
team
Reported on by relatives
or neighbours
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Did not give an address
at original admission
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5.6.1 Recurrence of malnutrition  
Table 28 shows recurrence of malnutrition reported by carers at FUSAM visit. Recurrence of 
both oedematous and non-oedematous malnutrition was significantly higher in children who 
were found to have died. Recurrence of non-oedematous malnutrition was also higher in HIV 
positive children still alive long term compared to HIV negatives still alive.  
At original admission, oedematous malnutrition represented almost 70% of all SAM. In 
contrast, recurrences of SAM comprised similar numbers of oedematous and non-oedematous 
episodes (13% and 9% overall).  
If SAM did recur, it mostly resulted in readmission to inpatient care. Small numbers of 
recurrences were treated as outpatients: CMAM services were just starting up in Blantyre 
district towards the end of the study period. SAM recurrences in HIV negative patients were 
less likely to be admitted than recurrences in HIV positive children. 
 
Table 28 Recurrence of malnutrition in children followed up at long term FUSAM visit: by mortality and 
by HIV status 
 All FUSAM 
patients 
by long term (≥90day)  mortality 
(as determined at FUSAM visit) 
 
  by  HIV status  
(children  ALIVE at FUSAM visit 
only) 
 
 
 
(n=543) 
Late death 
 
(n=64) 
Alive at  
> 1year 
(n=462) 
P†  
HIV 
positive 
(n=139) 
HIV 
negative 
(n=315) 
P† 
Malnutrition 
Recurrence (any) 
107/512 
(21%) 
28/56  
(50%) 
77/446 
(17%) 
<0.001  
30/133 
(23%) 
44/305 
(14%) 
0.04 
Oedematous  
65/510 
(13%) 
16/55  
(29%) 
48/445 
(11%) 
<0.001   
15/133 
(11%) 
31/304 
(10%) 
0.73 
Non-
oedematous  
44/509  
(9%) 
13/54  
(24%) 
30/445 
(7%) 
<0.001  
16/132 
(12%) 
13/305 
(4%) 
0.002 
Admission  for 
inpatient care 
 (if SAM) 
82/97 
 (85%) 
21/23  
(91%) 
59/72 
(82%) 
0.35‡  
27/29 
(93%) 
30/41 
(73%) 
0.03 
† Chi
2
 test. ‡Fisher exact results where expected cell value is less than 5 
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5.6.2 Clinical progress since discharge 
Table 29 summarises clinical progress since discharge from MOYO treatment. Compared to 
children found alive at FUSAM, those who died had similar numbers of outpatient visits in the 
preceding 6 months but significantly more inpatient admissions. These did not include 
admissions or visits immediately before death. Of the 64 late deaths identified at FUSAM, 32/64 
(50%) reported dying at home and 21/64 (33%) reported dying in hospital. 
Incidence of all symptoms asked about was significantly greater in the 2 weeks prior to 
death than in the 2 weeks prior to FUSAM visit for those found still alive. Exact causes of death 
could not be determined, but the incidence rate ratio (IRR) was highest for fast breathing (IRR 
31.8, 95% CI 19.7 to 53.2) suggesting respiratory disease as the main cause of mortality.   
Of patients found alive at FUSAM, HIV positive patients were significantly more likely 
than HIV negatives to have been admitted for inpatient care in the past year. They were also 
more likely to have had an outpatient consultation in the last 6 months. Except for cough and 
fast breathing symptoms in the past two weeks were similar in HIV positive and negative 
patients. 
Table 29 Inpatient admissions, outpatient visits and clinical symptoms at long term FUSAM visit: by 
mortality and by HIV status  
 All FUSAM 
patients 
by long term (>90day)  mortality 
(as determined at FUSAM visit) 
 
  by  HIV status  
(children  ALIVE at FUSAM visit 
only) 
 
 
 
(n=543) 
Late death 
 
(n=64) 
Alive at 
>1year 
(n=462) 
P†  
HIV 
positive 
(n=139) 
HIV 
negative 
(n=315) 
P† 
Any inpatient 
admissions  in last 
12 months  
 (non-SAM) 
88/517  
(17%) 
15/50  
(30%) 
72/456 
(16%) 
0.01  
35/137 
(26%) 
34/311 
(11%) 
<0.001 
Any outpatient 
visits in last 6 
months  (non-
SAM) 
190/496 
(38%) 
22/44  
(50%) 
166/446 
(37%) 
0.10  
60/134 
(45%) 
104/306 
(34%) 
0.03 
Any clinical 
symptoms in last 2 
weeks 
186/501 
(37%) 
43/46  
(93%) 
139/442 
(31%) 
<0.001  
42/131 
(32%) 
97/306 
(32%) 
0.94 
Symptoms in last 2 weeks (total patient days with symptom standardized to per 1000 days observation) 
Total days of 
observation 
7014 644 6286   1904 4298  
Fever 67 144 60 <0.001  56 63 0.31 
Diarrhoea 32 130 23 <0.001  25 22 0.53 
Vomiting 17 60 12 <0.001  14 12 0.45 
Fast 
breathing 
14 12 4 <0.001  8 2 <0.001 
Cough 45 135 35 <0.001  61 25 <0.001 
Oedema 14 98 5 <0.001  6 5 0.64 
Other 24 65 19 <0.001  17 20 0.34 
† Chi2 test.
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5.6.3 Access to supplementary feeding following discharge 
Upon discharge from MOYO therapeutic feeding, all children are referred for four months 
supplementary feeding (SFP). Table 30 shows that most children received some SFP but only 
about half got the full four months recommended. Receipt of SFP was not associated with 
reduced long term mortality. It was also similar amongst HIV positive and negative patients.  
 Most carers (232/450, 52%) reported no problems with the SFP service. The commonest 
reported problem was food being out of stock (57/450, 13%). Next most common were problems 
with SFP staff: being rude or unhelpful for example (41/450, 9%). The least common problems 
are grouped together as ‘other’. They included a sick or depressed carer; the child being 
temporarily looked after by somebody other than the carer; the carer being advised by friends 
or relatives not to do and the child being well, so that SFP was perceived as not needed.  
Table 30 Access and duration of supplementary feeding post discharge from TFP 
 All FUSAM 
patients 
by long term (>90day)  mortality 
(as determined at FUSAM visit) 
   by  HIV status  
(children  ALIVE at FUSAM visit 
only) 
  
 
(n=543) 
Late death 
 
(n=64) 
Alive at  1yr 
 
(n=462) 
P† 
 HIV 
positive 
(n=139) 
HIV 
negative 
(n=315) 
P† 
Had SFP (any) 391/489  
(80%) 
39/49 
(80%) 
349/434 
(80%) 
0.89  102/125 
(82%) 
242/302 
(80%) 
0.73 
Had ≥4 months 
SFP 
239/489 
(49%) 
23/49 
(47%) 
215/434 
(50%) 
0.73  71/125 
(57%) 
142/302 
(47%) 
0.07 
† Chi2 test. 
 
Figure 16 Carer reported problems with SFP (n=450) 
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9%
4%
2%
2%
2%
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Problems with SFP staff
(e.g. rude or unhelpful)
Too far / lack of transport
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Child died at <4 months
Child not referred
Carer too busy
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5.6.4 Access to TB services 
Of 543 patients reviewed at FUSAM visit, 39/494 (8%) answering the question about TB 
reported ever having treatment. Table 31 shows details of TB treatment and explores differences 
amongst: those found dead and those found alive at FUSAM; HIV positive and negative 
children found alive at FUSAM. It shows that TB was significantly more prevalent among 
children who died and among HIV positive children. In these cases TB most likely reflects high 
risk patients. Most cases were diagnosed while the child was still under MOYO TFP care (where 
children were investigated on the basis of clinical suspicion e.g. due to a positive family history; 
chronic cough; non-response or poor response to other treatments). Small numbers do not allow 
easy evaluation of the effect of TB treatment. Most children received the recommended 
treatment period of ≥6 months. Those having less than 6 months treatment were more likely to 
be late deaths (p=0.04): this may just reflect high risk patients who died within 6 months of start 
of treatment rather than being because they didn’t complete treatment. Problems and reasons for 
not completing full treatment include: unhelpful TB clinic staff; the child dying whilst still on 
treatment. Contact screening and treatment of other children in the family was poor: only 6/39 
(15%) carers reported this had been done. 
Table 31 TB treatment described at long term follow-up visit 
 All FUSAM 
patients 
by long term (>90day)  mortality 
(as determined at FUSAM visit) 
   by  HIV status  
(children  ALIVE at FUSAM visit 
only) 
  
 
(n=543) 
Late death 
 
(n=64) 
Alive at  1yr 
 
(n=462) 
P†‡ 
 HIV 
positive 
(n=139) 
HIV 
negative 
(n=315) 
P†‡ 
Ever had TB 
treatment 
39/494 
(8%) 
12/46 
(26%) 
27/439 
(6%) 
<0.001  
16/133 
(12%) 
10/299 
(3%) 
<0.001 
IF TB:         
Started pre-
MOYO 
8/39  
(21%) 
3/12  
(25%) 
5/27 
(19%) 
0.68  
4/16  
(25%) 
1/10  
(10%) 
0.62 
Started whilst 
on MOYO ward / 
OTP 
25/39 
(64%) 
7/12  
(58%) 
18/27 
(67%) 
0.72  
11/16 
(69%) 
7/10  
(70%) 
1 
Started post-
MOYO 
6/39 
(15%) 
2/12  
(17%) 
4/27 
(15%) 
1  
1/16 
(6%) 
2/10 
(20%) 
0.54 
If TB:  
had ≥6 months 
treatment 
29/39 
(74%) 
6/12 
(50%) 
23/27 
(85%) 
0.04  
13/16 
(81%) 
9/10 
(90%) 
1 
If TB: 
Were other 
children 
screened or 
treated 
6/39  
(15%) 
0/12  
(0%) 
6/27 
(22%) 
0.15  
3/16 
(19%) 
3/10 
(30%) 
0.64 
If TB:  
No problems 
reported with 
the treatment 
24/39 
(62%) 
5/12 
(42%) 
19/27 
(70%) 
0.15  
13/16 
(81%) 
6/10 
(60%) 
0.37 
† Chi2 test.  ‡Fisher exact results where expected cell value is less than 5 
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5.6.5 Access to HIV services 
Of 543 patients seen at FUSAM visits, 195 were already known HIV seropositive from their time 
in programme. Table 32 describes their treatment, focusing on use of ARV medication and 
cotrimoxazole prophylaxis.  
A total of 89/159 (56%) children reported having started ARVs. Numbers on ARVs were 
20% higher among those still alive than those who died, though this difference was just short of 
statistical significance at 0.05 level. Baseline HIV clinical staging was however similar. The effect 
of ARV start time could not easily be compared due to small numbers, but it is notable that few 
patients who died had started ARVs prior to MOYO.  
ARV compliance was good among those reporting: 69/71 (97%) reported last taking 
ARVs ‘today’ (or on the day of death if died) and 69/71 (97%) reported last missing a dose more 
than a month ago (or more than a month prior to death).  
Table 32 HIV related services: antiretrovirals (ARVs) and cotrimoxazole prophylaxis 
 All HIV positive 
FUSAM patients 
by long term (>90day)  mortality 
(as determined at FUSAM visit) 
 
  
 
(n=195) 
Late death 
 
(n=48) 
Alive at  1yr 
 
(n=139) 
P†‡ 
 
On ARVs 89/159 (56%) 15/35 (42%) 74/122 (61%) 0.06  
If on ARVs:      
Started pre-MOYO 17/89 (19%) 1/15 (7%) 16/74 (22%) 0.29  
Started on MOYO (ward or 
OTP) 
28/89 (31%) 8/15 (53%) 20/74 (27%) 0.05  
Started after MOYO 44/89 (49%) 6/15 (40%) 38/74 (51%) 0.42  
Not on ARVs because 
assessed not to be eligible 
yet 
14/159 (9%) 2/35 (6%) 12/122 (10%) 0.74  
On cotrimoxazole 149/161 (93%) 33/36 (92%) 115/123 (93%) 0.71  
If on cotrimoxazole:      
Started pre-MOYO 21/149 (14%) 3/33 (9%) 18/115 (16%) 0.41  
Started on MOYO (ward or 
OTP) 
121/149 (81%) 30/33 (91%) 90/115 (78%) 0.10  
Started after MOYO 7/149 (5%) 0/33 (0%) 7/115 (6%) 0.35  
If on cotrimoxazole:      
Last took dose today or 
yesterday 
95/149 (64%) 14/18 (78%) 81/115  (70%) 0.52  
Last took dose more than a 
month ago or never since 
OTP 
33/149 (22%) 3/18 (17%) 28/115 (24%) 0.56  
HIV clinical staging  (as recorded at  original admission) 
0 28/190 (15%) 5/48 (10%) 19/134 (14%) 0.51  
1 or 2 31/190 (16%) 5/48 (10%) 26/134 (19%) 0.23  
3 99/190 (52%) 30/48 (63%) 65/134 (49%) 0.10  
4 32/190 (17%) 8/48 (17%) 24/134 (18%) 0.85  
Severely low CD4  
(age adjusted) 
70/135 (52%) 22/38 (58%) 45/93 (48%) 0.32  
† Chi2 test.  ‡Fisher exact results where expected cell value is less than 5 
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The striking feature of table 33 is that a large proportion of mothers reported having had an 
HIV test, with many of those being tested on MOYO (along with their child – family testing and 
counselling was always offered alongside testing for the index child). In contrast, less than 50% 
of fathers had been tested. Siblings were even less likely to have been tested. (table 34) 
 
Table 33 Parental HIV status & treatment described at long term follow-up visit 
 All FUSAM 
patients 
by long term (>90day)  mortality 
(as determined at FUSAM visit) 
(HIV positive children only) 
 by long term (>90day)  mortality 
(as determined at FUSAM visit) 
(HIV negative children only) 
  
 
(n=543) 
Late death 
 
(n=48) 
Alive at  1yr 
 
(n=139) 
P†‡ 
 Late death 
 
(n=14) 
Alive at  1yr 
 
(n=315) 
P†‡ 
Maternal HIV 
status 
        
HIV + 
141/401 
(35%) 
19/23 
(83%) 
88/103 
(85%) 
0.75  - 
29/259 
(11%) 
- 
HIV - 
225/401 
(56%) 
1/23 
(4%) 
4/103 
(4%) 
1  
6/6 
(100%) 
210/259 
(81%) 
0.60 
Never tested 
35/401 
(9%) 
3/23 
(13%) 
11/103 
(11%) 
0.72  - 
20/259 
(8%) 
- 
If tested, when         
Pre-MOYO 
67/340 
(20%) 
2/19 
(11%) 
24/86 
(28%) 
0.15  
1/6 
(17%) 
36/220 
(16%) 
1 
At MOYO 
239/340 
(70%) 
15/19 
(79%) 
51/86 
(59%) 
0.11  
4/6  
(83%) 
164/220 
(75%) 
0.65 
After MOYO 
34/340 
(10%) 
2/19 
(11%) 
11/86 
(13%) 
1  
1/6 
(17%) 
20/220 
(9%) 
0.45 
If HIV +         
Never had ARVs  
(incl. on waiting 
list or not yet 
eligible) 
76/123 
(62%) 
10/17 
(59%) 
48/76 
(63%) 
0.74  - 
17/27 
(63%) 
- 
Yes, currently 
on ARVs 
45/123 
(37%) 
7/17 
(41%) 
26/76 
(34%) 
0.79  - 
10/27 
(37%) 
- 
Paternal HIV 
status 
        
HIV + 
43/319 
(13%) 
6/18 
(33%) 
24/77 
(31%) 
0.86  - 
13/211 
(6%) 
- 
HIV - 
102/319 
(32%) 
2/18 
(11%) 
5/77 
(6%) 
0.61  
4/5  
(80%) 
87/211 
(41%) 
0.16 
Never tested 
174/319 
(55%) 
10/18 
(56%) 
48/77  
(62%) 
0.60  
1/5 
(20%) 
111/211 
(53%) 
0.20 
† Chi2 test.  ‡Fisher exact results where expected cell value is less than 5 
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Table 34 Sibling HIV status & where tested 
 HIV serostatus  Where tested (if tested) 
 HIV (+) HIV (-) Never 
tested 
 Pre-
MOYO 
On MOYO After 
MOYO 
Sib 1 (n=289) 
2/258 
(1%) 
55/258 
(21%) 
201/258 
(78%) 
 13/47 
(28%) 
14/47 
(30%) 
20/47 
(43%) 
Sib 2 (n=242) 
4/213 
(2%) 
43/213 
(20%) 
166/213 
(78%) 
 13/43 
(30%) 
8/43 
(19%) 
22/43 
(51%) 
Sib 3 (n=161)  
1/140 
(1%) 
29/140 
(21%) 
110/140 
(79%) 
 10/28 
(36%) 
5/28 
(18%) 
13/28 
(46%) 
Sib 4 (n=94) 
2/86 
(2%) 
16/86 
(19%) 
68/86 
(79%) 
 5/16 
(31%) 
2/16 
(13%) 
9/16 
(56%) 
Sib 5 (n=45) 
2/45  
(4%) 
6/45 
(13%) 
37/45 
(82%) 
 1/6 
(17%) 
2/6 
(33%) 
3/6 
(50%) 
Sib 6 (n=17) 
0/14  
(0%) 
5/14 
(36%) 
9/14 
(64%) 
 1/4 
(25%) 
1/4 
(25%) 
2/4 
(50%) 
Sib 7 (n=8) 0/7 
2/7 
(29%) 
5/7 
(71%) 
 0/2 
(0%) 
1/2 
(50%) 
1/2  
(50%) 
Sib 8 (n=1) 
0/1 
(0%) 
1/1 
(100%) 
0/1 
(0%) 
 0/1 
(0%) 
0/1 
(0%) 
1/1 
(100%) 
ALL (n=857) 
11/764 
(1%) 
157/764 
(21%) 
596/764 
(78%) 
 43/147 
(29%) 
33/147 
(22%) 
71/147 
(48%) 
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5.6.6 TFP-based nutrition education sessions: do they improve knowledge or affect 
mortality? 
Of carers reporting, 230/428 (54%) said they attended nutrition education sessions whilst on 
MOYO and 198/428 (46%) said they did not. Background maternal education, an important 
potential confounder, was the same in those who did and those who did not attend the sessions. 
Table 35  explores whether attendance at the education sessions was associated with differences 
in knowledge or reported feeding behaviours. It also explores associations between nutrition-
related knowledge and long term mortality.  
 
Table 35 Basic nutritional knowledge: is it improved by attending TFP education sessions, and does it 
affect long term mortality? 
 All FUSAM 
patients 
By attendance of nutrition  
education sessions on MOYO 
 by long term mortality 
(as determined at FUSAM visit) 
  
 
(n=543) 
No 
 
(n=198) 
Yes 
 
(n=230) 
P†  Died  
 
(n=64) 
Alive 
 
(n=462) 
P† 
Maternal education 
None 60/511 
(12%) 
23/187 
(12%) 
23/218 
(11%) 
0.58  8/62  
(13%) 
51/433 
(12%) 
0.80 
Primary 360/511 
(70%) 
135/187 
(72%) 
148/218 
(68%) 
0.35  45/62 
(73%) 
303/433 
(70%) 
0.90 
Secondary or 
more 
91/511 
(18%) 
29/187 
(16%) 
47/218 
(22%) 
0.12  9/62  
(16%) 
79/433 
(18%) 
0.47 
Concerning Malawi’s “6 food groups” 
Aware that 
there are 6  
groups 
145/388 
(37%) 
48/156 
(31%) 
80/167 
(47%) 
0.002  17/41 
(41%) 
126/336 
(38%) 
0.62 
Able to name all 
6 food groups 
98/388 
(25%) 
35/156 
(22%) 
53/167 
(32%) 
0.06  10/41 
(24%) 
87/336 
(26%) 
0.84 
Unable  to name 
any  food group 
156/388 
(40%) 
69/156 
(44%) 
46/167 
(28%) 
0.002  20/41 
(49%) 
130/336 
(39%) 
0.21 
Concerning ideal breastfeeding practices 
Correctly states 
6 months for 
starting  liquids 
358/482 
(74%) 
148/192 
(77%) 
178/223 
(80%) 
0.50  27/46 
(59%) 
328/424 
(77%) 
0.005 
Correctly states 
6 months for 
starting  solids 
351/480 
(73%) 
143/191 
(75%) 
175/223 
(78%) 
0.39  28/46 
(61%) 
320/422 
(76%) 
0.03 
 
Correctly states  
BF should 
continue until at 
least 24months 
315/480 
(66%) 
118/182 
(65%) 
160/222 
(72%) 
0.12  32/47 
(68%) 
279/421 
(66%) 
0.80 
States that HIV 
positive mother 
should stop to 
BF at 6 months 
290/471 
(62%) 
131/187 
(70%) 
130/219 
(60%) 
0.03  23/44 
(52%) 
263/416 
(63%) 
0.15 
Changed feeding 
practices post-
SAM 
152/496 
(31%) 
7/196  
(4%) 
141/224 
(63%) 
<0.001  14/52 
(25%) 
138/430 
(32%) 
0.45 
† Chi2 test.  ‡Fisher exact results where expected cell value is less than 5 
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Summarising the table, knowledge of Malawi’s “6 food groups” was significantly better among 
those who attended health education than in those who did not. Carers who were aware of key 
breastfeeding facts (stated that infants should be breastfed for 6 months before any solids or 
liquids are started – i.e. they correctly described exclusive breastfeeding) were significantly 
more likely to have children who were alive at long term follow-up. However, this knowledge 
was not related to attendance at MOYO health education.  
Significantly more carers who attended health education reported changing feeding 
practices since discharge (figure 17 shows details of what changed). This had no obvious effect 
on long term mortality. Not shown in the table, 21/230 (9%) of those attending education 
sessions were found to have died at the FUSAM visit and 18/198 (9%) of those not attending 
also died.  
 Despite improvements following health education, better knowledge about Malawi’s 6 
food groups was also not associated with lower long term mortality.  
 
 
 
Figure 17 Reported changes in feeding practices (n=152 who reported having changed) 
 
 
 
 
29%
23%
25%
5%
5%
7% 6%
Offering more varied
foods
Offering more frequent
feeds
Mixing groundnuts into
porridge
More varied foods AND
adding groundnuts
More frequent foods AND
adding groundnuts
More varied AND more
frequent foods
Other
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5.7 Results - Growth catch-up in the ex-SAM child 
In this section I illustrate anthropometric changes both during and after treatment on MOYO. 
 
5.7.1 Overall z-score changes during treatment 
Figure 18 illustrates weight-for-height, weight-for-age and height-for-age z-scores at admission 
to programme, at OTP discharge (=discharge from programme) and at the long term FUSAM 
visit. The patterns of change are distinctive: 
• Weight-for-height improves during the programme and continues to improve in 
children surviving long term. By ≥1 year, average weight-for-height has corrected to the 
expected population z-score of 0.  
• Weight-for-age also improves during and after treatment. Unlike weight-for-height, 
there is however a persisting deficit of around -1.8 z-scores at ≥1 year. 
• Height-for-age shows minimal improvement, either during treatment or ≥1 year after 
treatment.  
 
Figure 18 Box plots
‡
 showing WHZ, WAZ and HAZ  at baseline, OTP discharge and at 1 year follow-up. 
WHZ admission (n=976); WHZ OTP discharge (n=966); WHZ 1 year (n=386) 
WAZ admission (n=1003); WAZ OTP discharge (n=993); WAZ 1 year (n=386) 
HAZ admission (n=992); HAZ OTP discharge (n=982); HAZ 1 year (n=386) 
(NB n=386 because not all FUSAM children were available to be measured e.g. if in school)
                                                 
‡
 In a boxplot: the box shows the upper and lower quartile values; the line in the middle of the box shows 
the median value; the whiskers show the upper and lower adjacent values (those within a 1.5 inter-quartile 
range of the nearest quartile); lastly, symbols show any remaining outliers. 
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The two tables below t-tests comparing Z-score changes from OTP (programme) discharge to 
final 1 year outcomes.  
Unpaired t-tests are presented first to reflect what is shown in the box-plot above. The 
magnitude of change is greatest for weight-for-height and least for height-for-age. All are 
statistically significant: 
Table 36 Changes in WHZ, WAZ and HAZ from programme discharge to 1 year (unpaired t-tests) 
 Mean z-score (SD) Difference  
(95% CI) 
P value 
 At OTP discharge 
 
At 1 year follow-
up 
1 year - OTP  
Weight-for-height 
(n=966 and 386) -1.96 (1.5) -0.04 (1.0) 
1.92 
(1.76 to 2.08) 
<0.0001 
Weight-for-age 
(n=993 and 386) -3.42 (1.4) -1.77 (1.1) 
1.66 
(1.50 to 1.82) 
<0.0001 
Height-for-age 
(n=983 and 386) -3.34 (1.4) -2.97 (1.4) 
0.37 
(0.21 to 0.53) 
<0.0001 
 
 
 
 
Paired t-tests better reflect individual level changes and are shown in table 37. Magnitude of 
these individual-level changes are less than for the groups as a whole. Increases in WHZ and 
WAZ from OTP discharge to 1 year follow-up are still statistically significant. HAZ changes are 
not: 
Table 37 Changes in WHZ, WAZ and HAZ from programme discharge to 1 year (paired t-tests) 
 Mean z-score (SD) Difference  
(95% CI) 
P value 
 At OTP discharge 
 
At 1 year follow-
up 
1 year - OTP  
Weight-for-height 
(n=386) -1.16 (1.1) -0.04 (1.0) 
1.11  
(0.99 to 1.23) 
<0.0001 
Weight-for-age 
(n=386) -2.64 (1.2) -1.77 (1.1) 
0.87 
(0.77 to 0.98) 
<0.0001 
Height-for-age 
(n=386) -3.03 (1.3) -2.97 (1.3) 
0.05 
(0.04 to 0.15) 
0.27 
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5.7.2 Z-score changes during treatment, by HIV status and admission diagnosis 
Boxplot 19 follows the same format as figure 18: WHZ, WAZ and HAZ at admission, at OTP 
(programme) discharge and at long term FUSAM follow-up. Differences in z-score changes by 
HIV status are illustrated first.  
a) Changes by HIV status 
Patterns of change by HIV are similar to overall patterns of change. WHZ, WAZ and 
HAZ at admission and OTP discharge are all higher in HIV negative patients than in HIV 
positives. By ≥1 year (see also table 38): 
• WHZ has recovered to the reference population mean of 0 in both HIV negative 
and positive groups.  
• WAZ has significantly improved (p<0.01) in both HIV negative and positive 
patients but both groups remain below the reference population mean, WAZ zero. 
• HAZ is the most depressed anthropometric index in both HIV positive and 
negative patients. There is no improvement following OTP discharge among HIV 
negative patients. There is small but statistically significant improvement among 
HIV positive patients (a HAZ improvement of 0.37 z-scores, p<0.01)   
 
Figure 19 Box plots showing baseline, OTP and 1 year WHZ, WAZ and HAZ, by HIV status 
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Table 38 presents formal statistical testing of the changes that can be observed in the box-plot 
on the previous page. 
 
Table 38 WHZ, WAZ and HAZ changes from OTP discharge to 1 year follow-up, by HIV (paired t-test) 
 Mean z-score (SD) Difference  
(95% CI) 
P value 
 At OTP discharge 
 
At 1 year follow-
up 
1 year - OTP  
Weight-for-height     
in HIV ○-  
(n=268) 
-1.07 (1.1) -0.12 (1.0) 0.95 (0.82 to 1.08) <0.0001 
in HIV ○+  
(n=112) 
-1.32 (1.2) 0.14 (1.0) 1.46 (1.21 to 1.72) <0.0001 
Weight-for-age     
in HIV ○-  
(n=269) 
-2.45 (1.1) -1.77 (1.1) 0.68 (0.57 to 0.78) <0.0001 
in HIV ○+  
(n=112) 
-3.06 (1.1) -1.74 (1.0) 1.31 (1.08 to 1.55) <0.0001 
Height-for-age     
in HIV ○-  
(n=268) 
-2.83 (1.3) -2.90 (1.3) -0.08 (-1.19 to 0.03) 0.15 
in HIV ○+  
(n=112) 
-3.51 (1.2) -3.13 (1.3) 0.37 (0.18 to 0.57) 0.0002 
 
 
 
 
 
 
b)  Changes by admission problem (oedematous or non-oedematous malnutrition) 
Oedematous and non-oedematous malnutrition reflect different underlying patho-physiology. 
Oedema also affects admission weight and thus admission weight-for-height and weight-for-
age. In this section therefore I examine whether initial oedema has any longer term impact on z-
score changes. Results in figures 20 and 21 are presented stratified by underlying HIV 
serostatus. 
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Patterns and magnitudes of z-score changes split by oedematous or non-oedematous 
malnutrition are similar to overall patterns of change.  
 
 
  
Figure 20 Box plots showing baseline, OTP and 1 year WHZ, WAZ and HAZ, by admission oedema, in 
HIV seronegative patients 
 
Figure 21 Box plots showing baseline, OTP and 1 year WHZ, WAZ and HAZ, by admission oedema, in 
HIV seropositive patients 
 
 
-1
0
-5
0
5
no oedema oedema
z
-s
c
o
re
-1
0
-5
0
5
no oedema oedema
z
-s
c
o
re
Graphs by OEDEMAcat
 WHZ          WAZ HAZ  WHZ          WAZ HAZ 
 
A
d
m
is
si
o
n
 
 
O
T
P
  
d
/c
  
F
U
S
A
M
 
 WHZ          WAZ HAZ  WHZ          WAZ HAZ 
 
A
d
m
is
si
o
n
 
 
O
T
P
  
d
/c
  
F
U
S
A
M
 
  Page  119
5.7.3  Weight-for-height changes during treatment 
The line graphs below show how weight-for-height of individual children changes over during 
and in the year following treatment. In both HIV seropositive and negative patients there is an 
initial dip in WHZ (corresponding mainly to loss of oedema) followed by steady rise thereafter.  
The importance of pair-wise tests of change is clear: whilst overall WHZ is greater at 1 year than 
at OTP, but this is not true for all children. Greater magnitude of catch-up is also evident for 
HIV positive survivors to 1 year. 
 
Figure 22 Weight-for-height z-scores in HIV seronegative children 
 
Figure 23 Weight-for-height z-score changes in HIV seropositive children 
N.B. The x-axis in these graphs is not directly proportional to time. In particular, the ‘gap’ from ‘OTP 
discharge’ to ‘1 year’ should ideally be larger than the other periods to reflect the greater duration. This 
has not been possible to represent visually so I ask the reader to kindly be aware of the scaling constraint. 
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5.7.4 Weight-for-age changes during treatment 
As with weight-for-height, the two line graphs below show an initial decrease in weight-for-age 
followed by a steady rise thereafter. Again the magnitude of 1 year catch-up is greater in HIV 
seropositive than in seronegative patients. Numbers surviving to 1 year are however less in HIV 
seropostive patients. The persisting weight-for-age is also evident in both groups.  
 
Figure 24 Weight-for-age z-score changes in HIV seronegative children 
 
 
Figure 25 Weight-for-age z-score changes in HIV seropostive children 
WAZ 
WAZ 
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5.7.5 Height-for-age changes during treatment 
To complete the nutritional profile from sections 5.7.3 and 5.7.4, height-for-age changes are 
shown in figures 26 and 27. HAZ remains relatively static during initial phases of treatment. By 
OTP discharge and at 1 year a large range very mixed changes are observed: some children’s 
height-for-age z-score increasing and other’s decreasing. There is no consistent pattern. Among 
those whose height-for-age increases, very few recover to 0, the expected population height-for-
age z-score.  
 
Figure 26 Height-for-age z-score changes in HIV seronegative children 
 
Figure 27 Height-for-age z-score changes in HIV seropostive children 
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5.8 Results - Growth catch-up compared to sibling controls 
 
5.8.1 Weight-for-height, weight-for-age and height-for-age compared to sib controls 
Figure 28 and table 39 show weight-for-height, weight-for-age and height-for-age of the ex-
MOYO child and sibling controls, both measured at FUSAM visit. Over 90% of siblings were 
reported never having SAM. There are notable differences according to anthropometric index: 
• Weight-for-height is similar in the ex-MOYO child and sibling controls. Both are close to the 
population reference z-score of 0.  
• Weight-for-age low in both groups, over one standard deviation below the reference 
population mean. It is lowest in ex-MOYO children. As a group, these are 0.5 z-scores, 
significantly below, sibling controls.  
• Height-for-age is also low in both groups. It is lowest in ex-MOYO children, who are almost 
3z scores below reference median and over 1z score, significantly below, sibling controls.  
 
Figure 28 Boxplot showing weight-for-height, weight-for-age and height-for-age of the ex-MOYO child 
(M) compared to sibling controls (S). n(MOYO)=386. n(sibling controls)=277 
Table 39 Weight-for-height of the ex-MOYO child compared to sibling controls (unpaired t-test) 
 Mean weight-for-height z-score (SD) Difference 
(95% CI) 
P value 
 MOYO child 
 (M) 
N=386 
Sibling 
(S) 
N=277 
 
M – S 
 
Weight-for-height -0.04 (1.0) -0.07 (0.9) 0.03 (-0.12 to 0.19) 0.69 
Weight-for-age -1.77 (1.1) -1.22 (1.1) -0.55 (-0.71 to -0.38) <0.0001 
Height-for-age -2.97 (1.3) -1.83 (1.4) -1.13 (-1.34 to -0.93) <0.0001 
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5.8.2 Weight-for-height compared to  sib controls, by birth order 
The boxplot and table below explore the hypothesis that size may depend upon birth order. The 
MOYO child is presented first for simplicity: 257/925(28%) were actually firstborns. Of the 
others, 242/925(26%) were second-born, 188(20%) third-born and 238(26%) fourth-born or later.  
It can be seen that weight-for-height of ex-MOYO child is similar to that of all siblings, 
no matter what their birth order. Paired t-tests in table 40 confirm no significant differences 
between the MOYO child and individual siblings in the same family. An ANOVA test of 
multiple means, together with Scheffe’s multiple comparison test gives similar results. All 
groups have a z-score close to the reference population mean of zero.  
 
Figure 29 Boxplot showing weight-for-height of the MOYO child at 1 year compared to sibling controls. 
(M) = ex MOYO child; S1 = firstborn child in the family; S2 = second-born child etc. 
 
Table 40 Weight-for-height of the ex-MOYO child compared to sibling controls (paired t-tests) 
 Mean weight-for-height z-score (SD) Difference 
(95% CI) 
P value 
 MOYO child 
 (M) 
Sibling 
(S) 
 
M – S 
 
Sib 1 (n=53) -0.068 (1.1) -0.24 (0.8) 0.17 (-0.15 to 0.50) 0.28 
Sib 2 (n=68) 0.04 (1.0) -0.08 (0.9) 0.12 (-0.16 to 0.40) 0.38 
Sib 3 (n=54)  -0.00 (0.8) -0.09 (0.9) 0.08 (-0.22 to 0.39) 0.57 
Sib 4 (n=25) -0.43 (1.0) 0.12 (1.3) -0.55 (-1.20 to 0.10) 0.09 
Sib 5 (n=22) 0.04 (1.2) 0.10 (1.0) -0.05 (-0.64 to 0.53) 0.85 
Sib 6 (n=8) -0.17 (1.2) 0.24 (0.9) -0.41 (-1.43 to 0.60) 0.36 
Sib 7 (n=6) -0.32 (1.7) 0.35 (0.8) -0.67 (-2.95 to 1.60) 0.48 
Sib 8 (n=1) 0.78 0.77 0.01 - 
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5.8.3 Weight-for-age compared to  sib controls, by birth order 
Following the same format, weight-for-age z-scores are shown below. Two points are 
important: 
a) Median weight-for-age of all children in the family is low. 
b) Weight-for-age z-score of ex-MOYO children is lower than that of sibling controls, 
irrespective of their birth order. Paired t-tests in table 41 show statistically significant 
differences. Similar results are obtained using ANOVA multiple mean comparisons or non-
parametric Wilcoxon signed-rank tests. 
 
Figure 30 Boxplot showing weight-for-age of the MOYO child at 1 year compared to sibling controls. 
(M) = ex MOYO child; S1 = firstborn child in the family; S2 = second-born child etc. 
 
 
Table 41 Weight-for-age of the ex-MOYO child compared to sibling controls (paired t-tests) 
 Mean weight-for-age z-score (SD) Difference 
(95% CI) 
P value 
 MOYO child 
 (M) 
Sibling 
(S) 
 
M – S 
 
Sib 1 (n=53) -1.82 (1.3) -1.35 (0.9) -0.47 (-0.78 to -0.16) 0.003 
Sib 2 (n=68) -1.76 (1.1) -1.11 (1.0) -0.64 (-0.91 to -0.38) <0.0001 
Sib 3 (n=54)  -1.82 (0.9) -1.41 (1.3) -0.41 (-0.76 to -0.62) 0.02 
Sib 4 (n=25) -2.33 (1.1) -1.27 (0.9) -1.07 (-1.66 to -0.48) 0.001 
Sib 5 (n=22) -1.71 (1.2) -1.00 (1.0) -0.71 (-1.30 to -0.12) 0.02 
Sib 6 (n=8) -2.05 (1.3) -0.67 (1.6) -1.38 (-2.74 to -0.02) 0.05 
Sib 7 (n=6) -1.96 (1.5) -1.2 (1.3) -0.76 (-2.85 to 1.33) 0.39 
Sib 8 (n=1) -0.11 0.51 -0.63 - 
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5.8.4 Height-for-age compared to  sib controls, by birth order 
Again following the same format, height-for-age z-scores of ex-MOYO children compared to 
sibling controls are shown. Two points are notable: 
a) Height-for-age of all children is low. It is approximately 2 z-scores below normal for firstborn 
though to fifth-born sibs. Group sizes of sibs 6, 7 and 8 are too small to comment. 
b) Height-for-age of ex-MOYO children is lower than that of sibling controls, Paired t-tests in 
table 31 show statistically significant differences. Similar results are obtained using either 
ANOVA with Scheffe’s multiple comparison test or non-parametric Wilcoxon signed-rank tests. 
Height-for-age deficit in the ex-MOYO child is more marked than the weight-for-age deficit and 
ranges from 0.8 to over 1.6 z-scores.  
 
 
Figure 31 Boxplot showing height-for-age of the MOYO child at 1 year compared to sibling controls. 
(M) = ex MOYO child; S1 = firstborn child in the family; S2 = second-born child etc. 
 
Table 42 Height-for-age of the ex-MOYO child compared to sibling controls (paired t-tests) 
 Mean height-for-age z-score (SD) Difference 
(95% CI) 
P value 
 MOYO child 
 (M) 
Sibling 
(S) 
 
M – S 
 
Sib 1 (n=53) -3.09 (1.2) -1.78 (1.1) -1.31 (-1.68 to -0.95) <0.0001 
Sib 2 (n=68) -3.08 (1.2) -1.66 (1.2) -1.43 (-1.77 to -1.09) <0.0001 
Sib 3 (n=54)  -3.06 (1.0) -2.24 (1.6) -0.83 (-1.24 to -0.41) 0.0002 
Sib 4 (n=25) -3.54 (1.3) -1.95 (1.2) -1.59 (-2.26 to -0.93) <0.0001 
Sib 5 (n=22) -3.03 (1.0) -1.64 (1.2) -1.39 (-2.00 to -0.77) 0.0001 
Sib 6 (n=8) -3.35 (1.3) -1.19 (2.2) -2.16 (-4.13 to 0.18) 0.04 
Sib 7 (n=6) -3.30 (0.9) -2.50 (2.0) -0.80 (-2.76 to 1.16) 0.34 
Sib 8 (n=1) -1.21 -0.16 -1.04  
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Chapter 6 
DISCUSSION 
 
Since they address two distinct factors underlying SAM outcomes, PRONUT and FUSAM will first 
be discussed in separate sections. A final conclusion will draw together final implications of both 
studies. 
 
 
6.1 PRONUT 
6.1.1 Key findings 
 In the MOYO setting, Synbiotic2000 ForteTM, prescribed in RUTF at an average daily dose of 
>1010 organisms per day, had no significant effect improving pre-specified nutritional or clinical 
outcomes from SAM. Even though negative, this is an important finding. PRONUT is, to my 
knowledge, one of the largest probiotic/prebiotic RCTs to date. It is also one of very few based in a 
low-income, high mortality, developing country. Putting the 795 patients in context, a 2004 
Cochrane review of probiotics in the treatment of diarrhoea included 1917 patients from 23 studies, 
only 2 of which were set in “high child and adult mortality” countries(59); a 2006 Lancet meta-
analysis of probiotics in diarrhoea prevention had 4844 patients from 34 trials, only 1 of which was 
developing country and community based(60). 
 A post-hoc observation of reduced outpatient mortality amongst children receiving 
Synbiotic is interesting. If true, it is also important clinically. I emphasise that this observation 
should not be over-interpreted, but do believe that it justifies further research.  
 
 
6.1.2 Strengths and weaknesses 
Study strengths 
Biological plausibility of observed results 
 A lack of Synbiotic efficacy for SAM inpatients might be because these children are the 
most vulnerable, with greatest impairment of all physiological systems(72). Some causes of early 
death are unlikely to be affected by known Synbiotic actions e.g. re-feeding syndrome and 
electrolyte imbalance(100),(101).   
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 Possible benefits for children surviving inpatient care is consistent with known Synbiotic 
effects like immune stimulation and improved gut environment and integrity. These take time and 
cannot occur until organ, cellular and immune functions have begun to recover. Such recovery 
would be greatest in outpatients after initial discharge – as was observed. Repeat admissions, which 
imply repeat episodes of severe illness would dilute any inter-group differences - also consistent 
with observed results, where outpatient differences are most pronounced during 1st episode of 
outpatient care but attenuated when all subsequent admission episodes are taken into account.  
 Antibiotics may also plausibly modulate the observed inpatient/outpatient differences. In-
vitro testing showed cotrimoxazole sensitivity in 2 of 4 Synbiotic organisms. Following standard 
protocols, all inpatients received cotrimoxazole. Half also had parenteral antibiotics. Children who 
were HIV seropositive continued on long term cotrimoxazole prophylaxis after ward discharge 
during and after outpatient treatment. Antibiotics may have reduced gut colonization by and hence 
efficacy of Synbiotic. In contrast, HIV negative outpatients, in whom the possible outpatient 
Synbiotic effect was strongest, received no antibiotics. 
Use of definitive outcomes for maximal relevance and applicability to developing country SAM settings 
 Hard outcomes like nutritional cure and death are rare in functional food studies(60),(102). 
Examining them, PRONUT stands out as directly relevant to nutrition policy makers; to 
programme managers(88); and, most importantly, to families and communities whose children die as 
a result of SAM(103).   
Generalizability 
 For maximal generalizability to ‘real world’ nutrition programmes, PRONUT was set in a 
government hospital providing routine service work. A key decision was to enrolled a typical 
rather than selected patient caseload(104). Included were children with disabilities and other 
conditions whose growth patterns are commonly abnormal(105). PRONUT was powered to explore 
both whole-group and sub-group effects.  
Minimal losses to follow-up 
 Another strength of the study was that we found final outcome for all but 26/795 (3.2%) of 
randomised patients. This was made possible because of the efforts of a dedicated community team 
and minimises the follow-up bias which is a common problem for field based studies in developing 
countries. 
Safety 
 In MOYO’s high-risk patients, no excess sepsis, particularly no Synbiotic-associated sepsis, 
is important. No excess mortality was observed, as was discussed in one recent study on 
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probiotics/prebiotics in severe pancreatitis(106). Increased inpatient vomiting, severe diarrhoea and 
cough, and a non-significant increase in inpatient mortality were noted. One explanation for these 
observations is chance. Known probiotic effects do not offer a clear explanatory mechanism for 
these findings. Increased severe diarrhoea may be due to osmotic effect of prebiotics. It would be 
interesting therefore for future studies to distinguish prebiotic and probiotic effects. With continued 
careful monitoring of risks as well as benefits, we believe that further work using these functional 
foods in HIV and SAM is justified. 
Study weaknesses 
Several limitations could also explain the predominantly negative results: 
Synbiotic sharing and cross contamination  
 Though inter-group RUTF sharing was discouraged, it cannot be excluded. Faeco-oral 
probiotic cross-contamination was also possible(107). Dilution of true group differences would result. 
Such sharing and contamination would be maximal whilst patients were living closely together 
during inpatient care. It would be minimal during home-based treatment as close neighbours on 
different groups are unlikely. This would also plausibly explain our observed trends towards group 
differences during outpatient treatment alone. 
Synbiotic specificity 
 Probiotics and prebiotics are large and diverse groups, each with specific effects in specific 
patients. This heterogeneity, combined with a paucity of other data on their use in the treatment of 
SAM, makes comments on the consistency of PRONUT findings with other studies difficult. 
Relevant to this current study,  previous  work (using Bifidobacterium bifidum with Streptococcus 
thermophilus probiotics) found an effect on CD4 and diarrhoea in HIV positive patients(108); whilst 
another study (using Lactobacillus GG) have found no effect in healthy Malawian children(109). 
Hoping to demonstrate proof of principle in SAM, PRONUT used a probiotic/prebiotic with a 
proven track record in other patient groups(91),,(110),(92). Another formulation might have shown 
different results.  
Possible suboptimal Synbiotic dose 
 Probiotics have approximately linear dose-response effects, at least on diarrhoea outcomes.  
The commonly accepted efficacy ‘threshold’ is >108 organisms per day (102). Regular quality control 
checks showed that prescribed doses were >1010 CFU per day, comfortably above this lower limit. 
Higher doses are possible in principle, but might not be possible in practice given the cost of a log 
unit dose increase. Also perhaps responsible for negative results is a suboptimal consumed dose of 
RUTF (and thus of Synbiotic mixed into the RUTF). This might have happened at home if carers 
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shared the RUTF with other children. PRONUT had only carer reports rather than direct 
observation to confirm non-sharing and compliance. Adequate weight gain was however also 
consistent with the RUTF being eaten rather than shared to any important extent. 
Synbiotic dose regime & gut colonization 
 Probiotics are often ingested as a single large bolus dose. PRONUT patients consumed 
RUTF (and thus Synbiotic) in divided amounts spread throughout the day. Probiotic effects depend 
on successful transit through the upper gastrointestinal (GI) tract to sites of action in the small and 
large intestines. Some probiotic organisms always die during transit. Larger single doses (perhaps 
timed away from antibiotic administration – there was occasionally overlap with our regime) might 
have colonized the gut better and had more effect. Resources were unavailable to directly confirm 
the success of the PRONUT regime and adequate  colonization had to be assumed based on other 
research(107). It is plausible in SAM given the fact that gastric acidity, normally a barrier to live 
probiotic transit, is reduced. 
Prebiotic effects 
The four prebiotics in Synbiotic may have caused non-specific overgrowth of enteric flora 
which mitigated against the probiotic component. Unfortunately stool cultures were not done to 
test this possibility. This is another issue for future research: probiotics alone or pro/prebiotic 
combinations for malnutrition? 
Lack of clinical effects 
 Clinical effects like reduced diarrhoeal or respiratory symptoms would have been 
consistent with known probiotic effects. Clinical effects might also have suggested mechanisms for 
the possible reduction in outpatient mortality. One isolated outpatient finding was reduced severe 
diarrhoea – though again patient numbers were small. Beneficial clinical manifestations make a true 
outpatient mortality effect more likely - but equally their absence does not exclude a true effect. 
Benefits can be subtle, at immune system level for example. Another possibility is that true 
symptom differences were missed, obscured by the noise inherent to any self-reported variable. 
Group imbalances in days of outpatient observation might also have played a role. To address such 
limitations, future work might add laboratory-measured clinical response indicators(108). 
 Unbalanced groups at entry to outpatient care 
 At randomization, groups appeared well balanced. Minor differences at point of entry to 
outpatient care (lower % HIV; less malnourished according to WHZ in the Synbiotic group) raise 
the possibility of confounding or bias at this point  
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6.1.3 Meaning of the study and implications for future policy and research 
 Overall outcomes observed in PRONUT study highlight the need for effective, 
evidence-based SAM interventions. Control group cures were low, 51.3%(203/396) and deaths 
high, 30.0%(119/396). Such statistics are unfortunately not unusual(46),(4),(53). HIV and late 
presentation to care, with complications of SAM already present are major factors underlying 
these poor outcomes. In this setting, Synbiotic2000 ForteTM, prescribed in RUTF at an average 
daily dose of >1010 organisms per day did not improve outcomes from current therapies. There 
is therefore no evidence at present, either from PRONUT or from other studies, to recommend 
routine use of functional additives to standard RUTF. 
           An observation of reduced mortality in Synbiotic outpatients is important to explore in 
future studies. Since PRONUT was not designed to look at outpatients alone, bias, confounding 
or chance cannot be excluded as an explanation for this finding. An effect is however 
biologically plausible. SAM associated enteropathy is a particularly important problem which 
probiotics may address. Since PRONUT was published, a ‘viewpoint’ article in the Lancet 
argued that enteropathy may account for a far greater proportion of malnutrition than currently 
recognised(111).  If true, this would make future exploration of other functional additives even 
more important: not just for children with SAM but for those with other less acute but more 
prevalent forms of malnutrition(112). Future studies using probiotics in malnutrition should focus 
on randomising SAM outpatients and possibly even children with moderate malnutrition, 
whose treatment is receiving increasing international interest. Such research would nest well in 
CMAM (Community Management of Acute Malnutrition) programmes, which focus on early 
identification and outpatient treatment of children with malnutrition. In discussing current 
results, this is exactly the patient group who might benefit most from any true 
probiotic/prebiotic effects. 
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6.2 FUSAM 
 
6.2.1 Key findings 
In the HIV prevalent MOYO setting, overall SAM mortality is markedly above SPHERE targets 
of <10%(88). In total, 427/1024 (41%) of children admitted for treatment are known to have died. 
Mortality was highest during initial inpatient treatment: 23%(238/1024).  In FUSAM, 
8%(84/1024) more died within 90 days of admission and 10%(105/1024) during long term 
follow-up. These FUSAM deaths may not have been noted by many nutrition programmes 
which only monitor patients in the short and medium term.   
 To properly interpret these results, it is important to note key subgroups. Though still 
short of SPHERE standards, these give a much more optimistic perspective of TFP performance:  
• Mortality probability among HIV negative patients is 19% (95% CI 15 to 23%) overall. 
This compares to overall 69% (63 to 74%) 2 years mortality for HIV positive patients.  
• Late mortality is less among HIV negative patients than among HIV positive. 90 day 
HIV negative mortality is 13%(11 to 17%) and rises by 6%. This contrasts a 23% rise in 
HIV positive mortality, from the 90 day ‘baseline’ of 46% (42 to 51%). 
• If a child achieves initial programme cure, the chances of long term survival are good: 
365/471 (77%) of cures were still alive at a year or more after their first admission. 
HIV was the biggest single risk factor for both short and long term mortality, associated 
with over 4 times the hazard of death. Increased severity of wasting and underweight at 
original admission were also significantly associated with increased total mortality as well as 
increased 90 day mortality. Oedematous patients were less likely to die both short and long 
term. This contrasts some historical studies where kwashiorkor was associated with excess 
mortality(26). It may reflect differences in the local pathophysiology of kwashiorkor, but equally 
may just be due to greater awareness and hence earlier presentation of oedematous 
malnutrition in Malawi. Age was a risk factor only in <12 month age group, whose hazards 
were 2.3 times above the reference 48-60 month age group (adjusting for oedema, HIV and 
admission anthropometry) 
Mortality hazards for other potential risk factors varied by HIV status and timing of 
death. Due to the large number of risk factors explored results should be interpreted with care: 
by chance alone 1 in 20 will be statistically significant. Underlying disability was the most 
striking, biologically plausible risk factor for both short and long term mortality in both HIV 
positive and negative children.  Others, including HIV staging and severity of symptoms prior 
to admission were not clearly and consistently associated with death. Parental education, 
occupation and family socioeconomic status also did not independently affect mortality. 
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The long term anthropometric profile of survivors was mixed. Mean weight-for-height 
z-score of children still alive had recovered almost to NCHS reference mean: -0.04(SD1.0, 
n=386). This compares to baseline of -1.16(SD1.0). Height-for-age z-score remained low and 
unchanged: -2.97(SD 1.3) compared to -3.03(SD 1.4) at baseline. Putting these in context, mean 
sibling weight-for-height was -0.07(SD 0.9, n=277) and height-for-age -1.83(SD 1.4, n=277). A 
fertile area for future work is to explore these differences: could different interventions have led 
to better catch-up growth (especially focusing on HAZ catch-up? Why does one child in a 
family but not another develop overt malnutrition? Which packages of care could be developed 
to better benefit the whole family? (noting for example the low uptake of HIV testing among 
fathers) 
 
 
6.2.2 Strengths and weaknesses  
Strengths 
Two key features of FUSAM make it stand out from routine TFP programme data: 
The first strength is having information on long term outcomes, up to 2 years after the 
original admission date. Many programmes would miss late mortality so would overestimate 
their true public health impact.  
The second strength is low losses to follow-up. Large numbers of unknown final 
outcomes can easily bias results. If the major reason for default is death, programme success 
would again be an overestimated. Another possible reason for default is that the child is better 
and the carer sees no reason to return for further follow-up: this pattern of defaulting would  
underestimate true cures. In FUSAM, we had long term outcome information on 899/1024 (88%) 
of children, but we also had baseline profile of those whose final outcome was unknown. For 
most variables, this was more similar to known survivors than to known deaths. This allows us 
to speculate that more unknowns survived than died and that our overall survival may be an 
underestimate.   
 
Weaknesses 
 FUSAM is closely linked with PRONUT and relies on baseline data collected for the 
former. By the time funding was obtained and logistics organised for FUSAM, a large number 
of patients had already died. Resource limitations meant that when FUSAM finally started we 
were not able to revisit families of already known deaths. Additional FUSAM variables (e.g. 
starting and compliance with cotrimoxazole prophylaxis or ARV medications) were not thus 
available for all deaths.  This missing data may have biased our findings on treatment and post-
treatment factors associated with mortality. This is why the more complete baseline variables 
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rather than FUSAM-only variables were given prominence in the analysis and subject to more 
in-depth multivariable analysis. 
 It is critical to emphasise that FUSAM examined mortality risk factors for patients 
already enrolled in treatment. From a public health viewpoint it also important to know risk 
factors for all SAM patients in the population. This enables better decisions to be made about 
programme enrolment criteria. Whilst often plausible to assume that risk factor within 
programme are similar to those in the general population (e.g. HIV seropostivity; more severe 
wasting predicting higher risk of death), this cannot be taken as proven. Even if the risk factor 
itself is the same, the magnitudes of effect is likely to be different depending on the reference 
population.  
 Several of our variables relied on carer reports of symptoms experienced, family status 
and treatment received. This raises the possibility of reporting and recall bias. I suggest that 
systematic over or underreporting is unlikely given no consistent, strong associations between 
mortality and clinical status, family status and socioeconomic status. However, the increased 
‘noise’ inherent to these more subjective, self-reported variables may have obscured small but 
real risks. 
 The last potential bias in our study related to seasonal variations in risk of malnutrition. 
Though recruitment was spread over most of a year and captured both rainy (hungry) season 
and dry (post-harvest) seasons, there may have been variations in nutritional status depending 
on what season a child was admitted and followed up in. Logistical constraints led to variations 
in time to follow-up. Had a constant time been possible, perhaps different magnitudes of z-
score change might have been observed. I doubt however that the overall pattern of findings 
would have been significantly different. One of the advantages of using sibling controls was 
that they were measured at the same time as the ex-MOYO child. Where MOYO-sib differences 
are seen they cannot therefore be ascribed solely to seasonal variations. 
 
 
6.2.3 Meaning of the study: generalizability 
Generalizability is the key issue for many studies, and especially so for FUSAM: 
i) Generalizability to other settings: 
Whilst in many ways a typical resource poor developing country setting, MOYO had 
inputs and resources (in terms of staff time, clinical expertise, continuity of drug, food and 
equipment supplies) far above many TFPs in Malawi and elsewhere in Sub-Saharan Africa. For 
FUSAM, I believe that this strengthens rather than weakens the overall message that patient 
profile at admission (notably HIV status and severity of wasting) is the key risk factor for poor 
outcomes. If treatment had more of an impact on reducing mortality, then the effect of 
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admission profile would be attenuated and would not be so strongly correlated with mortality. 
One might also expect uptake of MOYO or post-MOYO interventions like ARVs, TB treatment, 
health education and SFP to have been more clearly related to mortality. If MOYO’s treatments 
do not clearly make a great impact on outcomes, then most other treatment programmes are 
similarly unlikely to be able to do so. 
ii) To CMAM therapeutic feeding programme 
Despite its OTP component of care, MOYO is still fundamentally a traditional TFP. It is 
reactive in nature, admitting patients coming to the programme rather than going out to 
actively case find. This is different to CMAM programmes which actively seek patients with 
uncomplicated SAM in the community. The relative impact of pre-TFP status and TFP 
treatment may thus also be different. 
iii) To feeding programmes which use WHO growth standards 
 MOYO recruited patients using NCHS-based case definitions of SAM and analysed z-
scores using NCHS growth references. As outlined in the introduction chapter 2.2.4, new WHO 
growth standards are now increasingly being used. These label more children with SAM, and 
also suggest using an alternative % of weight gain discharge criterion. Again, all of this means 
that the risks and magnitude of risk cannot be directly extrapolated from FUSAM to a 
programme using WHO standards. 
 
 
6.2.4 Comparison with other related studies 
There are few other studies looking at long term outcomes following SAM. It is important 
therefore to briefly review the ones which are present in the literature. The striking issue with 
all of these is their age. Pre-HIV it is inevitable that most report better outcomes than FUSAM. 
Indeed, the best comparison may be between FUSAM’s HIV negative patients and these 
studies:  
• Niger, 1992(113) 
Of children 174 discharged from a TFP, 107(=61%) were followed up. At 3-16 months follow-up 
17% had died. Though compared to FUSAM this appears better, there is clearly much larger 
probability of bias due to 39% unknowns, a proportion of whom will have been deaths. 
• Zaire, 1987(114) 
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In an endemic malnutrition area, 171 SAM children discharged from hospital were followed up 
and 81.6% found still alive at the end of 5 years. Similar to FUSAM, risk of death was highest in 
the first year following discharge. 
• India, 1999(115) 
Discharged SAM children were compared to never malnourished siblings. Different to FUSAM, 
the ex-SAM children in this study had better wt/ht than their non-SAM sibs. The reason for the 
observation is uncertain and differs from FUSAM, which showed ex-SAM patients as more 
malnourished in the long term. Maybe in the Indian setting, the ex-SAM children were 
perceived as more vulnerable and therefore got preferential treatment/rations at home. 
• Tanzania, 1987(116) 
 87% of 566 children who had been discharged from an NRU were followed over a year. The 
mortality after discharge was 8% and relapse rate was 13%. 75% were well, with good catch-up 
of wt/ht, but not ht/age. This mortality is clearly better than in FUSAM, but anthropometry 
findings consistent. 
• Guinea Bissau, 1995(117) 
In this retrospective cohort study, 1038 severely malnourished children (defined by weight-for-
age <60% NCHS standards) were followed up over 3 years. 354 had received nutritional 
rehabilitation whereas 684 did not, due to limited programme capacity. Up to 3 years, the 
relative risk of death in the rehabilitated group was 0.75 (0.59 to 0.99). The mortality difference 
was greatest in the first three months. Weight-for-age z-scores improved from a baseline of -4.52 
to -2.76. This is consistent with FUSAM’s partial reversal of low weight-for-age. 
 
 
6.2.5 Implications for policy and practice 
There are four main messages and implications arising from FUSAM. Fortunately, all of these 
fit with rather than fight against current policy direction: 
 
First, FUSAM suggests that similar TFP programmes (especially those in HIV prevalent 
settings such as sub-Saharan Africa) which only report short and medium term outcomes are 
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likely to be underestimating their mortality, and thus overestimating their true public health 
impact. A change of emphasis is urgently needed.  
 
Second, FUSAMs risk factor profile implies that efforts to enrol patients at an earlier 
stage of SAM are likely to be beneficial. Such proactive approaches to care, consistent with 
CMAM-type nutrition programmes(9)  are rapidly rolling out worldwide. FUSAM, rather than 
suggesting a change of direction is needed, reaffirms this existing direction. The results firmly 
imply that reactive programmes, which like MOYO do not use active case findings, should no 
longer be seen as an effective or acceptable approach to SAM. 
   
Third, FUSAM is consistent with a push to earlier ARV therapy as a means of 
addressing high mortality amongst HIV positive children. It was striking that starting ARV 
treatment, compliance with ARV treatment and compliance with cotrimoxaxole did not seem to 
significantly reduce mortality in FUSAM’s HIV positive population. One interpretation is that 
this treatment comes too late. Again, a more proactive approach diagnosing and treating HIV 
before SAM develops is likely to be important. Such early treatment is now recommended and 
many countries are rapidly scaling up access to HIV diagnostic and treatment services(52).   
  
Fourth, a life course and more holistic approach is needed for SAM in general. Even 
with WHO growth standards effectively enrolling a larger and less severely wasted group of 
children, more proactive approaches are needed to address SAM before it develops. Such 
primary prevention strategies could include treatment of MAM but also treating the wider 
social and economic circumstances which give rise to malnutrition in the first place. Whilst 
these social factors were not independently associated with mortality risk (adjusting for 
admission anthropometry) in our study, they are linked to risk of low weight-for-height. An 
important observation is that in the year following FUSAM, there were less admissions to 
MOYO than seen for many years. This was not obviously due to CMAM (which was only just 
rolling out) but, probably, due to a very successful fertilizer subsidy programme which the 
government had introduced in an attempt to improve crop yield for the poorest smallholder 
farmers in the community.  
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6.2.6 Unanswered questions and future research  
FUSAM raises many questions for future research. 
One which could relatively easily and quickly be answered is whether community case 
finding and early enrolment of SAM patients to treatment improves their long term outcomes. 
The case for improved short term outcomes in CMAM programmes has already been forcefully 
made(2),(34) – albeit without any evidence from gold standard randomised controlled trials. Long 
term follow-up of ex-CMAM patients is needed to determine whether their outcomes are, as I 
would expect, indeed better than from a MOYO-type programme.  
Long term follow-up of patients from programmes using WHO growth standards is 
also needed. One key difference to NCHS is that discharge is now recommended using a % 
weight gain criterion rather than a target weight as before. There could be potential problems 
with this. Notably that patients who are extremely malnourished at baseline would still be 
relatively wasted at discharge even having gained their 15-20% weight. 
Research is needed as to optimal timing of ARVs. Could ARVs earlier in a TFP lead to 
the same benefits as ARVs pre-SAM? Or is the latter the only way to make significant impact on 
HIV-related mortality? 
More emphasis is needed into primary prevention of malnutrition. Not just for SAM 
but for all forms of malnutrition, notably stunting. It is especially disappointing that stunting 
was largely unaffected even in otherwise successful MOYO treatment. Related evidence from a 
classic Pediatrics paper(118) suggests that impact on child malnutrition needs not just early but 
even prenatal intervention if the immediate onset of stunting is to be avoided: 
Figure 32 Onset of stunting, wasting and underweight (Shrimpton et al, Pediatrics, 2001) 
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 More work is needed on how to optimise outcomes for those who do slip through the 
primary prevention nets. What is it about some children in a family that they become severely 
malnourished whereas others do not? Which interventions, targeted at which SAM subgroup, 
would have most impact minimising the SAM-related mortality and morbidity risks described 
in this thesis? Recognizing the particularly high mortality in MOYO, could any interventions 
make additional reductions in death there (e.g. stricter implementation of the “10 Steps” 
guidelines; a modified feeding protocol; a modified feed) 
 
 Finally, as a general principle, I would urge for any future studies to be interventional 
rather than just observational in design. As I hope that PRONUT and FUSAM have 
demonstrated, observational trials can take advantage of and indeed link rather neatly to 
intervention projects. They provide useful background data to help formulate the next 
intervention(s). As PRONUT also demonstrated, what is plausible and promising in theory does 
not always work as expected (if at all!) in practice. Children with SAM need and deserve the 
best possible programmes and policies. These must be both effective and cost-effective The best 
possible programmes and policies are those which are robustly evidence-based. This means 
gold-standard randomized controlled trials wherever possible. 
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Chapter 7 
CONCLUSIONS 
 
Acute malnutrition and in particular outpatient-focused CMAM strategies are currently high on 
the international child health and nutrition policy agenda(9). It is important to capitalise on this 
and build two concluding messages and implications arising from PRONUT and FUSAM: 
 
1) In PRONUT, addition of a functional food, Synbiotic2000 ForteTM, to standard RUTF did not 
improve outcomes. Explanations other than no effect include deaths from causes unaffected by 
Synbiotic actions; organism sensitivity to cotrimoxazole antibiotics; Synbiotic sharing or cross-
infection between children; suboptimal dose/dose regime.  
The observation of reduced outpatient mortality may be due to bias, confounding or 
chance, but is biologically plausible, and could be explored in future studies using different 
functional foods. It is relevant not just to SAM but to MAM and other less acute forms of 
malnutrition. It would be especially relevant if the recently resurrected hypothesis of 
enteropathy-associated malnutrition accounts for more malnutrition than recognised by current 
treatment strategies(111).   
 
2) Given the overall negative findings of PRONUT and the risk factors identified in FUSAM, it 
is more promising in the short term to pursue high quality, high coverage rollout of existing 
interventions. It is important to treat both SAM and HIV as early as possible. Community-based 
CMAM-type strategies are likely to play a key role identifying and treating high risk patients as 
well as proving long term support to those discharged from treatment. 
 
 
Opportunities for future research on SAM should be taken. These should focus on community 
based strategies and should include work on primary prevention of SAM. The potential to 
make a difference to 13 million SAM-affected children and over 1 million SAM-related deaths 
has never been better. 
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Treatment of Severe Acute Malnutrition (SAM) using probiotic/prebiotic-enhanced 
therapeutic food in a HIV prevalent setting: A double-blind efficacy RCT in Malawi(The 
“PRONUT study” ~ PRObiotics in malNUTrition) – The Lancet, Vol 374, Issue 9684, p 136 
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39(1): 23-26; doi:10.1258/td.2008.080096. http://td.rsmjournals.com/cgi/content/full/39/1/23  
 
A.2 Related to theme of Severe Acute Malnutrition 
2009 
i. Kerac M, Blencowe H, Grijalva Eternod C, McGrath M, Shoham J, Seal A. Prevalence of 
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Annex B. Presentations to meetings – summary 
 
B.1 Policy & General meetings (directly & indirectly PhD-related) 
2009  
i. SPHERE (Humanitarian Charter & Minimum Standards in Disaster Response), 2010 
update meeting  
Core working group for nutrition Save the Children UK, London, October 22
th
 to 23
rd
 
2009 
International consultative meeting for the revision of the nutrition components of the 
Sphere Handbook,  
ii. Global Nutrition Cluster Annual Meeting 
Bonhill House, London UK, October 20
th
 to 21
st
 2009 
- Presented summary of MAMI (Management of Acute Malnutrition in Infants) project 
http://oneresponse.info/GlobalClusters/Nutrition/Documents/GNC%20Annual%20Meeti
ng%20Report%2020-21%20October%202009.pdf 
http://oneresponse.info/GlobalClusters/Nutrition/Pages/Global%20Cluster%20Meetings.
aspx 
iii. SPHERE (Humanitarian Charter & Minimum Standards in Disaster Response), 2010 
update meeting  
 Mt Soche Hotel, Blantyre, Malawi, August 10
th
 to 11
th
 2009 
Malawi consultative meeting for the revision of the nutrition components of the Sphere 
Handbook,  
- Presentation on implications of new WHO-Growth standards & latest evidence 
regarding infants <6months 
 
2007 & before 
iv. World Bank (International) Development Marketplace 2007 (Health, Population & 
Nutrition),  
 World Bank, Washington DC, USA. May 21
st
 to 23
rd
 2007 
 Poster presentation (finalist project, last 104 / 2800 original applications worldwide): 
~ “Community-Therapeutic Care – New Generation” Development of a new, cost-
effective therapeutic food for severely malnourished children 
 http://siteresources.worldbank.org/DEVMARKETPLACE/Resources/finalistsbook.final.p
df (page 13) 
v. National CTC Review Workshop,  
 Malawi Institute of Management, Lilongwe, Malawi, April 19
th
 2006 
Lecture presentation (Marko Kerac, representing co-authors: Sadler K, Kerac M, 
Collins S, Khengere H,  Nesbitt A)  
 ~  “CTC experience and protocols, MOYO house, QECH, Blantyre” 
  
 
B.2 Academic Meetings (directly and indirectly related to PhD) 
2009 
vi. MAINN (Maternal & Infant Nutrition & Nurture) Conference 
 University of Lancashire, UK, September 7
th
 2009 
 Workshop presentation:( led by Marko Kerac ) 
Kerac M, McGrath M, Bizouerne C, Wilkinson C, Shoham J, Seal A MAMI (Management of Acute 
Malnutrition in Infants). A review of current field management of acutely malnourished infants 
under six months of age 
vii. CAPGAN (Commonwealth Association of Paediatric Gastroenterology & Nutrition)
     Blantyre, Malawi, August 12
th
 to 16
th 
2009 
 http://www.mmj.medcol.mw/issues/vol21_3abstracts.pdf 
 Accepted for oral presentation 
• Marko Kerac presented: 
1) Probiotic/prebiotic-enhanced therapeutic food for treatment of severe acute 
malnutrition in an HIV  prevalent setting: a double-blind efficacy RCT in Malawi. 
M.Kerac, J.Bunn A.Seal, M.Thindwa, A.Tomkins, K.Sadler,P.Bahwere, S.Collins 
   
  Page  149
2) Child growth standards for child health & nutrition programmes treating wasted 
infants aged <6 months: secondary data analysis of 21 DHS datasets. M.Kerac, 
M.McGrath, C.Grijalva-eternod, H.Blencowe, J.Shoham, A.Seal 
• Co-author presented (presenting author underlined) 
3) Long-term follow-up of children treated for severe acute Malnutrition: a longitudinal 
cohort study. M.Kerac,  G Chagaluka, S Collins, P Bahwere, R Mathisen, S Chitekwe, 
J Bunn.  
4) Mortality a year after admission with HIV and severe acute Malnutrition in Malawi: a 
cohort study. J. Bunn,  G.Chagaluka, M.Kerac 
5) A review of bacterial infections in malnourished infants aged under 6 months: 
implications for Case management in developing countries. H.Bailey, M.Kerac, A.Seal. 
6) Modification of the Prudhon index for HIV prevalent settings. J.Bunn, V.Nyirongo, 
M.Kerac 
• Accepted for poster presentation (author underlined presented) 
7) Evaluating the Moyo chart – a novel, low-cost, weight-for-height slide chart for 
improved assessment of nutritional status in children. C.Sikorski, M.Kerac, 
M.Fikremariam,
 
A.Seal. 
8) Routine antibiotics for uncomplicated & complicated severe acute 
malnutrition in children aged 6-59 months: a review of the evidence base 
underyling current practice. G.Alcoba-Wright, M.Kerac 
viii. MSF (Medecins Sans Frontiers) Scientific Day 
 London, UK, June 11
th
 2009 http://www.msf.org.uk/sciday09.event 
Co-author of lecture presentation (presented by Carlos Grijalva-Eternod, 
representing co-authors Grijalva- Eternod C; Kerac M; Blencowe H, McGrath M; 
Shoham J; Seal) 
~ “Wasting in infants < 6 months: prevalence and implications for emergency feeding 
programmes of the 2006 WHO Child Growth Standards”  
ix. Royal College of Paediatrics & Child Health Spring Meeting (International Health / 
VSO section) 
  York, UK, April 1
st
  2009 
 http://ichg.org.uk/publications/CHILD2015_Global_Communications_Package_ICHG_VSO_RCP
CH_2009.pdf 
a) Lecture presentation (Dr Marko Kerac, representing co-authors: Blencowe H; Kerac 
M; McGrath M;  Grijalva-Eternod C; Shoham J; Seal A) 
~ “Disease burden and risk-benefit implications of using new WHO Child Growth 
Standards to diagnose  Severe Acute Malnutrition in infants <6 months age: Secondary 
data analysis of 21 developing country DHS  surveys” 
b) Co-author of lecture presentation  (presented by Dr Hannah Blencowe, 
representing co-authors: Blencowe H; Kerac M; Molyneux E) 
~ “'Task-shifting' to reduce neonatal mortality in a tertiary referral hospital in a 
developing country" 
x. UCL Research Student’s  poster day – 
 UCL, London, UK, March 6
th
 2009 
Poster presentation (presented by Dr Marko Kerac, representing co-authors: Kerac 
M; Blencowe H; McGrath M; Grijalva-Eternod C; Seal A) 
~ “Acute Malnutrition in <6 month old infants: Developing country disease burden & 
implications of the new WHO Child Growth Standards"  
 
 
2008 
xi. Royal Society of Tropical Medicine & Hygiene “Research in Progress” day 
 SOAS, London, UK, December 18
th
 2008 
Two poster presentations: (presented by Marko Kerac, representing co-authors 
listed) 
a). “PRONUT” Study ~ A double blind randomised controlled trial to evaluate the 
efficacy of pre/probiotic  enhanced Ready-to-Use Therapeutic Food (RUTF) in the 
treatment of severe acute childhood malnutrition. Kerac M; Bunn J; Seal A; Thindwa M; 
Bahwere P; Sadler K; Tomkins A; Collins S 
b) “Acute Malnutrition in <6 month old infants: Developing country disease burden & 
implications of the new WHO Child Growth Standards" Blencowe H, Kerac M, McGrath 
M, Grijalva-Eternod C, Seal A 
xii. Institute of Child Health Research Students’ poster day – 
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 ICH, London, UK, November 26
th
 2008 
Poster preparation (presented by Dr Andrew Seal, representing co-authors: Kerac M, 
Blencowe H, McGrath  M, Grijalva-Eternod C, Seal A) 
~ “Acute Malnutrition in <6 month old infants: Developing country disease burden & 
implications of the new WHO Child Growth Standards"  
 
2007 
xiii. Institute of Child Health Research Students’ poster Day 
 ICH, London, UK, November 28
th
 2007 
Poster preparation (presented by Dr Andrew Seal, representing co-authors: Kerac M; 
Bunn J; Seal A;  Thindwa M; Bahwere P; Sadler K; Tomkins A; Collins S) 
~ “PRONUT” Study ~ A double blind randomised controlled trial to evaluate the efficacy 
of pre/probiotic  enhanced Ready-to-Use Therapeutic Food (RUTF) in the treatment of 
severe acute childhood malnutrition 
xiv. 11
th
 COMREC National  Research & Dissemination Conference,  
College of Medicine, Blantyre, Malawi, November 24
th 
2007 
http://www.medcol.mw/com/Program.pdf 
Lecture presentation (Marko Kerac, representing co-authors: Kerac M; Bunn J; Seal 
A; Thindwa M;  Bahwere P; Sadler K; Tomkins A; Collins S) 
~ “PRONUT” Study ~ A double blind randomised controlled trial to evaluate the efficacy 
of pre/probiotic enhanced Ready-to-Use Therapeutic Food (RUTF) in the treatment of 
severe acute childhood malnutrition 
xv. International Policy & Research Planning Workshop: Blantyre Technical Review ~  
Improving the Management of Severely Malnourished Children with HIV in Sub-
Saharan African,  
 Queen Elizabeth Central Hospital, Blantyre, Malawi, January 28
th
-30
th
 2007 
 Three lecture presentations (Marko Kerac, representing co-authors)  
a) “Increasing therapeutic feeding programme capacity by offering RUTF in place of 
F100”: Kerac M, Lim J,  Bunn J.  
b) “Potential use & effect of probiotics in severely malnourished Malawian children” 
Kerac M 
 c) “Data handling, data quality & longitudinal analysis” Kerac M 
xvi. 2
nd
 Malawi Annual HIV Nutrition Meeting,  
 College of Medicine, Blantyre, Malawi, Jan 27
th
 2007 
 Lecture presentation (Marko Kerac, representing co-authors (Kerac M, Bunn J) 
 ~ “Excess mortality risk associated with HIV infection in a large Malawian NRU”  
 
2006 and before 
xvii. 10
th
 COMREC (College of Medicine Research & Ethics Committee) National 
Research & Dissemination Conference,  
 College of Medicine, Blantyre, Malawi, November 11
th 
2006 
Lecture presentation (Marko Kerac, representing co-authors: Thurstans S, Kerac M, 
Maleta K, Banda T,  Nesbitt A) 
 ~ “HIV Prevalence in Malawian NRUs” 
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Annex C. Ethical approvals and patient consent forms 
 
 
C.1 PRONUT ethical approval 
 
C.1.1 Original 
 
 
 
 
 
 
 
UNIVERSITY OF MALAWI 
Principal College of Medicine 
Private Bag 360 
Chichiri 
Blarityre 3 
Malawi 
Telephone: 01 671 911/01 674377  
Fax: 01 674700/01 674740  
Telex: 43744 
Prof. R.L. Broadhead, MBBS, FRCP, FRCPCH,DCH 
Our Ref.: MC/COMREC/16 
31 5t January, 2005 
Dr S. Collins 
C/o Concern Worldwide 
P.O Box 1747 Lilongwe 
Dear Dr Collins, 
P.O3/04/236 -A study to compare the efficacy of three formulations of readv-to-use therapeutic 
foods in the treatment of severe acute malnutrition 
I write to inform you that COMREC reviewed and approved the progress report which 
you submitted. I am pleased to inform you that COMREC approved the continuation of 
the study for another 12 months with effect from 1 5t January, 2005. 
However, on the issue of change of site, the committee would like you to send 
documentation as proof of your permission to conduct the project at Umoyo 
Rehabilitaion at QECH. 
This renewal is subject to continued adherence to the College of Medicine requirements 
for all COMREC approved research studies. 
Yours sincerely, 
__ 
Dr .I. Kumwenda 
CHAIRMAN -COMREC 
C.1.2 Update 
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C.2 Informed voluntary consent form (English) 
 
MOYO ‘PRONUT’ STUDY 
~ INFORMED VOLUNTARY CONSENT FORM~ 
PLEASE KEEP THIS FOR YOUR INFORMATION 
PLEASE SHOW THIS TO YOUR HEALTH CARE PROFESSIONAL  
IF SEEKING TREATMENT OUTSIDE OF MOYO DURING THE COURSE OF THE STUDY: 
Any health professional should administer appropriate initial treatment and then refer the child back to Moyo 
as soon as possible. Thank you for your cooperation. 
 
I understand that: 
 My child is suffering from severe acute malnutrition. This condition is frequently associated with 
diarrhoea. The current standard treatment includes a routine antibiotic treatment and for nutritional 
rehabilitation a therapeutic milk during the stabilization phase and local made Plumpy’nut during 
outpatient care. In most cases, successful recovery occurs in 4 weeks. 
 This research is carried out to find improved and sustainable methods of treatment of severe acute 
malnutrition. In view of this, a new formulation of RUTF is being compared to local made 
Plumpy’nut: 
o This new recipe is locally made Plumpy’nut with the addition of a mixture of probiotic and 
prebiotics called Synbiotic 2000 forte
®
 (Medipharm AB, Kågeröd, Sweden). Recent results 
from prospective controlled trials in post operative patients suggest that combinations of 
pre- and probiotics, referred to as 'synbiotics' can reduce greatly the incidence of post 
operative infection, shorten recovery times and reduce the need for antibiotics.  Synbiotic 
2000 contains probiotic bacteria that are normally present in the gut and have been used in 
human trials without any adverse effects.  
o Probiotics are organisms similar to those found in eating yogurt. Very rarely they can cause 
infection. If my child develops fever or other adverse reactions, I will return as soon as 
possible to the ward where I will receive appropriate treatment.   
 The potential benefits to the target population are quicker recovery, reduced incidence of diarrhea and 
other illnesses, and therefore better treatment of both severely and moderately malnourished children.  
 Confidentiality of each study participant will be maintained at all times through the allocation of a 
unique identification number.  
 
If you are volunteer to participate in the trial you should expect the following: 
1. Your child will be admitted in the nutrition programme for treatment of acute severe malnutrition until 
reaching the discharge criteria. 
2. After admission, when your child is ready for solid foods, he/she will be given one of the 2 formulations of 
RUTF (1 experimental and the local made Plumpy’nut).   
3. If you do not participate in the trial, you will not be denied treatment. 
4. You have the right to withdraw from the study after initial enrollment. 
5. Contact details for the study team are below, in order that response to queries can be as quick and efficient 
as possible: 
Dr Marko Kerac, LEAD INVESTIGATOR 
c/o MOYO HOUSE Nutritional Rehabilitation Unit, Queen Elizabeth Hospital, Chipatala Avenue, 
Blantyre 
(Post: c/o Department Paediatrics, P/Bag 360, Blantyre 3) (Tel: 01 874 333; 01 877 333; 01 875 694) 
 
Minimising Risks: 
Your malnourished child will be evaluated by trained personnel on presentation to a health centre or NRU.  He 
will be included in the study if he is suffering from uncomplicated severe acute malnutrition. If he is suffering 
from complicated severe acute malnutrition, he will be treated for the complications according to the standard 
protocol and be included in the study when he has improved and is ready to eat RUTF. 
Your malnourished child will be closely monitored by the study team through out the study. In the exceptional 
case of your child showing any adverse reaction to the nutritional treatment prescribed we will immediately 
withdraw your child from the study, return your child to standard nutritional treatment and will treat, to the best 
of our ability, the adverse reactions presented.  
 
If you agree to participate, please sign your name below or give your left thumb impression. Thank you. 
 
Signature of Patient ………………………………..   Signature of Investigator 
………………………. 
 
Date................       Date....................... 
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C.3 Informed voluntary consent form (Chichewa) 
 
MOYO ‘PRONUT’ STUDY 
~ FOMU YOVOMEREZA ~ 
CHONDE SAMALANI BWINO FOMUYI 
CHIKALATACHI NDIPO KUMBUKIRANI KUYITENGA NDIKUYIWONETSA KWA DOTOLO 
PAMENE MUKUPITA KUKALANDIRA CHITHANDIZO KU ZIPATALA ZINA PA NYENGO YONSE 
YA IMENE MULI MUKAFUKUFUKUYU 
Kwa onse ogwira ntchito ya chipatala: chonde mutitumizire mwanayo kuno ku MOYO HOUSE mutatha 
kumupatsa chitandizo choyambilira. Zikomo. 
 
NDIVOMEREZA KUTI: 
~ Mwana wanga akuperewera zakudya zoyenera za magulu, mthupi mwake. Ndipo kutsegula m’mimba kumadza 
pafupi pafupi chifukwa chavutoli. Matendawa amagonjetsedwa pakumwa mankhwala opha tizilombo m’mimba mwa 
mwanayo ndipo kupereweredwa kwa zakudya kumagonjetsedwa ndi mkaka wokhala ndi zakudya zomanga ndi 
kulimbitsa thupi nthawi imene agonekedwa ku chipatala komanso mwanayo akaonetsa kusintha, amapatsidwa 
chiponde cha mtedza pamasiku amene akuyendera ku chipatala kuchokera kunyumba. Pa ma sabata anayi, mwanayo 
amasonyeza kusintha kusonyeza moyo wathanzi ndithu. 
~ Kafukufukuyu akuchitika ndi cholinga choti papezeke njira zabwino zokhalitsa zogonjetsera kupereweredwa kwa 
zakudya mthupi mwa mwana. Pachifukwa ichi, chiponde chapangidwanso china chatsopano (chopangidwada kwathu 
konkuno): 
• Mtundu wa chakudya chimenechi ndicho chiponde cha mtedza, mkaka, sugar chosakanizidwa ndi synbiotic 
2000 forte (ndipo muli zipangizo zina zokhala ngati zamu yogati). Mankhwala a synbiotic 2000 forte 
(medipharm AB, kagerod,Sweden) ayesedwa ndipo zotsatira zake zaonetsa kuti odwala sangapitilirenso 
kugwidwa ndimatenda otsekula m’mimba kapena kuchepekedwa zakudya mthupi, komanso zimathandiza 
munthu kuchira msanga. Ndipo mankhwala ena ophera tizilombo toyambitsa matenda mthupi saliofunika 
pafupipafupi. Synbiotic 2000 forte anayesedwa kuwanthu popanda chokhumudwitsa chirichonse. 
• Probiotics ndi tizirombo tofanana ndi tomwe timapezeka mu Chakudya ngati Yogati, tomwe timayambitsa 
matenda mu ana ochepa kwambiri monga kutentha thupi koma kawiri kawiri sitiyambitsa matenda. Ngati 
mwana wanga atenda thupi, kapena mavuto ena, ndidzabwelera naye mwansanga ku Chipatala kumene 
ndikalandire chithandizo choyenera.  
~ Phindu lake kwa ofunika kupatsidwa chakudyachi likuyembekezeka kukhala: kuchira mofulumira, kuchepetsa 
matenda otsegula m’mimba ndi matenda ena, komanso kuchiza matenda a kusowa kwa zakudya mthupi. 
~ Chinsisi cha mwana aliyense wolandila chithandizo cha zakudya za chiponde (chakudya chokonzeratu chobwezera 
thanzi mthupi chopatsidwa kwa anthu amatupi onyentchera chifukwa chamatenda) chidzasungidwa bwino lomwe 
posalemba dzina la mwanano m’malo mwake aliyense adzapatsidwa nambala ngati chizindikiro chake. 
NGATI MWADZIPEREKA KUTHANDIZA NAWO PA KAFUKUFUKUYU, MUVOMEREZE KUTI: 
1. Mwana wanu adzagonekedwa ku chipatala pa ndondomeko yolandira chakudya chamagulu komanso 
chakudya cha mankhwala othetsa kusowa kwa zakudya mthupi mpaka nthawi imene adzapezere bwino 
ndikutuluka mchipatala. 
2. Pamena mwana wanu agonekedwa kuchipatala adzapatsidwa chimodzi mwa zakudya za mitundu iwiri ya 
RUTF (chiponde); choyamba chosakaniza mankhwala a synbiotic 2000 forte; chachiwiri chopanda 
mankhwala.(pamene mwana wayamba kupeza bwino)  
3. Ngakhale musalowe nawo mu kaundula wakafukufukuyu, muli ololedwa kulandila mankhwala ndi 
chithandizo. 
4. Simulioumilizidwa kukhalamo mkaundula wakafukufuku mukhoza kutulukamo nthawi ina iri yonse. 
5. Ngati muli ndi mafunso mukhoza kufunsa kwa: 
Dr Marko Kerac, LEAD INVESTIGATOR 
c/o MOYO HOUSE Nutritional Rehabilitation Unit, Queen Elizabeth Hospital, Chipatala Avenue, Blantyre 
(Post: c/o Department Paediatrics, P/Bag 360, Blantyre 3) (Tel: 01 874 333; 01 877 333; 01 875 694) 
 
CHITETEZO 
Mwana wanu adzayesedwa ndipo adzalowa nawo mkaundula wa kafukufuku wa matenda osowa zakudya mnthupi. 
Adzapatsidwa chakudya chamankhwala ndiponso chamagulu ndipo adzalembedwa mu kafukufuku pamene mwanayo 
wayamba kupeza bwino. 
Mwana wanu adzaonedwa pafupi pafupi ndi anthu omwe akonza kafukufukuyu panyengo yonse mwanayo adzakhala 
ku chipatala. Ngati mwana wanu adzasonyeza kusagwirizana ndi zakudya zamankhwalazo, adzaimitsidwa 
ndikuchotsedwa mukawundula wakafukufukuyo, ndipo adzaperekedwa ku ndondomeko ya zakudya zamagulu kuti 
alandile chithandizo choyenera kufikira achire ndithu. 
Ngati muvomereza ndi kugwirizana nazo zonse zalembedwazi, chonde lembani dzina lanu pamusipa kapena 
kusindikiza chala chanu. Zikomo 
 
 
PROJECT IYI YAPANGIDWA APURUVU NDI ‘COMREC’ (College of Medicine Research & Ethics Committee), 
ref. P03/04/236 
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C.4 FUSAM ethical approval form 
 
 
 
 
UNIVERSITY OF MALAŴI 
 
Principal College of Medicine 
 Private Bag 360 
Prof. R.L. Broadhead, MBBS, FRCP, FRCPCH, DCH  Chichiri 
 Blantyre 3 
 Malawi 
Telephone: 01 671 911/01 674 377 
Fax: 01 674 700/01 674 740 
Our Ref.: MC/COMREC/16 
Telex: 43744 
 
 
4th February, 2008 
 
Dr M. Kerac 
Paediatrics Department 
P/Bag 360 
Blantyre 3 
 
Dear Dr Kerac, 
 
P.03/04/236 –A study to compare the efficacy of three formulation of ready-to-use 
therapeutic foods (RUTF) in the treatment of severe acute malnutrition 
 
I write to inform you that COMREC reviewed your revised expansion for follow up of the above 
research project which you resubmitted.  I am pleased to inform you that your request for 
expansion has been approved. 
 
Yours sincerely, 
 
 
 
 
 
Prof. J.M. Mfutso Bengo 
SECRETARY - COMREC 
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Annex D. MOYO Ward forms and protocols 
 
D.1 Weight chart 
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D.2 Drug and inpatient symptom chart 
 
D.3 Protocol for as
 
 
 
 
sessing inpatient symptoms and appetite
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D.4 Inpatient ‘phased feeding’ protocol 
 
Phase 1 
(STABILIZATION phase) 
 
WHAT: 
 F75 milk ~ amount according to weight 
PHASE 1 PATIENTS ARE SEEN DAILY ON ROUNDS 
 
 
 
WHO: 
 ALL patients 
    
   EXCEPT: 
   ~ patients <6months old      
     give F100 dilute 
   ~ patients with VERY SEVERE oedema    
      see chart  reduce feed volume 
 
 
WHEN: 
 ALL patients get phase 1 on admission.  
 It should continue for a MINIMUM of 1 day. 
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Phase 1 
(STABILIZATION phase)  
 
KEY MESSAGES FOR CARERS 
WHAT IS WRONG WITH MY CHILD? 
He/she is sick with severe malnutrition. 
 
HOW CAN MY CHILD GET BETTER? 
To get better, the child needs: 
~ special medicine-foods (F75 milk; Chiponde) 
~ medicines ~ as prescribed by the doctor / nurse 
 
WHAT IS PHASE ONE FEEDING? 
When a child first arrives on MOYO, the body is too sick and weak for normal 
food ~ it may get sicker unless feeding is done correctly. 
Phase 1 feeding involves use of a special milk called ‘F75’ 
‘F75’ is a special milk made just for sick malnourished children. It helps the 
body get stronger and prepares it for the next phase of feeding. 
 
HOW MUCH F75 MILK DOES MY CHILD NEED? 
It is important to give the right amount of F75 milk: not too much / not too little.  
Always keep the ‘ticket’ saying how much milk your child needs:~ 
always show it to the kitchen staff who will then give you the correct amount 
 
HOW OFTEN DOES MY CHILD NEED F75 MILK? 
F75 needs to be given every 3 hours: 6am; 9am; noon; 3pm; 6pm; 9pm; 
midnight; 3am. (= 8 feeds per day) 
Do not miss the night feeds ~ sick children can get worse if feeds are missed. 
 
WHAT ABOUT BREAST FEEDING & OTHER FOODS? 
CHILDREN STILL BREAST FEEDING SHOULD CONTINUE TO BREAST FEED 
The best time to breast feed is immediately before getting f75 milk 
No other foods should be given during phase one 
 
WHAT SHOULD I DO IF MY CHILD IS HAVING PROBLEMS? 
The child should be encouraged BUT NEVER FORCED to eat milk 
 
If the child is finishing <3/4 of the milk, GET HELP  TELL NURSE / DRS 
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TRANSITION Phase 
 
WHAT  
 The purpose is to slowly get used to RUTF whilst avoiding fluid 
 overload. This is achieved by: 
 i) Continuing FULL F75 milk prescription (same as Phase 1) 
 AND  
 ii) Introducing RUTF ~ aim for target # pots/day according to chart 
 
no other food / fluid is added for 1st 24-48hrs 
 iii) After 48hrs, all children should be offered extra water with 
 RUTF 
 
WARD ROUNDS 
TRANSITION PHASE PATIENTS ARE SEEN DAILY ON ROUNDS 
 
WHEN 
 A patient is ready to move onto transitional phase when: 
   
  a) ACTIVE Appetite has returned:  
   ~ finishing whole phase1 milk amounts READILY & QUICKLY 
   (it is not enough to be struggling to finish / if feeds are 
forced) 
    ~ hungry or crying for more food 
   ~ no longer needs NGT 
AND  
  b) Clinically improving: 
   ~ more alert & active 
   ~ diarrhoea improving / no longer needing regular RESOMAL 
AND  
  c) Oedema settling (if kwashiorkor): 
   ~ visibly decreasing 
   ~ weight reducing (certainly NOT increasing) 
   (N.B oedema DOES NOT have to have resolved completely) 
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TRANSITION Phase 
 
MESSAGES TO GIVE TO CARERS 
WHAT IS TRANSITION PHASE? 
“Transition” phase feeds are given to children who are improving, so that they 
can SLOWLY get used to eating enough RUTF. 
 Whilst on transition phase, 3 hourly milk feeds should continue exactly as 
before, BUT: 
RUTF is added to the diet 
 
WHAT IS RUTF (CHIPONDE)? 
RUTF is a medicine-food which is: 
energy-giving; body-building; health restoring 
Eating enough RUTF is vital for the child to get better 
 
HOW MUCH RUTF DOES MY CHILD NEED TO EAT TO GET BETTER? 
The doctor/nurse will tell you how much your child should be aiming to eat per 
day. This depends on body size: keep your ticket to help you remember. 
 
HOW SHOULD THE CHILD EAT RUTF 
 RUTF should be eaten direct from the pot (using CLEAN hands or spoon) 
 RUTF will make him/her thirsty & his/her the mouth dry, so: 
 ~ The child should continue to drink milk, every 3 hours, as before. 
 Eat spoonfuls of RUTF before and between mouthfuls of milk: 
 ~ this will help wash down the RUTF, making it easier to eat. 
 ~ do not wait until after milk to eat RUTF - else the stomach will become too 
 full and the child be unable to eat the RUTF or will vomit. 
 Sick children may not like to eat, so offer SMALL, REGULAR amounts::  
  ~ start with a taste only / < ½ spoonful, together with each milk feed 
  ~ gradually increase the amount of RUTF taken with each feed.  
  ~ your ticket will show how many spoonfuls of RUTF you should be  
  aiming for with each milk feed once appetite has returned fully 
 
WHAT IF MY CHILD IS HAVING PROBLEMS EATING RUTF? 
 Try mixing a small amount in with the milk to make it easier to swallow 
 NEVER FORCE FEED! (This will only make a problem worse!!!) 
 If a child is vomiting or refusing RUTF take a break and continue milk 
 feeds  alone. Restart slowly. With time, the amount taken will gradually 
increase. 
 Make sure the child has no mouth sores / candida: ask the doctor for help! 
* CHILDREN STILL BREAST FEEDING SHOULD CONTINUE TO BF * 
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Phase 2 
(REHABILITATION phase) 
 
WHAT   
Phase 2 feeds (on MOYO) include: 
  i)  RUTF (the MOST important food!) 
    ~ should easily finish at least 50% of target q 
    amount 
  ii)  F75 milk 
    ~ same VOLUME as before 
    ~ reduced FREQUENCY: only SIX times a days 
    (i.e no longer needs midnight & 3am feeds) 
  iii)  Phala @ 6am, 6pm 
  iv) Extra water, as desired 
 
WARD ROUNDS 
PHASE 2 PATIENTS ARE SEEN ONLY TWICE WEEKLY ON ROUNDS 
(but clinical history / feed history is filled daily) 
 
WHEN 
 A patient is not moved onto phase 2, but moves him/herself 
 when: 
  a) Appetite is good enough: 
   ~ is easily able to finish at least 50% of his/her daily RUTF 
target 
   (N.B when reaches target, can have more if wanted)   
  b) Clinically stable 
   ~ alert & active 
   ~ admission problems improving / improved 
    DOES NOT NEED DAILY CLINICAN REVIEW 
AND  
  c) (If Kwashiorkor) 
   ~ oedema SETTLING AND is not more than ++ 
   (NB does NOT have to have settled completely) 
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PHASE 2 
(REHABILITATION phase) 
 
MESSAGES TO GIVE TO CARERS 
The child is continuing to get better and is making good progress: 
He/she is now almost ready to leave hospital to finish treatment at home 
 
 
WHY RUTF? 
RUTF is the most important part of home treatment: 
~ To continue to get better it is vital to continue to eat the full ‘target’ amount of 
RUTF that is given out 
~ RUTF should not be shared (it is for malnourished children only) 
 
 
WHAT ABOUT OTHER FOODS / WHAT IF THE CHILD IS STILL HUNGRY? 
If still hungry after finishing the daily RUTF ration, it is OK to eat other foods 
BUT 
RUTF should be eaten as priority, before other foods  
(children have small stomachs that will easily get filled ~ they will vomit if you 
try to give too much) 
 
CHILDREN STILL BREAST FEEDING SHOULD  
CONTINUE TO BREAST FEED REGULARLY 
 
 
HOW SHOULD THE CHILD EAT RUTF? 
Basic instructions as for Transitional phase: 
AND 
Since the child is now eating more RUTF, he/she may be more thirsty than 
usual. He/she can now drink extra milk or water(boiled), according to thirst 
 
OTHER 
Use soap for child’s hands and face before feeding. Keep food clean and lid on 
pot between feeds 
 
 
With diarrhoea, never stop feeding. Give EXTRA food and EXTRA water. 
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FEED PROBLEMS 
(moving back a phase) 
 
 
WHAT   
Sometimes, a child gets worse rather than better.  
Children who deteriorate during their inpatient stay may need to move 
BACK to an earlier feeding phase. 
 
 
WHEN 
A child should move back to phase 1 if: 
 
  a) Appetite deteriorates 
   ~ having significant problems eating RUTF 
   ~ refusing RUTF  
AND/OR  
   
  b) Clinically deteriorates 
   e.g.: 
   ~ any complication needing IV infusion 
   ~ significant re-feeding diarrhoea 
   ~ tense abdominal distension 
AND/OR 
   
  c) Oedema worsens / develops fluid overload 
   ~ increasing oedema in a child with kwashiorkor 
   ~ new onset oedema in a child with marasmus 
   ~ rapid increase in size of live 
   ~ other signs of fluid overload (bilateral crepitations;  
   gallop rhythm; raised JVP) 
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D.5 OTP protocols 
(patients and their carers would be directed around various ‘stations’ of the OTP clinic, each 
focusing on a particular activity) 
  
MOYO OTP: 
~ station (1) ~ 
CLINIC BOOK & WEIGHT 
 
REGISTER child’s arrival in OTP clinic book 
(check which group ~ 1 or 2 ~ write in CORRECT book)  
 
 
 
FILL OTP form: 
HMIS #; child initials;  today’s date;  
date originally discharged (to help find details if health passport lost);  
which # visit this is(count in passport/ask mother) 
 
 
WEIGH child (two people to check) 
If weight changed by more than ( > ) 1kg  
 CHECK WEIGHT AGAIN  
 
 
WRITE weight: 
FIRST on OTP form ~~~ SECONDLY in health passport 
 
 
CHECK TARGET WEIGHT(80% wt/ht)  
and  
NUMBER OF VISITS & decide: 
does this child need to go to station 2 OR direct to station 3? 
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MOYO OTP 
~ station (2) ~  
LENGTH & MUAC 
NEED TO MEASURE LENGTH & MUAC IF… 
i) CHILD nutritionally ‘CURED’ 
=  REACHED target weight (80% wt/ht) on TWO consecutive visits 
OR 
ii) ‘FAILURE’ of nutritional Therapy 
= still not cured on 5th visit / 10 weeks 
 
…if neither of above, go direct to station (3) 
 
work in teams of two but:   
*** MEASURE INDEPENDENTLY *** 
BOTH REMEASURE if: 
Difference of more than, >0.7cm btw lengths  
Difference of more than, >0.5cm btw MUACs 
 
CALCULATE AVERAGE of measurements 
 
COMPARE to BASELINE length / MUAC: 
BOTH REMEASURE if: 
Length or MUAC~ 
decreased  
OR  
increased by > 2cm 
 
CALCULATE AVERAGE of LAST measures &  
WRITE FINAL LENGTH/MUAC on OTP sheet 
NB NOTE ON SHEET IF MEASURING HEIGHT (standing) rather than LENGTH (lying dow
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MOYO OTP 
~ station (3) ~ 
RUTF & SYMPTOM QUESTIONNAIRE 
 
Complete patient questionnaire 
(+ sign who is filling questionnaire) 
 
If has fever TODAY  
 send to Malaria project for MPS / PCV before clinician review 
(write request in health passport) 
 
IF ANY PATIENT SICK TODAY 
=> ALERT CLINICIAN 
 
MOYO OTP 
~ station (4) ~ 
CLINICAN REVIEW 
(+/- investigations, as appropriate) 
 
REVIEW OTP FILE 
(+ send back for review @ appropriate station if needed) 
 
REVIEW HISTORY 
+/- EXAMINE PATIENT: 
a) Clinically WELL but not cured 
or 
 
b)Clinically WELL AND CURED 
 
Clinically NOT well 
or 
 
NOT YET CURED 
Discharge (D/C) to: 
~ SFP (Supplementary Feeding Programme) 
~ Other, as needed  
(e.g. ARV/ Cotrim Clin/ Umodzi Pall. Care ) 
Needs further R/V @ 
MOYO OTP: 
Give date to come back in 2 weeks for: 
~ more RUTF  
~ further clinical review 
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MOYO OTP 
~ station (5) ~ 
OTP REGISTER 
 
REGISTER child in main OTP register 
if D/C, write, in red pen:  
a) SFP destination 
b) final height (+change since baseline)      
c) final MUAC (+ change since baseline)  
 
 
Give any appropriate medications 
 
 
Ensure carer understands any follow-up 
instructions 
 
If D/C: Give & explain SFP form 
 
 
 
MOYO OTP 
~ station (6) ~ 
RUTF distribution & clinic book 
 
(check which group ~ 1 or 2 ~ write in correct book) 
 
Give RUTF according to prescription 
(N.B. children being discharged get sachets rather than bottles) 
 
 
Collect OTP clinic sheet & ensure all sections filled 
(return to appropriate station if any missing details)  
 
Carer’s left thumbprint in book  
to confirm receipt of transport allowance & RUTF 
 
~ CARER & CHILD CAN GO HOM
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Annex E. PRONUT study forms and questionnaires 
 
E.1 Recruitment and consent 
 
 
 
 
 
Page 1/1 PRONUT form 01: RECRUITMENT HMIS no: Y06__/__/__/__
1) RECRUITMENT (all MOYO children are initially considered eligible for study)
1) EXCLUSION CRITERIA: (***** DO NOT RANDOMIZE / INCLUDE IN STUDY *****)
1.1 Is child <6 months (==>needs F100 dilute feeds)
==> IS eligible
2) CONSENT FOR TAKING PART IN STUDY:
2.1 If eligible, read consent form in Chichewa (or other appropriate lanuguage)
(ensure understanding / refer any questions to senior investigator before signing) (tick when done)
2.2 If eligible , does carer wish to take part in the study?
if NO ~ 2.2.1) If carer agrees, still complete all forms (to see if any differences btw study/non-study group?)
2.2.2) Thank carer & ask, if possible, to give reason for declining:
if YES~ (give carer copy of study information / consent form)
Name, signature (AND/OR) LEFT THUMBPRINT of carer
Name & signature of person obtaining consent
3) BASIC DETAILS  
Ensure routine paperwork, incl weight & drug chart completely filled: (tick when done)
If readmission: WRITE ADMISSIONS REGISTER IN RED: consider whether to use same or new HMIS number:
If ORIGINAL  episode: a) AFTER  JULY 2006 (i.e. SAME  HMIS YEAR) ==> use OLD HMIS number
b) BEFORE  JULY 2006 (i.e. OLD  HMIS year) ==> use NEW HMIS number
4) ABSOLUTE WITHDRAWL (==> NO MORE RUTF TO BE GIVEN)
4.1 Date of withdrawal: ____ d/_____m/200__
4.2 Timing of withdrawal:
4.3 Give reason: NOT malnutrition 1.1 RENAL (nephrotic / nephritic /other)
give correct Dx & details: 1.2 MALIGNANCY:
1.3 CARDIAC:
1.4 OTHER:
Patient carer request withdrawl
say why if possible
Other
5) ELIGIBILITY FOR PRIMARY ANALYSIS (==> CONTINUE RUTF but NOT for main analysis)
5.1 Eligible for primary analysis
5.2 If no, why not? 1) Cerebral palsy / syndrome 5) Other
2) Age >5years ( 60 months ) DETAILS:
3) Weight <4kg
4) Not SAM (ie wt/ht>70%; >-3Z; MUAC>11.0cm)
DATE: _____ / _____ / 2006 Interviewer Initials:
1 = yes 0 = no
Explain that the study may not start immediately ~ only when the child is eligible for REHABILITATION feeds.                                                                                                                                                                     
A second, verbal consent will then be requested to confirm willingness to take part                                                                                                                                           
Any decision may be changed at any time without affecting the patient's clinical care 
***** WITHDRAWAL FROM STUDY / REVIEW OF ELIGIBILITY*****
3 = OTP, post rnd.
1 = yes: 0 = no
1
3
1 = pre-randomization 2 = IP, post rnd.
2
==> NOT eligible
1 = yes, (<6months) 0 = no (>6m)
does want to take part does NOT want
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E.2 Baseline anthropometry 
 
 
 
 
 
Page 1/1 PRONUT form 02: Anthropometry
2) Anthropometry
1) CHILD:
1.1 Sex 1 = male 2 = female
1.2 Date of Birth _____ d / ______m / ________y
1.3 Age today (NB check DOB & AGE are consistent and correct) ______yrs/______months
(completed  months)
1.4 Is date of birth: 99 = DK
2) BASELINE ANTHROPOMETRY
2.1 BASELINE / ADMISSION WEIGHT:
2.1.1 Weight assessed by:
2.1.2 If not study team, is it likely: 0 = wrong: if so, what is 1st correct wt:
2.2 BASELINE OEDEMA
Both  repeat if any difference in grade:
initials
2.2.1
2.2.2
2.2.4 Oedema assessed by:
2.2.5 If not study team, is it likely: 0 = wrong: if so, what is 1st correct oedema:
2.3 BASELINE LENGTH
2.3.1 Which was done? 1 = length (measured lying down)
Both  repeat if: >0.7cm difference (or, if readmission, height  or  >2cm)
initials
2.3.2
2.3.3 cm
2.4 BASELINE MUAC
Both  repeat if: >0.5cm difference (or, if readmission, MUAC or >2cm)
initials
2.4.1
2.4.2
3) ARRIVAL AT MOYO / TFP
3.1 Check admission date(S) on front sheet is correct tick when done
3.2 Admission:
3.2.1 admitted via WHERE: circle / code from list below
3.2.2 date orginally admitted/seen: _____ d / ______m / ________y
1 = via PSCW
2 = readmission from MOYO OTP (if readmission, check old notes)
3 = referred from other FEEDING programme (SFP/OTP) - which:
4 = referred from other hospital / clinic (NOT feeding cente) - which:
5 = other (specify) 
date ____d/ _____m/200___
2= others
1 = correct
HMIS no:
Child Initials:
Y06__/__/__/__
.
BASELINE WEIGHT
checked by:
rechecked by:
cm
1 = accurate 2 = estimated
2= others
Oedema 2 ? ===> BASELINE OEDEMA
+ ++ +++
1 = study team
MUAC 1 ? ===> MUAC 2 ? ===> MUAC 3 BASELINE MUAC
Oedema 1 ? ===>
1 = study team
0
1 = correct
length 1 ? ===> length 2 ? ===> length 3
2 = height (measured STANDING)
BASELINE LENGTH
0 = referred / came via other1 = direct from home to MOYO (via QECH U5/A&E)
if not direct:
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3) Clinical
1) HISTORY OF PRESENTING COMPLAINT (2 week history)
# days 
had 
problem                                                     
0-14 days          
Was/Is 
problem:                              
1= minor;
2= mod.                      
3= severe
Where did 
you go for
treatment?                                        
select one 
(or more) 
from list                                                                                                                                   
1.1 Fever
1.2 Diarrhoea
?other:
1.3 Vomiting
1.4 Abdominal pain
1.5 Fast / Difficult breathing
(chest problem~WITH  OR WITHOUT  cough)
1.6 Cough 
(but NO  fast or difficult breathing)
1.7 Oedema / swelling (say where started)
1.8 Anorexia
1.9 Flaky paint / kwashiorkor-type rash
1.10 Other(1 - describe)
1.11 Other(2-describe)
1.12 Other(3-describe)
TREATMENTS:
0 = Did not go for any treatment 5 = from shop / marker / stall
1 = Continued treatment from MOYO OTP clinic (e.g cotrim, TB, other….) 6 = from relative/friend/elder
2 = INPATIENT admission where: 7 = from traditional healer
3 = Outpatient/clinic (NOT incl. OTP today) total # visits 8 = other
4 = from pharmacy 99 = DK
2) BREAST FEEDING
2.1 Complementary feeding: at what age were other foods 1st started? ______months
2.2 Breast feeding: Is (NAME) still BF? 1 = yes  0 = no 99 = DK
if no: 3.2.1 How old was he/she when BF stopped? ______yrs/______months
3.2.2 Why was BF stopped (ask re  PMTCT advice):
(loss of appetite)
Y06__/__/__/__
In the PREVIOUS 2 WEEKS                                                                                                                                                                              
did (NAME) have:                                                                                                                                                                                                                                
(if not had, write '0' in 1st column and leave 
others blank)                                                                                                                                                             
99 = DK (all columns)
Details of treatment:                                                                                                                                                                                                          
list 
antibiotics                                                                                                                                                                                        
any other drugs                                                   
(NOT incl. those given today)                                                                                                              
HMIS no:
ORS?   (1 = yes / 0 = no)
( ≥ 3 abnormally loose or watery stools/24h)
HISTORY
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3) PAST MEDICAL HISTORY (ask to see health passport if available)
3.1 Does carer have (NAME)'s health passport?
0 = no
3.2 When (NAME) was born, what size was he/she?:
3=very small 99 = DK
3.3 TB Has (NAME) had contact with anyone with TB? 1 = yes  0 = no 99 = DK
3.3.1 Is the contact: 1=mother 2=father 3=other male 99 = DK
3.3.2 Is the contact: 99 = DK
3.3.3 Is the contact sputum +ve 1 = yes  0 = no 99 = DK
3.3.4 Did child ever have: prophylaxis (=isoniazid only) 1 = yes  0 = no 99 = DK
treatment(=multiple tabs) 1 = yes  0 = no 99 = DK
3.4 VCT & HIV Ever had an HIV test(before  MOYO)? 1 = yes  0 = no 99 = DK
if yes: 3.4.1 Result? 2 = confidential 99 = DK
if (R): 3.4.2 Is (NAME) taking REGULAR cotrim. 1 = yes  0 = no 99 = DK
3.4.3 Is (NAME) on a waiting list for ARVS? 1 = yes  0 = no 99 = DK
3.4.4 Is (NAME) already on ARVS? 1 = yes  0 = no 99 = DK
if yes to 3.4.2 or 3.4.3: start date / planned start date _____d/ _____m/_______y 
3.4.5 Service provider 1=QECH 2=DREAM 3 =other:
4) VACCINATIONS (see also health passport)
Has (NAME) ever had: ("definate" = documented / "probable" = carer thinks so)
4.1 BCG 0 = no 99 = DK
4.2 DTP3 0 = no 99 = DK
4.3 Measles 0 = no 99 = DK
(N.B if not had measles -> arrange to give if >6 months age)
5) DEVELOPMENT & DISABILITY (show pictures / check definitions)
CAN (NAME) USUALLY :
5.1 Walk alone (at least 5 steps) 0=NO (A) 1=YES (A) 2=NO (R ) 3=YES (R ) 99 = DK
5.2 Sit without support 0=NO (A) 1=YES (A) 2=NO (R ) 3=YES (R ) 99 = DK
5.3 Stand with assistance 0=NO (A) 1=YES (A) 2=NO (R ) 3=YES (R ) 99 = DK
5.4 Crawl on hands / knees 0=NO (A) 1=YES (A) 2=NO (R ) 3=YES (R ) 99 = DK
5.5 Walk with assistance 0=NO (A) 1=YES (A) 2=NO (R ) 3=YES (R ) 99 = DK
5.6 Stand alone for >10 seconds 0=NO (A) 1=YES (A) 2=NO (R ) 3=YES (R ) 99 = DK
5.7 Any concerns that (name) cannot do many of things normal for a child his/her age?
1 = yes  0 = no 99 = DK
if yes: 5.7.1 Circle any that apply: meningitis
5.7.2 BRIEFLY describe:
5.7.3 What help or support are you getting?
2 = Physio 4 = other
1 = Cheshire homes (Feed the Children) 3 = MAP 99 = DK
6) OTHER STUDIES / RESEARCH PROJECTS
6.1 Is (NAME) taking part (currently or recently) in any other projects? 1 = yes  0 = no 99 = DK
Ask specificially about: ROTAVIRUS STUDY/ PMTCT/ ANY FEEDING STUDY
if yes: 6.1.1 DETAILS
6.1.2 STUDY ID / REF. No.
Date ____d/____m/200_ Interviewer initials:
if yes:
(A) ssessed
1 = normal (average) size or bigger
1 = yes (official passport)
2 = smaller than average
(R) eported
1 = household 2 = other
2 = yes, probable
2 = other female
0=NOT REACTIVE 1 = REACTIVE
2 = yes(temporary / exercise book)
1 = yes, definite
1 = yes, definite
0 = None
2 = yes, probable
2 = yes, probable1 = yes, definite
NOT had these problems
problems at birth cerebral malaria
problems with hearing or vision problems with hand movements
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Date ____d/____m/200_ Interviewer initials:
Page 3/4 PRONUT form 3: Clinical
7) FAMILY HISTORY (NOTE DETAILS OF HIV IF KNOWN)
7.1 List all  children born to same mother, including any who died
child
oldest (#1)
2
arrow 3
to identify 4
THIS 5
child 6
7
8
9
0 = <8hr 1 = 8-24hr 2 = 24-48h 3 = >48hr
exact:
1) GENERAL
1.1 Admission temperature?
1.2 Appearance / conscious level:
4=low BCS
1.2.1 if BCS <5:  /5
1.3 Dysmorphic features / Cerebral Palsy / Other severe disability 1 = yes 0=no;   99=DK
if yes  describe:
(comment on tone / reflexes / head circ ~ as needed)
1.4 Any traditional medicine charms or amulets? 1 = yes 0=no;   99=DK
2) HANDS, HAIR & SKIN (see table for other relevant features)
2.1 gen Hair changes (thin / fragile / discoloured) 0 = nil 1 = mild 2 = mod. 3 = severe
2.2 gen Flaky-paint dermatosis 0 = nil 1 = mild 2 = mod. 3 = severe
2.3 gen Clubbing? 0 = nil 1 = mild 2 = mod. 3 = severe
2.4 (2) Fungal nail infection 1 = yes 0=no;   99=DK
2.5 (2) Skin: (circle which  present) papular pruritic eruptions;
herpes zoster; extensive warts; extensive molluscum 1 = yes 0=no;   99=DK
2.6 (4) Kaposi's sarcoma 1 = yes 0=no;   99=DK
3) MOUTH
3.1 gen Sores 0 = nil 3 = severe
3.2 (2) Angular chelitis; gingival erythema; recurrent ulcers 1 = yes 0=no;   99=DK
3.3 (3 / 4) Candida 0 = nil 3 = severe
3.4 (3) Oral hairy leucoplakia; ulcerative teeth & gums (circle) 1 = yes 0=no;   99=DK
3.5 (4) Chronic herpes simplex >1 month - on lips OR skin 1 = yes 0=no;   99=DK
CLINICAL EXAMINATION
TIME: (after adm.)
3 =miserable/irritable
2 = moderate1 = mild
1 = mild (tongue) 2 = mod. (also on mouth lining/palate)
details of illness or death(incl month,year death if died)
o
C
Approx date of Birth                                                                                                                                                                                         
(day) / month / year
1 = normal & alert
.
2 = lethargy / apathy
Y06__/__/__/__HMIS no:
0=died/ 1=ill/ 2=well
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4) MAJOR SYSTEMS
4.1 (1) Persistent generalised lymphadenopathy (>1cm @ ≥2 sites) 1 = yes 0=no;   99=DK
4.2 (2) Parotid enlargement (persistent, unexplained) 1 = yes 0=no;   99=DK
4.3 (2) Recurrent, chronic URTI 1 = yes 0=no;   99=DK
current, with ≥1 event in last 6/12. e.g sinusitis, otitis media, bronchitis, croup, ear discharge
4.4 (2) Ear discharge (chronic, >1/12) 1 = yes 0=no;   99=DK
4.6 gen Heart failure 3 = unlikely
4.7 gen Dehydration? 0 = nil 1 = mild 2 = mod. 3 = severe
4.8 gen Peripheries 2 = cool 3 = cold
4.9 gen Respiratory distress 2 = mod. 3 = severe
4.10 gen Tachypnoea 0 = no
4.11 gen Chest signs 0 = no
4.12 Is this severe pneumonia? 3 = unlikely
4.13 (2) Hepatosplenomegaly liver cm / Spleen cm 1 = yes 0=no;   99=DK
4.14 OTHER 1 = yes 0 = no
(describe)
4.15 PREVIOUS WEIGHT copy growth chart from passport into file 1 = done 0 = chart n/a
Previous highest weight: WHEN (mth, year) _______ / 0___ WHAT: kg
(see case definitions)
(Circle and write "?" if approximate / 99(=DK) if unable to say)
5) OUTPATIENT VISITS: how many in last 6 months (not  incl this one) TOTAL #
Ask if any kwash/oedema/malnut NOT resulting in admission) 1 = yes 0 = no 99 = DK
Details:
6) INPATIENT ADMISSIONS: how many in last 6 months (not  MOYO/not this one) TOTAL #
(Circle and write "?" if approximate / 99(=DK) if unable to say)
Details:
7) OTHER:
7.1 (3) Any persistent diarrhoea (>14 days, unexplained, no response to Rx) 1 = yes 0=no;   99=DK
7.2 (3) Any persistent fever? (>1 month, no response antibiotics/antimalarials) 1 = yes 0=no;   99=DK
7.3 (3) Any MODERATE malnut./SFP (NOT including after NRU discharge)? 1 = yes 0=no;   99=DK
7.4 (3) Ever had pulmonary TB? (WHEN__________________________) 1 = yes 0=no;   99=DK
7.5 (3) Ever had lymph node TB? (WHEN______________) 1 = yes 0=no;   99=DK
7.6 (4) Ever had extrapulmonary / disseminated TB? 1 = yes 0=no;   99=DK
7.7 (3) Unexplained blood problems? (anaemia/neutropenia/thrombocytopenia) 1 = yes 0=no;   99=DK
7.8 (3) Ever had severe recurrent pneumonia? ~ current AND ≥1 in last 6/12 1 = yes 0=no;   99=DK
if yes was child admitted to hosptial? 1 = yes 0=no;   99=DK
did child need oxygen whilst in hospital? 1 = yes 0=no;   99=DK
7.9 (4) Ever had PCP pneumonia? 1 = yes 0=no;   99=DK
7.10 (3) Ever been diagnosed with HIV chronic lung disease or LIP? 1 = yes 0=no;   99=DK
7.11 (4) Recurrent severe bacterial infection? 1 = yes 0=no;   99=DK
(e.g. empyema; pyomyositis; bone or joint infection; meningitis ~ NOT PNEUMONIA)
7.12 (4) CNS problems: HIV encephalopathy; crypro meningitis; lymphoma; PML 1 = yes 0=no;   99=DK
7.13 (4) Other: CMV retinitis; HIV rectal fistula; cryptosporidiosis; isosporiasis; herpes 1 = yes 0=no;   99=DK
7.14 (4) Ever had severe malnutrtion / admitted to NRU (OR CTC programme) 1 = yes 0=no;   99=DK
how many admissions before this?             # when LAST admitted 
where admitted 1=MOYO 2 = other 99 = DK
did child reach cure? 0 = no 1 =yes: WHEN discharged? 99 = DK
did child have SFP after? 0 = no 1 =yes: WHERE 99 = DK
Date ____d/____m/200_ = CLINICIAN initials
Additional Hx
if yes
1 = yes: describe
1 = warm(normal))
2 = possible1 = definate / probable
0 = nil
1 = definate / probable
1 = mild
1 = yes: note rate
2 = possible
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Page 1/3 PRONUT form 4: Geography
4) Geography
1 MAIN RESIDENCE (= home of main carer / where child spends MOST  time)
1.1 DISTRICT
1.2 TA / WARD
1.3 VILLAGE / TOWNSHIP
1.4 IS RESIDENCE: 99=DK
2) MAP LOCATION (MAIN RESIDENCE)
To help locate residence on map, please state:
2.1 NEAREST (GOVERNMENT)  SCHOOL(S)
Name (must include school on the map):
Distance of school from residence:
2.2 NEAREST (GOVERNMENT) HEALTH CENTRE(S)
Name (must include health centre on the map):
Distance of health centre from residence:
2.3 BEST GUESS LOCATION
MAJOR grid square
small grid square letter number
3) ACCESS TO MOYO FROM HOME
Decribe your journey from home to MOYO:
From To
3.1
3.2
3.3
3.4
3.5
3.6
codes: *TRAVEL: 1=walk / 2=bicycle / 3=minibus / 4=ambulance / 5=hitchhike / 6=other
**TIME If possible, estimate # HOURS(99 = DK)
if unable to say in hours: +=short time; ++=medium time; +++=long time(as percieved by carer)
HMIS no: Y06__/__/__/__
1 = urban 2 = rural 
Home
LETTER NUMBER
walk
Travel means* Cost (MK)**Time (if known)
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4) DIRECTIONS TO RESIDENCE
(start from major local landmark - e.g school, health centre, shop)
Please include names of at least two people to ask to help find house:
+ WHO are they?
1)
2)
3)
5) SECONDARY RESIDENCE (i.e. 'home' village / other place where spends SIGNIFICANT time)
5.1 DISTRICT
5.2 TA/WARD
5.3 VILLAGE / TOWNSHIP
5.4 REASON FOR SECONDARY RESIDENCE
1=work 99 = DK
6) Directions to residence (SECONDARY RESIDENCE ~ if applicable)
Use local clinic / school (ON MAP) as landmark
6.3 Please include names of at least two people to ask to help find house:
+ WHO are they? 1)
2)
6.4 BEST GUESS LOCATION
MAJOR grid square
small grid square letter number
Date ____d/____m/200_ Interviewer initials:
2 = family / 'home' district 3 = farmland 4 = other
LETTER NUMBER
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Page 3/3 PRONUT form 4: Geography HMIS no: Y06__/__/__/__
CHILD INITIALS:
7) DIRECT DROP / GPS (Main residence)
7.1 DATE ____d/____m/_______y
7.2 GIVEN LIFT FROM 1 = inpatient discharge 3 = other
7.3 Description of home location:
a) Basic directions from QECH:
b) Where to leave car:
c) Approx time walking from car: mins
d) Landmarks / directions to help find house
7.4 GPS TECHNICAL Number of satellites: #
Accuracy meters
7.5 WAYPOINT NUMBER #
7.6 GPS COORDINATES
7.6.1 Elevation meters
7.6.2 South
o ' . "
7.6.3 East
o ' . "
Date ____d/____m/200_ Driver initials:
2= OTP clinic
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5) Socio-economic status
1) CARERS
1.1 CARER Who is with child now / answering this questionairre?
6 = other family~ who
7 = other non-family~who
99 =DK
1.2 MAIN (usual) CARER
If main carer is not with child why not:
1.3 PARENTS
1.3.1 Is mother alive? 1 = yes 0 = no 99 = DK
if mother alive but is not main carer, why not?
1.3.2 Is father alive? 1 = yes 0 = no 99 = DK
1.3.3 If both alive, are they together? 1 = yes 0 = no 99 = DK
1.4 Mother's D.O.B (if known)
1.5 If DOB not known, how old was mother when (NAME) was born
(99 = DK)
1.6 WHAT IS / WAS MAIN  OCCUPATION OF: (describe AND write correct code in box)
1.6.1 Mother describe: code
1.6.2 Father describe: code
1.6.3 (Main carer - if not parent) code
Active Unemployed Inactive
1 =  mlimi / ganyu 6 = worked before, seeking work 9 = never worked, not looking
2 = employee 10 = housewife
3 = family business 11 = student
4 = self-employed 12 = other
5 = employer 99 = DK
1.7 LITERACY = Can read/write ~ (use 'test' sentence to check)
1.7.1 Mother 1 = yes 0 = no 99 = DK
1.7.2 Father 1 = yes 0 = no 99 = DK
1.7.3 (MAIN Carer - if not parent) 1 = yes 0 = no 99 = DK
1.8 HIGHEST EDUCATION LEVEL ACHIEVED (write correct code in box)
1.8.1 Mother
1.8.2 Father
1.8.3 (MAIN Carer - if not parent)
None = 0
Primary S1 = 1 S2 = 2 S3 = 3 S4 = 4 S5 = 5 S6 = 6 S7 = 7 S8 = 8
Secondary F1 = 9 F2 = 10 F3 = 11 F4 = 12 F5 = 13 F6 = 14
Higher University / other higher = 15 other =16_______________ 99 = DK
8 = never worked before, looking 
for work
1=same as in qn above
6 = neighbour
Y06__/__/__/__
1 = mother
2 = father
_______d / _______m / 19____
3 = grandmother
2 = other, from list above:
4 = aunt
5 = uncle
99 = DK
years
7 = worked before , not looking 
for work
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2 FAMILY SOCIOECONOMIC STATUS ~ WEALTH INDEX DHS
2.1 GENERAL
Tenure 99 = DK
How many sleeping rooms are there? (excl. bathroom/storerooms/garage)
How many household members are there? #
(people who usually stay in the same house together; eat meals together; make provisions for food together)
2.2 HOUSEHOLD POSESSIONS & ASSETS In the dwelling is there:
1 = yes 0 = no 99 = DK
1 = yes 0 = no 99 = DK
1 = yes 0 = no 99 = DK
A motorcycle (or motorscooter) 1 = yes 0 = no 99 = DK
1 = yes 0 = no 99 = DK
1 = yes 0 = no 99 = DK
1 = yes 0 = no 99 = DK
A mosquito net 1 = yes 0 = no 99 = DK
A television 1 = yes 0 = no 99 = DK
A cellphone 1 = yes 0 = no 99 = DK
A telephone (landline) 1 = yes 0 = no 99 = DK
A bed with a mattress 1 = yes 0 = no 99 = DK
A sofa set 1 = yes 0 = no 99 = DK
A table and chair(s) 1 = yes 0 = no 99 = DK
A refrigerator 1 = yes 0 = no 99 = DK
A domestic worker not related to household head 1 = yes 0 = no 99 = DK
Do members of household work their own agricultural land? 1 = yes 0 = no 99 = DK
2.3 WATER SOURCES What is the MAIN source of drinking water for the household?
1 = piped INSIDE DU (dwelling unit) 5 = open well (SHARED/PUBLIC) 9 = surface water
2 = piped OUTSIDE DU (in yard/plot); 6 = borehole/protected well (OWN plot) (river, stream, pond, lake, dam)
3 = piped (COMMUNITY stand pipe) 7 = borehole/protected well (SHARED/PUBLIC) 10 = other
4 = open well (OWN yard / plot) 8 = from a spring 99 = DK
2.4 TOILET What is the MAIN type of toilet used by household members?
1 = own (exclusive) flush 4 = traditional pit latrine (SHARED) 7 = no facility (bush / field)
2 = shared flush toilet 5 = VIP (ventilated improved pit) latrine (OWN) 10 = other
3 = traditional pit latrine (OWN) 6 = VIP latrine (SHARED) 99 = DK
2.5 FLOORING  What is the MAIN type of flooring in your dwelling?
1 = nicely finished (circle which) 2 = finished ( cement, vinyl/asphalt strips ) 10 = other
(parquet/polished wood; ceramic tiles; carpet)3 = wood or plank
4 = natural materials     ( earth / sand / dung ) 99 = DK
2.6 ROOFING What is the MAIN type of roofing in your dwelling?
1 = cement 4 = iron sheets 10 = other
2 = asbestos 5 = natural materials
3 = iron and tiles 99 = DK
2.7 FUEL FOR COOKING What fuel does the household MAINLY use for cooking?
1 = electricity 4 = charcoal, coal or lignite 10 = other
2 = gas (LPG / natural gas / biogas) 5 = wood or straw
3 = paraffin / kerosene 6 = dung 99 = DK
2.8 DOMESTIC ANIMALS goats pigs cattle sheep chickens
How many of the following are owned: (0 if nil, 99 if DK)
Date ____d/____m/200__ Interviewer Initials:
An oxcart
A paraffin lamp
Electricity
A bicycle
2 = rented1 = owner
A car (or truck)
3 = other
A radio
THIS REFERS TO THE HOME OF THE MAIN  CARER / WHERE THE CHILD USUALLY  STAYS
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Page 1/2 PRONUT form 07: OTP Review HMIS no: Y06__/__/__/__
Child Initials:
7) OTP Review date
1) VISITS
1.1 Date originally discharged from MOYO?
1.2 Which number OTP is this? (e.g 1st, 2nd, 3rd etc) visit #
2) ANTHROPOMETRY
2.1 TODAY's WEIGHT:
2.2 ?CURE: ( = target weight (>80% wt/ht) on TWO consecutive visits) 1 = yes 0 = no
2.3 ?NUTRITIONAL FAILURE ( = not cured @ 5th visit/10 weeks OTP) 1 = yes 0 = no
if no, GOTO q.3
2.4 DISCHARGE LENGTH Both  repeat if: >0.7cm difference; OR if child shorter OR if grown >2cm
initials
2.4.1
2.4.2 cm
2.4.3
2.4.5 Length increase from baseline cm
2.4.6 Is baseline length likely 1 = correct 0 = incorrect
2.5 DISCHARGE MUAC Both  repeat if: >0.5cm difference; OR if MUAC shrunk OR if increased >2cm
initials
2.5.1
2.5.2
2.5.4 MUAC increase from baseline cm
2.5.5 Is baseline MUAC likely 1 = correct 0 = incorrect
3) FOOD & APPETITE
3.1
How many bottles were:
3.1.1 Given @ last visit # pots given
3.1.2 Average number pots eaten / day # pots eaten/day
3.1.3 Left UNFINISHED # pots unfinished
if any unfinished, why:
3.1.4 IF ALL POTS eaten by child , how many days ago were they finished # days
3.1.5 Any problems eating the RUTF? 1 = yes 0 = no 99 = DK
If  YES Describe:
What was done?:
Did it help?
3.2
Is (NAME) getting food from other projects / feed programme? 1 = yes 0 = no 99 = DK
If YES: 3.2.1 Details : what / from who / how much / how often?
if any YES:
MUAC 3MUAC 2MUAC 1
_____d/_____m/______y 
.
length 1 length 2 length 3
checked by:
rechecked by:
FINAL LENGTH
FINAL MUAC
cm
CIRCLE HEIGHT if height rather than length measured
_____d/_____m/______y 
RUTF (Ready-to-Use Therapeutic Foods)
OTHER FOODS ~ feed programmes / projects
PLEASE CHECK:                                                                                                                                                                                
1) MUAC @ EVERY VISIT (same rules as below); 2)CD4 at 1st/2 week visit(=routine test)
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Page 2/2 PRONUT form 07: OTP Review
4) CLINICAL PROGRESS (2 week history)
# days had 
problem                                                     
0-14 days          
Was/Is 
problem:  
1= minor;                               
2= mod.                      
3= severe
Where did you 
go for
treatment?                                                
select one (or 
more) from list 
below                                                                                                                                     
Today, is 
problem:                    
0 = all gone                                                                                                                    
1 = better;                                                                                                                                                                                                  
2 = same;                                                                                                                                                                                                  
3 = worse
4.1 Fever
4.2 Diarrhoea
?other:
4.3 Vomiting
4.4 Abdominal pain
4.5 Fast / Difficult breathing
(chest problem~WITH  OR WITHOUT  cough)
4.6 Cough 
(but NO  fast or difficult breathing)
4.7 Other(1)
4.8 Other (2)
TREATMENTS:
0 = Did not go for any treatment 5 = from shop / marker / stall interviewer
1 = Continued MOYO treatment given @ last visit (e.g cotrim, TB, other….) 6 = from relative / friend / elder initials
2 = INPATIENT admission 7 = from traditional healer
3 = Outpatient/clinic (NOT incl. OTP today) total # visits 8 = other
4 = from pharmacy 99 = DK
5) ANY INPATIENT ADMISSIONS NOT ALREADY MENTIONED? 1 = yes 0 = no 99 = DK
if yes: dates: from to
diagnosis / details:
6) ANY OTHER MEDICINES NOT ALREADY MENTIONED? 1 = yes 0 = no 99 = DK
WHAT: x  per day # days
6) CLINICAL EXAMINATION
6.1 Detailed examination:~
(only if problems / unwell)
6.2 DIAGNOSIS: 1 = well 2 = URTI 3 = LRTI 4 = GE 5=other
7) INVESTIGATIONS NEEDED? 0 = no
7.1 MPS (0 = neg; 1 = +; 2 = ++; 3 = +++)
7.2 PCV PCV %
7.3 OTHER(e.g CXR, mantoux)
7.4 CD 4 (routine test for HIV ® children) RESULT(%)
8) OUTCOME
1= POOR ==> severe problem ideally needing readmission
if readmission needed, does carer agree: 1 = yes 0 = no details:
2= FAIR ==> problem(s), but OK for home treatment
3= GOOD/not YET cure ==>needs further review
4= GOOD/CURE ==> FOR D/C (=achieved 80% target wt on TWO consecutive visits)
5= FAILURE OF NUTRITIONAL THERAPY ( = not cured @ 5th visit/10 weeks OTP)
6= Other (e.g transfer out)
9) TTO MEDICATIONS(s) 4 = Iron
1 = cotrimoxazole 5 = other (1)
2 = ARVs started on: 6 = other (2)
3 = TB meds started on: 7 = other (3)
10) FOLLOW-UP: 4 = ARV clinic - start date:~
10.1 Clinical 5 = TB clinic
(circle ALL that apply) 2 = ARV staging clinic 6 = Disability clinic: which_______________
3 = Cotrim clinic 7 = Other 
10.2 SFP
Date ____d/____m/200_ Clinician initials
Note any relevant details
0 = NONE ~ no routine fup needed
1 = CONTINUE MOYO fup in 2/52
2 = yes(review of Ix ordered @ last visit)
ORS?   (1 = yes / 0 = no)
1 = yes (needs today)
Details of treatment:                                                                                                                                                                                                          
list antibiotics  / ORS /                                                                                                                                                                                        
any other drugs                                                   
(NOT incl. those given today)                                                                                                              
( ≥ 3 abnormally loose or watery stools/24h)
↓ CLINICIAN TO COMPLETE REST OF FORM ↓
ASK RE COTRIM / TB /HIV
0 = no1 = yes: ~ which:~
0 = nil
e.g dose; duration; start date
(circle all that apply ~ incl TB/ARV etc
0 = to do today (tick when done)
In the PREVIOUS 2 WEEKS ,                                                                                                                                                                              
did (NAME) have:                                                                                                                                                                                       
(if not had, write '0' in 1st column and leave others 
blank)                                                                                                                                                               
99 = DK (all columns)
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Annex F. PRONUT study additional details and results 
 
F.1 RUTF quality control: concentration of Synbiotic organisms 
Table 43 Quality control testing of randomly selected RUTF batches 
  
( a )                            
SYNBIOTIC GROUP 
concentration of 
lactic acid bacteria          
 (date of lab testing) 
( b )                          
daily dose of 
probiotic 
(av. 1.19 pots RUTF 
/day eaten:               
300g RUTF per day      
= 5.95g Synbiotic/ 
day) 
( c )             
 CONTROL GROUP 
concentration of 
lactic acid bacteria 
(date of lab 
testing) 
( d )                          
daily dose LAB  
average 1.19 pots 
RUTF /day eaten:               
300g RUTF per 
day 
RUTF date of 
manufacture 
CFU/g = ( a ) * 300 
 
CFU/g = ( c ) * 300 
 15
th
 Jan 2006 (Pilot batch not used in study. Laboratory incubated @ 30°C)  
Baseline (2 weeks 
after manufacture) 
6.43 x 10^9               
(31st January 2006) 
1.93 x 10^12 
 
n/a n/a 
After 1 month 
5.03 x 10^8               
(28
th
 February 2006) 
1.51 x 10^11 
 
n/a n/a 
After 2 months 
2.23 x 10^8                            
(31
st 
March 2006) 
6.69 x 10^10 
 
n/a n/a 
After 3 months 
3.50 x 10^8                  
(28
th
 April 2006) 
1.05 x 10^11 
 
n/a n/a 
 13
th 
Jul  06 (this and all subsequent batches as used in study) 
 Baseline (2 weeks 
after manufacture) 
1.9 x 10^8          
(August 2006) 
5.70 x 10^10 
 3.3 x 10^2                  
(August 2006) 
9.9 x 10^4 
 Late (2 months 
after manufacture) 
3.65 x 10^8     
(September 2006) 
1.10 x 10^11 
 <1*10^2                                
(September 2006) 
<3.0 x 10^4 
 10
th
 Aug  06          
Baseline sample 
3.16 x 10^8         
(September 2006) 
9.48 x 10^10 
 5.5 x 10^2                         
(September 2006) 
1.7 x 10^5 
Late sample n/a n/a 
 2.8 x 10^5                                 
(October 2006) 
8.4 x 10^7 
Longer term 
stability  (approx 5 
months after 
manufacture) 
2.7 x 10^8                   
(January 2007) 
8.10 x 10^10 
 
n/a n/a 
 16
th 
Sept  06          
Baseline sample 
2.2 x 10^8 
(October 2006) 
6.60 x 10^10 
 2.8 x 10^6                  
(October 2006) 
8.4 x 10^8 
Late sample 1.6 x 10^8 4.80 x 10^10  n/a n/a 
 10
th 
Oct  06          
Baseline sample 
2.3 x 10^8       
(November 2006) 
6.90 x 10^10 
 3.0 x 10^3 &  
<1 X 10^3             
(November 2006)            
(analysed x2) 
9.0 x 10^5 
Late sample n/a n/a  n/a n/a 
Longer term 
stability 
5.6 x 10^7                  
(January 2007) 
1.68 x 10^10 
 
n/a n/a 
5
th
 Nov 06          
Baseline sample n/a n/a  n/a n/a 
Late sample 
1.2 x 10^8                   
(January 2007) 
3.60 x 10^10 
 <1 x 10^5                         
(January 2007) 
<3.0 x 10^7 
 3
rd 
Jan 07          
Baseline sample 
1 x 10^8                                  
(January 2007) 
3.00 x 10^10 
 <1 x 10^5                         
(January 2007) 
<3.0 x 10^7 
Late sample n/a n/a  n/a n/a 
n/a = not available (sample not sent since did random selection of some batches, but not routine testing of all). 
Notes: a) Concentrations apparently going UP with time are due to non-homogenous mixing. 
b) Some control batches had small concentrations of lactic acid bacilli (LAB) due to non-sterile nature of milk 
powder used in the RUTF recipe. The lab assay could not distinguish between Synbtioic2000 Forte
TM
 LAB and others. 
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KEY:
= no concern re probio sepsis, 
NO FURTHER LAB WORK-UP 
NEEDED
THE 
ORGANISMS 
TO IDENTIFY:
1) Pediococcus pentosaceus 16:1 LMG P-20608,, 
= mid level concern - 
STANDARD LAB CULTURES
2) Lactobacillus paracasei subsp paracasei F-19 LMG P-17806
= high level concern FURTHER 
LAB WORK-UP NEEDED
3) Lactobacillus plantarum 2362 LMG P-20606.
4)  Leuconostoc mesenteroides 23-77:1 LMG P-20607
-ve +ve
=+ve =+ve = -ve
store 
sample
treat initially with standard 2nd line antibiotics - 
modifications guided by clinical progress and lab 
sensitivites)
IDENTIFICATION & TREATMENT STRATEGY FOR POSSIBLE PROBIOTIC-INDUCED SEPSIS IN 
MOYO/PAEDIATIRCS                                                PRONUT STUDY
 (ACCORDING TO 
REFERENCES FROM HPA - 
Health Protection Agency UK 
& lab pilot, all four probio 
organisms WILL grow under 
standard blood culture 
conditions)
(most non-probiotic 
contaminants excluded 
by this step)
send back to europe for possible further testing by 
PCR/API to confirm whether ENDOGENOUS source or 
SYNBIOTIC source
organism obvious / 
could NOT be a 
probio org e.g 
obvious pure growth 
salmonella / strep 
pneumo
organism not obvious / SUSPICIOUS / 
could POSSIBLY be probiotic organism                                                                                     
==>FURTHER CULTURE NEEDED TO 
CHARACTERISE FURTHER
2nd culture of suspicious innoculum: 
MRS agar culture with vancomycin (the 
probio organisms WILL grow on MRS/ ALL 
are vanc resistant)
data/safety monitoring committee alerted - will break 
codes, check data & MAY have to halt study if any 
concerns
further micro sensitivites are available from this step to 
support patient care if patient still pyrexial / not 
responding to initial treatment
catalase 
test / gram 
stain of 
bacteria 
from 
culture
might  be one of the 4 probiotic 
organisms BUT could be an 
endogenous lactobacillus from 
patient's own GI tract
ALL IN STUDY 
'SYNBIOTIC'
SICK PYREXIAL CHILD IN STUDY
(likely low numbers since probiotic-
enhanced food only starts in 
rehabilitation phase, once children 
more stable)
BLOOD CULTURE TAKEN & arrives in Wellcome lab                                                                                                                                                            
(according to CURRENT  clinical criteria ==> should not be 
any significant increase in numbers of cultures taken)
ALL RELEVANT BLOOD CULTURES IDENTIFIED BY STICKER ON BOTTLE & FORM:
F.2 Possible probiotic sepsis laboratory protocol 
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F.3 Baseline clinical characteristics (detailed) 
Table 44 Baseline clinical characteristics in detail 
  Synbiotic (n=399) Control (n=396) 
Symptoms in 2 weeks prior to admission (total patient days with symptom standardized per 1000 days observation) 
  (Total patient days of observation) (5586) (5544) 
  Diarrhoea 310 268 
  Vomiting 180 141 
  Abdominal Pain 190 151 
  Fast and/or difficult breathing 44 42 
  Cough 288 269 
  Fever 245 221 
  Oedema 296 271 
  Anorexia 335 293 
  Flaky paint dermatosis 84 90 
  Other 156 124 
Outpatient consultations in 2 weeks prior to admission 
  One or more outpatient visits 276/388  (71.1%) 273/383 (71.3%) 
Medication use in last 2 weeks     
  Any medication 347/388 (84.9%) 335/381 (87.9%) 
  If used medications were antibiotics used? (if able to 156/306 (51.0%) 148/299 (49.5%) 
Past medical history / admissions (% of patients)     
  Any inpatient admissions (last 12 months, not SAM) 75/382 (19.6%) 72/372 (19.4) 
  Any outpatient visits in last 6 months 336/374 (89.8%) 340/370 (91.9%) 
  Any previous admissions for SAM (EVER) 55/390 (14.1%) 49/382 (12.8%) 
  Any outpatient based supplementary feeding (last 90/387 (23.3%) 81/376 (21.5%) 
Feeding history     
  Currently breast feeding 104/393 (26.5%) 114/388 (29.4%) 
  If not breast fed, age at which stopped (mean 19.6 ± 8.3 19.6 ± 8.3 
Growth chart in health passport (if available)     
  Weight decreasing on chart 152/232 (65.5%) 142/237 (59.9%) 
Reported Birth-weight     
  "Normal or bigger than normal" 340/377 (90.2%) 339/376 (90.2%) 
Immunization status (% of children recorded or reported immunized)     
  BCG 384/389 (98.7%) 375/378 (99.2%) 
  DTP (all 3 doses) 376/390 (96.4%) 370/378 (97.9%) 
  Measles  323/380 (85.0%) 330/372 (88.7%) 
Admission investigations     
  PCV (mean ± sd) 31.5 ± 6.7 31.1 ± 7.1 
  Malaria parasites on peripheral blood smear (any) 25/377 (6.6%) 28/357 (7.8%) 
TB       
  Had pulmonary TB in the past (ever) 15/391 (3.8%) 8/379 (2.1%) 
  Diagnosed with TB at any time during programme 19/396 (4.8%) 11/390 (2.8%) 
Inpatient antibiotics at any time whilst on ward  (all patients had 1
st
 line antibiotic,   
  Had 2nd line antibiotics (chloramphenicol / 192/396 (48.5%) 181/390 (46.4%) 
  Had 3rd line antibiotics (ceftriaxone) 31/396 (7.8%) 31/390 (7.9%) 
Inpatient days PRIOR to randomization 
  Total inpatient days observation prior to 1458 1424 
  Median inpatient days prior to randomization +/- IQR  2 +/-1 2 +/-1 
Inpatient Symptoms PRIOR to randomization, total patient days with symptom per 1000 days observation 
  days where no observation noted on chart 54 52 
  Abnormally loose/watery stool (any) 462 473 
         Diarrhoea (≥3 loose/watery stool / 24hrs) 300 272 
         Severe diarrhoea (≥6 loose/watery stool / 24hrs) 73 65 
  Vomiting (any) 295 258 
  Abdominal pain (any) 273 268 
  Cough (any) 552 540 
  Fever (any, reported) 442 471 
  Fever (documented, >37.5) 291 270 
Other signs & symptoms (symptoms either reported by carer or documented in child 'health   
  Hair Changes (any) 312/392 (79.6%) 327/385 (84.9%) 
  Dermatosis (any) 118/380 (31.1%) 115/381 (30.2%) 
  Finger clubbing (any) 35/396 (8.8%) 25/389 (6.4%) 
  Oral sores (any severity) 73/394 (18.5%) 61/387 (15.8%) 
  Angular chelitis 91/392 (23.2%) 69/382 (18.1%) 
  Oral candida (any) 127/391 (32.5%) 105/387 (27.1%) 
  Generalized lymphadenopathy 36/396 (9.1%) 40/388 (10.3%) 
  Parotid enlargement 7/394 (1.8%) 6/384 (1.6%) 
  Reported recurrent Upper Respiratory Tract 34/393 (8.7%) 41/381 (10.8%) 
  Reported chronic ear Discharge 25/392 (6.4%) 33/381 (8.7%) 
  Hepatospenomegaly 39/396 (9.8%) 26/390 (6.7%) 
  Reported persistent diarrhoea 97/388 (25.0%) 74/375 (19.7%) 
  Reported persistent fever 33/387 (8.5%) 32/375 (8.5%) 
  Unexplained blood problems 22/391 (5.6%) 13/380 (3.4%) 
  Reported Severe Recurrent Pneumonia 26/390 (6.7%) 27/380 (7.1%) 
  Reported Recurrent severe bacterial infection 7/389 (1.8%) 3/380 (0.8%) 
CD4 count (%) ~ taken at 1st outpatient visit, 2 weeks after discharge from ward, seropositive children only 
  CD4 <20% (of  seropositive children in whom CD4 61/92 (66.3%) 67/103 (65.0%) 
  CD4% (mean) 18.3 ± 9.6 (n=92) 17.8 ± 10.1 (n=103) 
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F.4 Baseline family and socioeconomic status (detailed) 
 
Table 45 Baseline family and socioeconomic status in detail 
  
Synbiotic                 
(n=399) 
Control                          
(n=396)   
Family Status   
 Mother   
 Mother alive 358/387 (92.5%) 350/384 (91.1%) 
 Main carer is mother 329/387  (85.0%) 321/384  (83.6%) 
 Mother's occupation is housewife 217/379  (57.3%) 196/377  (52.0%) 
 Mother literate 246/378  (65.1%) 243/366  (66.4%) 
 Mother educated to secondary school level or above 64/371 (17.3%) 81/368 (22.0%) 
 Father   
 Father alive 357/383 (93.2%) 353/382 (92.1%) 
 Parents together (if both alive) 261/329  (79.3%) 239/321 (74.5%) 
 Father is in paid employment 278/372 (74.7%) 277/359 (77.2%) 
 Father literate 334/364 (91.8%) 315/343 (91.8%) 
 Father educated to secondary school level or above 139/284 (48.9%) 140/269 (52.0%) 
Socioeconomic status   
 Family own their own house 234/386 (60.6%) 234/382 (61.3%) 
 Household assets   
 Electricity 39/386 (10.1%) 49/382 (12.8%) 
 Radio 220/385  (57.1%) 220/382  (57.6%) 
 Bicycle 73/386 (18.9%) 66/382 (17.3%) 
 Parafin Lamp 295/385  (76.6%) 307/382  (80.4%) 
 Mosquito net 223/386  (57.8%) 225/380  (59.2%) 
 TV set 33/386 (8.5%) 30/382 (7.9%) 
 Cellphone 57/386 (14.8%) 43/382 (11.3%) 
 Bed with mattress 152/386 (39.4%) 127/380 (33.4%) 
 Fridge 8/385 (2.1%) 8/382 (2.1%) 
 Family own their own land 231/382  (60.5%) 223/381  (58.5%) 
 Main household water source    
 Piped 208/386  (53.9%) 217/382  (56.8%) 
 Borehole / protected well 132/386  (34.2%) 117/382  (30.6%) 
 Main household toilet   
 Traditional pit latrine 373/386  (96.6%) 367/382  (96.1%) 
 Main household fuel for cooking   
 Charcoal 176/385 (45.7%) 166/380 (48.5%) 
 Wood or straw 202/385 (52.5%) 204/380 (53.7%) 
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Annex G. FUSAM study forms and questionnaires 
 
G.1 Main study form 
Page 1/6 HMIS no: Y06___/___/___/___
1) DATES 
1.1 Date of this follow-up VISIT
2) OUTCOME OF FOLLOW-UP VISIT
2.1 What was outcome of follow-up visit?
1 = Child seen ~
1c=other
2 = Child not seen: but information reliable (e.g from main carer / close relative)
3 = Child not seen: information may be unreliable (e.g family friend or neighbour)
4 = Unsuccessful search  (child not found, no information available)
3) CARER / PERSON ANSWERING QUESTIONS
3.1 Who is child's main carer / answering this questions now?
6 = other family~ who
7 = other non-family~who
3.2 Who was ORIGINALLY with child whilst on MOYO
If different, why has carer changed? 3=other 77 = n/a 99=DK
3.3 Does carer agree to answer questions about progress since MOYO? 1 = yes 2 = no 77=n/a
4) HOW IS CHILD NOW?
4.1 How is child now (or how was child when last seen?)
1 = Child DIED (fill table opposite: ask re problems prior to death)
if died: 3=other 99 = DK
2c=hospital other:
2 = Child well (according to reporter)
3 = Child still sick (according to reporter)
99 = Don't know / no info available
4.2 Date of final outcome (i.e. date today if alive OR date died OR date last seen if has since moved away) 
(if approximate, put circle around box)
5) FOLLOW-UP WEIGHING / GROWTH MONITORING
5.1 Is the child's health passport available to see now? 0 = no 1 =yes
5.2 Has the child been weighed since MOYO (not SFP) 0 = never 1 =yes 77 = NA 99 = DK
5.2.1 if yes: how many times SINCE MOYO is weight plotted on growth chart
4 = aunt
77 = n/a (no passport)
INITIALS
______d / ______m /2007
______d / ______m /______y
99 =DK
2 = hospital
2a= hospital MOYO 2b=QECH/PSCW
2=other, from list:1=same as above
1a = seen @ OTP 1b = seen @ field visit
1 = mother
3 = grandmother
WHERE DIED
if hospital, which:
2 = father
1 = home
5 = uncle
6 = neighbour
1 = death 2=sickness
MOYO 1 year follow-up
77 = NA
EXPLAIN REASON FOR FOLLOW-UP VISIT +                                                                                                                                       
obtain verbal consent to ask further questions
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6) ANY RECURRENCE MALNUTRITION IN *** LAST 1 YEAR *** ? (or since MOYO disch if died)
(NB Includes repeat admissions to MOYO since ORIGINAL EPISODE and/or MALNUTRITION AT DEATH)
6.1 TOTAL episodes of KWASHIORKOR / swelling =
6.2 TOTAL episodes of MARASMUS /  getting thin =
If any episodes of repeat malnutrition:
Did child go for medical (clinic/hospital) attention? 0 = no 1 =yes 77 = n/a 99 = DK
How many times admitted to NRU (inpatient admission) 77 = n/a 99 = DK
How many times had CTC ( RUTF/OTP only ) 77 = n/a 99 = DK
How many times given advice / multivits / other (circle) -but NO RUTF 77 = n/a 99 = DK
How many times referred to SFP programme alone 77 = n/a 99 = DK
Brief details - as relevant (e.g was child readmitted to MOYO or other NRU/ which OTP was doing CTC):
7) INPATIENT ADMISSIONS *** LAST 1 YEAR *** (NOT SAM) ? number, # 99 = DK
BRIEF details of Dx / Rx (or between MOYO d/c and death if died)
8) OUTPATIENT VISITS *** LAST 6 MONTHS *** (NOT SAM)? number, # 99 = DK
NB non-routine visits only - not ARV, OTP clinics
(or between MOYO d/c and death if died)
9) CLINICAL PROGRESS / VERBAL AUTOPSY (2 week history OR 2 weeks prior death if died )
# days 
had 
problem                                                     
0-14 days          
9.1 Fever
9.2 Diarrhoea
9.3 Vomiting
9.4 Fast / Difficult breathing
(chest problem~WITH  OR WITHOUT  cough)
9.5 Cough 
(but NO  fast or difficult breathing)
9.6 Swelling (oedema)
9.7 Other (1)
REFER BACK TO MOYO / QECH IF SICK
4 = pharmacy
1 = antibiotic                                     
Details of 
treatment:                                                                                                                                                                                                          
(circle all that apply)                                        
(NOT incl. those 
given today)                                                                                                              
99 = DK
99 = DK
0 = none
1 = continued long standing treatment 
(e.g TB, COTRIM, ARV) 
3 = outpatient clinic
2 = inpatient admission
IN THE PREVIOUS 2 WEEKS ,                                                                                                                                                                          
(BEFORE TODAY                                                                                                                                                                                       
OR                                                                                                                                                                                                               
in 2/52 PRIOR TO DEATH  IF 
DIED)                                                                                                                                                                         
did the child have:                                                                                                                                                                                    
( ≥ 3 abnormally loose or watery stools/24h)
WHERE                                           
(if anywhere)                                 
did child get treatment in these 
2 weeks?                      (circle all 
that apply)                                               
99 = DK
5 = shop / market
6 = relative / friend
7 = traditional healer
8 = other
2 = antimalarial 
(SP/quinine)
3 = antipyretic 
(paracetamol / brufen 
etc)
4 = other / cannot say 
what
5 = ORS
99 = DK
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Page 3/6 MOYO 1 YEAR follow-up: Initials HMIS no: Y06___/___/___/___
10) TB medication
10.1 TB ever? 0 = no 99=DK
10.2 How many months did child have treatment for? # months 77 = n/a 99=DK
10.3 If TB, were other children in family screened or treated 0 = no 1 = yes 77 = n/a 99 =DK
10.4 "Any problems with the treatment?" and/or "Why did child not have full 6 months treatment"
30 = died<6m  99 = DK
11) SFP
11.1 # months 99=DK
11.2 Which SFP did child go to (if did not go, which was nearest)
11.3 "Any problems with the treatment?" and/or  "Why did child not have full 4 months SFP"
30 = died<4m  99 = DK
12) COMMUNITY FOOD RATIONS (other than SFP ) *** in your area *** in past year *** ?
12.1 Aside from SFP (above), were any other organizations offering food rations in your area?
0 = no, not aware of any 2 = yes, available, went, & told that child not eligible
1 = yes, food is available but child did not go 3 = yes, available, went AND received food
13) ACTIVITY LEVEL (usual - before illness that led to death if died)
99=DK
14) FEEDING PRACTICES
14.1 Is (oe was) child still breast feeding? 0 = no
If NO: age when 
stopped:
99 = DK
14.2 Did you attend any health / nutrition education sessions whilst on MOYO 0 = no 1 = yes 99 = DK
14.3 Did you feed your children differently after being on MOYO? 0 = no 1 = yes 99 = DK
if yes, describe (no prompts):
14.4 How many food groups are there?
14.5 What Breast Feeding advice would you give to a new mother in your area:
~ Babies can be given other liquids  (e.g water, teas, juices) alongside  BF from ~ months
~ Babies can be given other solid foods (e.g porridge, nsima) alongside  BF from ~ months
~ Ideally,a baby should BF until he/she is: _____years months 99 = DK
~ If a mother is HIV +ve, when should she stop to BF her child completely?
stop: months
How many months did child attend SFP for? (1 visit only=0.5m)
1=minimal activity 0=in bed all day
2 = started on MOYO ward /OTP 3 = start after MOYO OTP
3 = normal 2=some restriction
31 = still taking
32=not referred
Describe problem:
0 = no problems
Describe problem:
1=chakudya chokhutitsa? 2=chakudya chochokera ku nyama?  3=mafuta? 4=zipatso? 5=masamba?6=gulu la nyemba // 99=knows none
0 = should not BF at all
0 = no problems
1 = yes (in last 
24hrs)
name them (circle each group named - no prompts)
66=as long as possible
99 = DK / cannot say
by                                 years
1 = pre-MOYO
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15) HIV STATUS
15.1 Child HIV status (see from old notes or passport) 1= R
15.2 Is carer aware of the child's HIV status 0 = no 1 =yes
15.3 Is a Re-test needed: 0 = no
if yes: 99=DK
NB IF carer unaware of status, see status in notes/passport and counsel appropriately / refer back to VCT
IF HIV ( R ):
16) COTRIMOXAZOLE PROPHYLAXIS (should be ONE DAILY dose) circle ALL that apply
16.1 CoT ever? 0 = never 99=DK
16.2 When did child LAST take a dose of CoT (NB short TREATMENT courses from health centre do no count)
16.3 Where got CoT from?:
(after MOYO OTP)
16.4 "Any problems taking DAILY cotrim prophylaxis" (see codes, list all that apply)
 99 = DK
17) ARV medication (should be two DAILY doses) circle ALL that apply
17.1 On ARV? 0 = never
4 = not yet eligible: (say why not)
17.2 If EVER  ARV: Date started: _____dd/ _____mm/ ____yy TO:
17.3 If EVER  ARV: where 2 = health centre (which:) 77=n/a 99 = DK
17.4 When did child LAST TAKE  his/her ARV medication?
77 = n/a
99 = DK
17.5 When did your child last  miss a dose (tick one box only)
77=n/a (stopped/not taking) 99 - DK
17.6 "What problems were there (MUST be problem if missed dose/not taken today)" (see codes, list all that apply)
 99 = DK
18) Has home address changed?
19) EXTRA NOTES / ACTION FOLLOWING 1 YEAR FOLLOW-UP VISIT (Give details where relevant)
 0=no 1=advice: 2=refer to outpatient service: 3=readmit to MOYO/QECH
action
needed
Date ____d/____m/200_ Interviewer initials
1 = Retest done, still R 
2 = started on MOYO ward /OTP 3 = start after MOYO OTP
DETAILS
2 = started on MOYO ward /OTP
1 = yes: get new details 99 = moved but ?where0 = no, as before
1 =start pre-MOYO 3 = start after MOYO OTP
still taking now / at death date stopped     /      /
1a) general nutrtion advice
1b) other
77 = not applicable                                                                
e.g temporary carer / neighbour answering now
1 = yes: see flowchart+say why:
1 =start pre-MOYO
3 = counselled & referred now2 = retest done, NR
0 = NON-R 2=not tested
DETAILS
1 = missed within last week
5=missed nothing last 3/12
3=missed dose 2-4 weeks ago
4=missed dose 1-3months ago
2 = missed dose 1-2 weeks ago
0=today
4 = one week to one month 
ago
5 = more 
than 1 month 
ago
0 = no problems
1=yesterday
99 = DK
0=today 1=yesterday
6=never 
since MOYO 
OTP
2 = Dzana  (two 
days ago)
3 = three to seven 
days ago
0 = no problems
1 = QECH
99=DK
1=CoT clinic, QECH
2 = Health centre (which:) 3 = Other (where):
77 = n/a 
(never took)
2 = Dzana  (two 
days ago)
6=never 
since MOYO 
OTP
99 = DK
5 = more 
than 1 month 
ago
4 = one week to one month 
ago
3 = three to seven 
days ago
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Page 5/6 MOYO 1 YEAR follow-up: INDEX CHILD HMIS no:
MOYO 1 year follow-up ~ Family Clinical
s
e
x
DOB Age now Weight MUAC
length or 
height
Ever kwash or 
marasmus  
Notes/ details
1
 
=
 
m
a
l
e
 
/
 
 
2
=
f
e
m
a
l
e
(dd/mm/yy) (or age of 
death if 
died
(kg) (cm) (cm) 0=never                              
1=NRU admission                      
2=CTC                      
3=multivit/ drugs only 
4=advice only         5=nil 
Rx,         6=SFP
details of any SAM / inpatient / why died if died                                                                                                  
---                                                                                                                         
(Diagnosis, dates)
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DRAW ARROW ---> to idenitfy birth order of MOYO sib continue on separate sheet if needed
Basic details
0 = died              
1=alive,well 
2=alive,ill 
99=DK
INITIALS
How now?
anthropometry clinical progress (current, or before death if died)
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G.2 Anthropometry (including sibling anthropometry and clinical status) 
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Page 6/6 MOYO 1 YEAR follow-up: Y06___/___/___/___index child HMIS no:
MOYO 1 year follow-up ~ FAMILY HCT TESTS
Tested 
(stamp)
If tested, 
when
If not 
tested
PASSPORT:        
0=NR stamp             
----                 
1=R stamp               
----                
2=no stamp 
seen                  
----                
3=passport 
n/a
1=pre-
MOYO               
--- 
2=@MOYO               
---                  
3=after 
MOYO D/C
WHY 
NOT? 
(see code 
sheet)        
+ write in 
"NOTES"       
On COT? 
0=never                 
1=occ                           
2=daily                           
3=was taking, 
but now 
stopped
On ARV ?                
0=no                   
-----                   
1=yes                    
--------                       
2=waiting list         
------            
3=not eligible                   
------     
4=started, but 
now stopped
Notes                                                                         
e.g. details of PMTCT / reason for not testing - if 
unable to code accurately                                                                                
~~~~                                                                                           
also document any differences between test result 
reported and that written in passport                                                                                                                                                                                                  
~~~~~                                                                                                       
when MOTHER started ARV if she is taking
4.1 Mother
4.2 Father
4.3
Carer        
(if not mum or 
dad)
4.4
1stborn
4.5
2ndborn
4.6
3rdborn
4.7
4thborn
4.8
5thborn
4.9
6thborn
4.10
7thborn
4.11
lastborn
DRAW ARROW ---> to idenitfy birth order of MOYO sib NB WHY NOT ~ write in text AND (if possible) code from sheet
if tested     ( R )                                                                                                                     
IS (or WAS) the family member:
INITIALS
any PMTCT @ 
birth?                      
0=no                    
1=HIV test for 
mum only  
2=HIV test 
mum+baby  
3=HIV 
test+single 
dose ARV drug 
4=other         
99=dk.       
Tested for 
HIV?                  
REPORTED:        
0=tested~NR                              
---         
1=tested~R                              
---                   
2=never 
tested                       
---                 
99=DK
G.3 HIV status and testing 
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Annex H FUSAM study additional details and results 
 
 
H.1 Baseline patient profile at admission to MOYO 
 
H.1.1 Subtype of wasting 
Table 46 Subtypes of wasting showing those who were wased according to low MUAC only or low 
WHM only – by HIV status 
 All 
admissions 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 
year post 
admission 
(n=462) 
Unknown 1 
year 
outcome 
 
 (n=135) 
Severe wasting (all) 275/1024 
(27%) 
135/322 (42%) 55/105 (52.4%) 69/462 (15%) 16/135 (12%) 
 
Wasting (MUAC 
<11cm only) 
122/1024 
(12%) 
49/322 (15.2%) 32/105 (30.5%) 32/462 (7%) 9/135 (7%) 
 HIV ○-  29/459 (6%) 7/57 (12%) 3/20  (15%) 19/315 (6%) 0 
HIV ○+  81/445 (18%) 33/191 (17%) 29/83 (35%) 13/139 (9%) 6/32 (19%) 
HIV unknown 12/120 (10%) 9/74 (12%) 0 0 3/36 (8%) 
Wasting (WHM 
<70% only) 
13/1024 (1%) 7/322 (2%) 2/105 (2%) 
 
4/462 (1%) 0/135 (0%) 
 HIV ○-  2/459 (0.4%) 1/57 (2%) 1/20 (5%) 0 0 
HIV ○+  9/445 (2%) 5/191 (3%) 1/83 (1%) 3/139 (2%) 0 
HIV unknown 2/120 (2%) 1/74 (1%) 0 1/8 (13%) 0 
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H.1.2 Malnutrition severity at admission - details 
Admission anthropometry stratified by SAM type and by hiv status is shown in Table 13. As 
expected, weight-for-height is lowest among wasted patients and those who are HIV 
seropositive. Overall and in children with oedematous malnutrition, it is also lower in deaths 
than in those still alive at 1 year. Unknown final outcomes are more similar to those known 
alive than to deaths. Similar patterns are seen for weight-for-age and height-for-age z-scores. 
 
Table 47 Weight-for-height, weight-for-age and height-for-age at admission – by SAM type and HIV 
status 
 All 
admissions 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 
year post 
admission 
(n=462) 
Unknown 1 
year 
outcome 
 
 (n=135) 
Weight-for-height -2.25 (1.3) -2.77 (1.2) -2.65 (1.2) -1.92 (1.2) -1.86 (1.3) 
Oedematous 
patients 
-1.89 (1.2) -2.39 (1.2) -2.22 (1.4) -1.68 (1.1) -1.67 (1.2) 
Wasted patients -3.20 (0.9) -3.23 (1.0) -3.06 (0.8) -3.27 (0.8) -3.10 (1.2) 
in HIV ○-  -1.87 (1.2) -2.56 (1.2) -2.08 (1.6) -1.81 (1.2) -1.49 (1.3) 
in HIV ○+  -2.59 (1.2) -2.85 (1.2) -2.82 (1.0) -2.16 (1.3) -2.35 (1.2) 
in HIV unknown -2.60 (1.2) -2.72 (1.2) -1.55 (1.2) -2.37 (1.2) -2.36 (1.2) 
Weight-for-age -3.59 (1.3) -4.13 (1.1) -4.30 (1.1) -3.18 (1.2) -3.14 (1.4) 
Oedematous 
patients 
-3.15 (1.2) -3.67 (1.1) -3.73 (1.3) -2.91 (1.1) -2.85 (1.3) 
Wasted patients -4.71 (0.7) -4.73 (0.7) -4.79 (0.7) -4.61 (0.6) -4.82 (0.7) 
in HIV ○-  -3.09 (1.3) -3.86 (1.1) -3.74 (1.6) -3.00 (1.2) -2.66 (1.3) 
in HIV ○+  -4.02 (1.1) -4.21 (1.1) -4.45 (0.9) -3.58 (1.2) -3.71 (1.0) 
in HIV unknown -4.00 (1.3) -4.13 (1.2) -3.86 (0.2) -3.28 (1.8) -3.83 (1.6) 
Height-for-age -3.23 (1.4) -3.43 (1.4) -3.88 (1.3) -3.03 (1.4) -2.94 (1.5) 
in HIV ○-  -2.90 (1.4) -3.16 (1.4) -3.68 (1.6) -2.86 (1.4) -2.66 (1.5) 
in HIV ○+  -3.58 (1.3) -3.54 (1.3) -3.93 (1.2) -3.44 (1.3) -3.50 (1.3) 
in HIV unknown -3.27 (1.7) -3.36 (1.5) -3.97 (0.0) -2.86 (2.6) -3.02 (1.9) 
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H.1.3 HIV profile 
 
Table 48 Baseline HIV profile 
 All 
admissions 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 
year post 
admission 
(n=462) 
Unknown 1 
year outcome 
 
 (n=135) 
Child HIV status      
HIV ○-  459 (45%) 57 (18%) 20 (19%) 315 (68%) 67 (50%) 
HIV ○+  445 (43%) 191 (59%) 83 (70%) 139 (30%) 32 (24%) 
HIV unknown 120 (12%) 74 (23%) 2 (2%) 8 (2%) 36 (27%) 
HIV staging: 
HIV ○-  only n=440 n=52 n=20 n=307 n=61 
Stage 0 112 (25%) 7 (14%) 3 (15%) 86 (28%) 16 (26%) 
Stage 1 or 2 69 (16%) 6 (12%) 5 (25%) 51 (17%) 7 (11%) 
Stage 3 197 (45%) 35 (67%) 8 (40%) 129 (42%) 25 (41%) 
Stage 4 62 (14%) 4 (8%) 4 (20%) 41 (13%) 13 (21%) 
HIV staging: 
HIV ○+  only n=431 n=185 n=83 n=134 n=29 
Stage 0 44 (10%) 14 (8%) 9 (11%) 19 (14%) 2 (7%) 
Stage 1 or 2 57 (13%) 21 (11%) 6 (7%) 26 (19%) 4 (14%) 
Stage 3 235 (55%) 101 (55%) 53 (64%) 65 (49%) 16 (55%) 
Stage 4 95 (22%) 49 (27%) 15 (18%) 25 (18%) 7 (24%) 
CD4* n=208 n=31 n=63 n=93 n=21 
CD4 severely low  
(age adjusted %) 
126 (61%) 27 (87%) 40 (63%) 45 (48%) 14 (70%) 
CD4%, mean (SD) 17.9 (9.8) 12.9 (8.4) 17.1 (8.2) 20.5 (10.6) 16.3 (9.5) 
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H.1.4 Clinical profile 
Table 49 Baseline clinical profile in full 
 All 
admissions 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 
year post 
admission 
(n=462) 
Unknown 1 
year outcome 
 
 (n=135) 
Symptoms in previous 2 weeks 
Any 959/980 (98%) 309/311 (99%) 102/105 (97%) 447/460 (97%) 101/104 (97%) 
Fever 637/979 (65%) 205/311 (66%) 73/104 (70%) 293/458 (64%) 66/106 (62%) 
Diarrhoea 647/977 (66%) 231/310 (75%) 72/105 (69%) 280/456 (61%) 64/106 (60%) 
Vomiting 450/982 (46%) 163/313 (52%) 42/105 (40%) 203/458 (44%) 42/106 (40%) 
Abdominal 
pain 
377/923 (41%) 123/269 (46%) 37/104 (36%) 188/452 (42%) 29/98 (30%) 
Fast or 
difficult 
breathing 
143/970 (15%) 45/303 (15%) 20/104 (19%) 62/457 (14%) 16/106 (15%) 
Cough 580/977 (59%) 193/308 (63%) 76/105 (72%) 254/459 (55%) 57/105 (54%) 
Anorexia 503/953 (53%) 169/294 (57%) 51/104 (49%) 230/454 (51%) 53/101 (52%) 
Flaky paint 
dematosis 
174/967 (18%) 49/306 (16%) 14/104 (13%) 89/452 (20%) 22/105 (21%) 
Other 238/977 (24%) 84/314 (27%) 34/104 (33%) 101/454 (22%) 19/105 (18%) 
Outpatient consultations in 2 weeks prior to admission (any) 
Any 658/928 (71%) 204/271 (75%) 68/102 (67%) 318/456 (70%) 68/99 (69%) 
Medication use in 2 weeks prior to admission 
Any  843/951 (89%) 264/296 (89%) 95/103 (92%) 394/450 (88%) 90/102 (88%) 
Anaemia      
Any (PCV<30) 320/914 (35%) 103/294 (35%) 39/96 (41%) 141/424 (33%) 37/100 (37%) 
Severe (PCV <15) 18/914 (2%) 11/294 (4%) 1/96 (1%) 5/424 (1%) 1/100 (1%) 
Malaria  
(+ve thick blood 
film on admission) 
37/898 (4%) 9/292 (3%) 3/94 (3%) 21/415 (5%) 4/97 (4%) 
Has traditional 
medicine amulet or 
charm 
245/905 (27%) 87/266 (32%) 25/100 (25%) 108/444 (24%) 25/95 (26%) 
Breastfed  
(<2 year olds only) 
253/557 (45%) 102/192 (53%) 47/69 (68%) 79/243 (33%) 25/53 (53%) 
Disability 
(any) 
60/938 (6%) 24/282 (9%) 9/102 (9%) 22/453 (5%) 5/101 (5%) 
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H.1.5 Past medical history 
 
Table 50 Past medical history in full 
 All 
admissions 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 
year post 
admission 
(n=462) 
Unknown 1 
year 
outcome 
(n=135) 
Past inpatient and outpatient episodes  (any) 
Inpatient admissions   
(non-SAM,  
in past year) 
190/931 (20%) 88/283 (31%) 22/102 (22%) 69/444 (16%) 11/102 (11%) 
Inpatient admissions 
 (for SAM, ever) 
134/939 (14%) 47/282 (17%) 15/102 (15%) 57/452 (13%) 15/103 (15%) 
Outpatient episodes  
(last 6 months) 
797/884 (90%) 233/253 (92%) 90/98 (92%) 396/440 (90%) 78/93 (84%) 
Outpatient episodes 
(last 6 months, 
with symptoms 
suggestive of 
malnutrition) 
187/882 (21%) 60/254 (24%) 26/97 (27%) 84/437 (19%) 17/94 (18%) 
Outpatient episodes 
(for SFP, ever) 
203/910 (22%) 62/267 (23%) 29/102 (28%) 93/445 (21%) 19/96 (20%) 
Ex Low Birth weight 
(reported by carer) 
86/899 (10%) 29/257 (11%) 13/98 (13%) 39/449 (9%) 5/95 (5%) 
Ever  had TB 32/924 (3%) 15/273 (5%) 4/103 (4%) 10/450 (2%) 3/98 (3%) 
Ever had measles 
vaccine 
808/937 (86%) 232/290 (80%) 81/98 (82%) 401/448 (90%) 94/101 (93%) 
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H.1.6 Family profile 
Table 51 Family profile in full table 
 All 
admissions 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 
year post 
admission 
(n=462) 
Unknown 1 
year 
outcome 
(n=135) 
Orphan      
Mother died 72/916 (8%) 18/264 (7%) 10/102 (10%) 36/457 (8%) 8/93 (9%) 
Father died 64/908 (7%) 22/261 (8%) 9/102 (9%) 28/452 (6%) 5/93 (5%) 
Both dead 24/823 (3%) 9/240 (4%) 4/91 (4%) 10/410 (2%) 1/82 (1%) 
Previous child death 
in family 
233/970 (24%) 76/306 (25%) 24/103 (23%) 110/457 (24%) 23/104 (22%) 
Birth order of MOYO child 
First 257/925 (28%) 76/272 (28%) 26/103 (25%) 126/453 (28%) 29/97 (30%) 
Second 242/925 (26%) 70/272 (26%) 26/103 (25%) 115/453 (25%) 31/97 (32%) 
Third 188/925 (20%) 60/272 (22%) 20/103 (19%) 87/453 (19%) 21/97 (22%) 
Fourth or later 238/925 (26%) 66/272 (24%) 31/103 (30%) 125/453 (28%) 16/97 (16%) 
Maternal education      
None 101/876 (12%) 30/254 (12%) 13/98 (13%) 51/433 (12%) 7/91 (8%) 
Primary school 605/876 (69%) 164/254 (65%) 70/98 (71%) 303/433 (70%) 68/91 (74%) 
Secondary school 170/876 (19%) 60/254 (24%) 15/98 (15%) 79/433 (18%) 16/91 (18%) 
Paternal education      
None 27/652 (4%) 10/176 (6%) 1/68 (1%) 14/337 (4%) 2/71 (3%) 
Primary school 297/652 (46%) 77/176 (44%) 31/68 (46%) 156/337 (46%) 33/71 (47%) 
Secondary school 328/652 (50%) 89/176 (51%) 36/68 (53%) 167/337 (50%) 36/71 (51%) 
Mother  illiterate 315/885 (36%) 88/256 (34%) 35/100 (35%) 160/437 (37%) 32/92 (35%) 
Father illiterate 77/838 (9%) 25/233 (11%) 5/93 (5%) 36/423 (9%) 11/89 (12%) 
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H.1.7 Socioeconomic profile 
 
Table 52 Socioeconomic profile and residence details in full 
 All 
admissions 
 
(n=1024) 
Inpatient or 
OTP death 
 
(n=322) 
Late death  
 
 
(n=105) 
Alive at >1 
year post 
admission 
(n=462) 
Unknown 1 
year 
outcome 
(n=135) 
Mother’s occupation      
Housewife 
479/1024 
(47%) 
135/322 (42%) 55/105 (52%) 242/462 (52%) 47/135 (35%) 
Ganyu 
157/1024 
(15%) 
44/322 (14%) 16/105 (15%) 81/462 (18%) 16/135 (12%) 
Employee/ self 
employed 
208/1024 
(20%) 
63/322 (20%) 25/105 (24%) 95/462 (21%) 25/135 (19%) 
Other or 
unknown 
180/1024 
(18%) 
80/322 (25%) 9/105 (9%) 44/462 (10%) 47/135 (35%) 
Father’s occupation      
Unemployed 
211/1024 
(21%) 
76/322 (24%) 17/105 (16%) 66/462 (14%) 52/135 (39%) 
Ganyu 
155/1024 
(15%) 
38/322 (12%) 17/105 (16%) 86/462 (19%) 14/135 (10%) 
Employee/self 
employed/other 
or unknown 
658/1024 
(64%) 
208/322 (65%) 71/105 (68%) 310/462 (67%) 69/135 (51%) 
Rural residence 331/898 (37%) 82/256 (32%) 34/99 (34%) 191/451 (42%) 24/92 (26%) 
Admitted to MOYO: 
Direct to MOYO 
or readmission 
285/856 (33%) 90/244 (37%) 35/98 (36%) 124/427 (29%) 36/87 (41%) 
Via other QECH  
paediatric ward 
56/856 (7%) 22/244 (9%) 10/98 (10%) 21/427 (5%) 3/87 (3%) 
Referred from 
other clinic 
515/856 (60%) 132/244 (54%) 53/98 (54%) 282/427 (66%) 48/87 (55%) 
Wealth quintile      
Poorest 169/845 (20%) 43/240 (18%) 17/95(18%) 97/426 (23%) 12/84 (14%) 
2
nd
 poorest 169/845 (20%) 49/240 (20%) 14/95 (15%) 92/426 (22%) 14/84 (17%) 
Middle 169/845 (20%) 44/240 (18%) 23/95 (24%) 82/426 (19%) 20/84 (24%) 
2
nd
 richest 169/845 (20%) 50/240 (21%) 15/95 (16%) 83/426 (19%) 21/84 (25%) 
Richest 169/845 (20%) 54/240 (23%) 26/95 (27%) 72/426 (17%) 17/84 (20%) 
Main household water source 
Piped 502/913 (55%) 156/264 (59%) 59/101 (58%) 227/455 (50%) 60/93 (65%) 
Borehole 300/913 (33%) 74/264 (28%) 29/101 (29%) 177/455 (39%) 20/93 (22%) 
Well or spring 111/913 (12%) 34/264 (13%) 13/101 (13%) 51/455 (11%) 13/93 (14%) 
Main household toilet      
Flush toilet 22/913 (2%) 5/264 (2%) 4/101 (4%) 12/455 (3%) 1/93 (1%) 
Traditional pit 
(own) 
345/913 (38%) 110/264 (42%) 30/101 (30%) 179/455 (39%) 26/93 (28%) 
Traditional pit 
(shared) 
538/913 (59%) 148/264 (56%) 67/101 (66%) 259/455 (57%) 64/93 (69%) 
Bush toilet or 
other 
8/913 (1%) 1/264 (0.4%) 0/101 (0%) 5/455 (1%) 2/93 (2%) 
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K.2 Latest version of the MOYO chart, as field tested in Ethiopia, 2009  
(1
st
 Prize Poster, Royal Society of Tropical Medicine “Research in Progress” meeting, December 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
“They shall neither hunger anymore, nor thirst anymore;”
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Revelation 7:16 
